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INTRODUCTION
The outlook for the majority of patients who develop solid
tumours remains bleak, with many having disseminated disease at
the time of clinical presentation. Refinements in surgical and
radiotherapeutic techniques have failed to make a significant
impact on overall survival in these patients. Over the past
two decades great progress has been made in the development of
novel anti-cancer agents, and also the development of drug
analogues with an improved therapeutic index compared with the
parent compounds. However, apart from a few highly selected
treatment areas, such as Hodgkin's and non-Hodgkin's lymphoma,
leukaemia, choriocarcinoma and testicular teratoma, progress,
in terms of cure, has been limited
Lung cancer has been the commonest cancer in men for
many years and has recently 'achieved' a similar position in
women. However, with changing smoking habits its incidence is
no longer increasing in men, although it continues to do so in
women. Lung cancer is a serious problem which accounted for
25,000 male and 8,000 female deaths in England and Wales in
1980. The chemotherapy of these diseases raises many inter¬
esting problems, particularly as the drug sensitivity of
different cell types varies widely. Small cell lung cancer is
(xvii)
highly chemosensitive, although long term survival remains
remarkably elusive, whereas the non small cell carcinomas give
the best hope of cure with local treatments, but are normally
chemoresistant should the disease become disseminated.
In addition to the generally poor response to chemo¬
therapy, particularly in non-small cell carcinomas, one also
has to consider the toxicity of the drugs used. Cytotoxic
drugs generally have a low therapeutic index often causing
alopecia, as well as haematological, gastrointestinal and
neurological toxicities which are often dose-limiting.
The refractory nature of the majority of solid tumours to
chemotherapeutic agents, in addition to the toxicities
associated with these agents, have stimulated a great deal of
research into experimental model systems as a means of asses¬
sing the activity and side effects of these drugs used
singly or in combination.
Historically, rodent tumour systems were used but these
have little resemblance to human solid tumours in terms of
behaviour or chemotherapeutic response. Attention has there¬
fore switched to the use of human tumour cells for both
in vitro and in vivo studies. With regard to the latter, the
(xviii)
human xenograft model, growing in immuno-deficient animals has
been used widely with the xenografts apparently maintaining
human characteristics.
Cellular detoxication mechansims are very important in the
protection against cytotoxic drugs. A major detoxication
system involves the tripeptide glutathione and its related
enzymes. Alterations in glutathione levels have been shown to
modify the cellular response to anti-cancer drugs. With the
development of drugs that can manipulate glutathione homeo¬
stasis the potential exists for the development of more
effective drug combinations and schedules.
The use of human xenografts gives the opportunity to
assess the activity of new anti-cancer drugs, and also
investigate the potential of altering the scheduling of drugs
to improve the chemotherapy of solid tumours. In addition, by
manipulating the glutathione-redox system in these xenografts a
to jnodify
unique opportunity exists^tumours biochemically which could be
of value in the development of rational scheduled chemothera-
peutic regimens.
SECTION 1 - REVIEW OF THE LITERATURE
CHAPTER 1
CLINICAL MANAGEMENT OF LUNG CANCER
1.1 Introduction





The management of patients with lung cancer varies
according to the histological type. In small cell carcinoma,
the disease is almost invariably disseminated at the time of
presentation, with systemic chemotherapy therefore playing a
predominant role in management. However, other histological
subtypes such as squamous cell carcinoma, adenocarcinoma and
large cell carcinoma, generally grouped together as the non-
small cell carcinomas, are more frequently limited to the primary
site with consequently, an increased emphasis on local treatments.
2
1 .2 Surgery
Surgery is generally considered the treatment of choice
for the non-small cell carcinomas, assuming that the tumour is
resectable, although patients require sufficient cardiopul¬
monary reserve to withstand pneumonectomy. However, Paulson
(1968) from Californian figures, showed that in only 15? of
cases was the tumour confined to the lung, 30? had evidence of
regional dissemination and 55? had evidence of distant
metastases. Le Roux (1968) reported similar figures from
Edinburgh between 19^9-1964.
Fewer patients with small cell carcinoma are suitable for
resection in view of the high incidence of disseminated disease
at presentation, leaving chemotherapy with or without radio¬
therapy, as the treatment of choice (Takita, et £l 1973).
However, in tumours with no evidence of dissemination which are
found to be small cell in type and resectable at operation,
prognosis is similar to other histological types (Shields, et
al 1975). Surgery can therefore be recommended, probably with
adjuvant chemotherapy, for this small minority of patients, as
long term survival can result (Drakeley, et al 1979).
The results of surgery for lung cancer vary from centre to
centre with staging differences a significant factor.
Stanford, et al (1976) showed a 50? 5 year survival in a large
3
series of highly selected patients, with a 27$ 5 year survival
in surgically managed small cell carcinoma. However, most
series give a 5 year survival of around 40$ in patients without
nodal involvement and 15$ 5 year survival with nodes affected,
as reported by Wilkins, et al in 1978.
1.3 Radiotherapy
There is great variation in the sensitivity of various
sub-types of lung cancer to x-irradiation. Small cell car¬
cinoma is highly sensitive, but is often widely disseminated at
the time of presentation drastically limiting the effect of
radiation when used alone (Cox, et al 1979). In small cell
carcinoma radiation has been successfully employed as a
palliative measure in the treatment of bony or cerebral
metastases, although radiation does not influence survival in
these patients.
In contrast non-small cell carcinomas, particularly
squamous cell carcinomas, are more often limited to the
primary site but are less radiosensitive. In a large
unselected series, Deeley (1967) reported a 36$ 1 year
survival, with only 6$ 5 year survival using 5000 cGy. Similar
figures were obtained by Caldwell and Bagshaw (1968) using
6000 cGy. Palliatively radiation is used extensively with good
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effect, particularly in the control of haemoptysis, cough and
dyspnoea (Slawson and Scott, 1979)-
Recently there has been great interest in the use of
agents which potentiate or protect tissues against the effects
of ionising radiation. Radiosensitisation was successful
in vitro using misonidazole, although minimal clinical benefit
resulted because of dose limiting neurotoxicity (Brown, 1984).
Many other radiosensitisers have been tested, some showing
potential clinical applicability, such as bromodeoxyuridine
(Mitchell, et al 1983); SR 2508 (Brown and Yu, 1984) and RSU
1069 (Adams et al, 1984). Chemotherapeutic agents have also
been tested some showing apparent differential protection
against alkylating agent injury in tumours compared with normal
tissues (Phillips, et al 1983).
In non-small cell lung cancer combinations of radiotherapy
and surgery have shown enhanced 3 year survival rates in
patients with nodal involvement at the hilum or mediastinum
(Cox, 1985). Improvement in long-term survival rates is the
major contribution of radiation therapy when used in combin¬
ation with chemotherapy (Salazar and Creech, 1980), although
Bunn et al (1983) in a preliminary report, showed an increased
complete response rate with combined modality therapy (81%)
compared with chemotherapy alone (47%).
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1.4 Chemotherapy
1.Ha Small cell carcinoma - single agents
Chemotherapy is the treatment of choice for the vast
majority of patients with small cell carcinoma. Many agents
have been shown to have significant activity as shown in
Table 1.1 with prolongation of survival using single agents
shown on at least 3 occasions (Kokron et al, 1978; Green et al,
1969; Roswitt et al, 1986). In view of the widespread use of
combination chemotherapy regimes in this disease, single agent
data is no longer forthcoming, except in heavily pre-treated
patients.
1.lb Small cell carcinoma - combination chemotherapy
Combination chemotherapy is clearly superior to single
agent therapy both in terms of response rate and duration of
survival (Bunn and Ihde, 1981).
In 1976 Hansen et al reported an increase in response rate
and survival in patients treated with a 3 drug combination
including CCNU when compared with a combination of methotrexate
and cyclophosphamide. These 3 drugs have been used success¬
fully at the National Cancer Institute - VA group where Cohen
et al, (1977) reported a 96% objective response rate to a
6
combination of these agents, with a median survival of ^2
weeks. In the same study inferior results were obtained with
lower dosages of the same drugs. More recently, Smyth et al
using the same drugs but with methotrexate at a much higher
dose of 200 mg/m^ with folinic acid rescue, reported a 58$
response rate in 83 patients. The lower response rate in this
study is partly explained by the use of stricter criteria in
the assessment of response including repeat bronchoscopy.
Despite the lower response rate, median survival of these
patients was similar to that reported by Cohen et al (1977).
Most other combinations have given response rates in the region
of 80$, such as the 79$ response rate reported by Gracia and
Jimenez (1982) in 2h patients receiving a combination of
cyclophosphamide, vincristine, adriamycin and etoposide.
Similarly, Klastersky et al (1982) reported an 83$ response
rate to a combination of cis-platinum, adriamycin and etoposide
with a median survival of 15 months in the complete responders
and 10 months in the partial responders.
In an attempt to improve these results additional drugs
have been incorporated into the regimes with limited effect,
although in a controlled study of 105 patients Hansen et al
(1978) did show an increase in median survival from 25 to 33
weeks when vincristine was added to the 3 drug combination of
7










Table 1.1 Single agent chemotherapy in the treatment of small
cell lung cancer (Hansen and Rorth 1979; 1980)
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methotrexate, cyclophosphamide and CCNU. Despite the use of ^
and 5 drug combinations, the 2 year survival of patients with
this disease remains abysmal with no significant improvement in
response rate or survival over 3 drug combinations as shown in
Table 1.2. A number of regimens have been used in the treat¬
ment of this disease, but comparison of results is difficult,
as median survival of these patients can be affected by a
number of factors, such as stage of disease, site of metastases
and performance status. When allowances are made for these
variables, the duration of response in a number of studies,
utilising a wide variety of agents, is remarkably similar.
Irrespective of the induction regime employed, a median
survival of 6-10 months in extensive disease and 11-13 months
in limited disease can be expected.
Salvage chemotherapy in general has not been successful,
although Poplin et al (1982) reported a 31? response rate in 29
previously treated patients. These patients received a
combination of CCNU, vincristine, methotrexate and procar¬
bazine, with 5 complete responders, in whom a median survival
of 11 months was achieved. Other centres have used alternating
non cross-resistant schedules of drugs in an attempt to improve
responses, Cohen et al (1979) showed a marked benefit in terms
of response rate in patients treated with a regimen of metho-
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trexate, cyclophosphamide and CCNU alternating with vincris¬
tine, adriamycin and procarbazine although survival was not
affected. Others have failed to confirm this improvement
including Vincent et al (1980) and Aisner et al (1982), the
latter in a in a controlled study using cyclophosphamide,
adriamycin and etoposide switching half of the patients to
CCNU, vincristine, methotrexate and procarbazine at the time of
maximal response.
More recent developments include the use of high dose
chemotherapy with or without autologous bone marrow trans¬
plantation. Cyclophosphamide, melphalan and etoposide have all
been used at very high dosages, but it is too early to comment
on the duration of the responses and survival of patients in
these studies.
1. lie Non small cell carcinoma - single agents
In general non-small cell lung cancer is less sensitive
than small cell carcinoma to cytotoxic drugs. Squamous and
adenocarcinomas are considered more sensitive to the presently
available agents than large cell carcinoma in which response
rates of less than 10? are reported. Cyclophosphamide was the
most widely used single agent giving response rates of
approximately 20?, although recently many other agents have
Limiteddisease
Extensivedis as
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been tested including vindesine, etoposide, cis-platinum and
ifosfamide. The results of single agent data are summarised in
Table 1.3. Although responses are observed to cytotoxic drugs
in non small cell lung cancer, prolonged survival has never
been achieved.
1. J1d Non small cell carcinoma - combination chemotherapy
Until recently combination chemotherapy gave disappointing
results in non-small cell lung cancer with response rates no
better than for the best single agents. However, significantly
improved response rates have been reported by Gralla et al
(1981) using combinations of vindesine and cis-platinum. He
reported a 43% response rate to 2 separate combinations of
these agents showing an increased duration of response and
survival in responding patients treated with the higher dose
regimen. The incorporation of additional drugs into this
regime in an attempt to increase the response rate or duration
of response have so far proven unsuccessful (Kelsen et al,
1982; Itri et al, 1983). The activity of the cis-platinum,
vindesine combination has been confirmed in a randomised study
carried out by the West of Scotland Lung Cancer Group (Elliot
et al, 1984) who compared vindesine as a single agent with a
cis-platinum and vindesine combination. The combination gave a
12
response rate of 39? compared with 5? from vindesine alone.
Klastersky et al (1982) used a combination of cis-platinum with
etoposide reporting a 11? response rate in 87 patients.
There are few complete responders in these studies,
however, and duration of response is therefore correspondingly
short at 6-12 months. Although cytotoxic to the tumour, these
combinations are likewise toxic to normal host tissues causing
frequent alopecia, severe nausea and vomiting, myelosuppression
and neurotoxicity. Thus for approximately 10? of patients who
gain limited benefit from these combinations, a further 60?
suffer significant toxicity for no benefit. As yet, no
controlled study has shown increased duration of survival
resulting from chemotherapy in non small cell lung cancer.
1.5 Conclusion
Surgery remains the treatment of choice in non-small cell
carcinoma of limited extent, in addition to a minority of
patients with small cell lung cancer in conjunction with
adjuvant chemotherapy. Radiotherapy offers excellent palli¬
ation and occasional long term survival in all forms of lung
cancer. It gives valuable local control in intensive regimens
and when given prophylactically to the brain in small cell
carcinoma. Chemotherapy is recommended for all patients with
13
Pts 0.R
Ifosfamide 1.2 mg/m2 Morgan et al 1981 29 m
Cis-platinum 120 mg/m2 De Jaeger et al 1980 59 21?
VP-16 200 mg/day x 3 Anderson et al 1981 19 21?
Vindesine 3-4 mg/m2 wkly Gralla et al 1979 13 21?
Vindesine 3 mg/m2 wkly Mattson et al 1980 30 10?
Adriamycin 60 mg/m2 0'Bryan et al 1978 56 11?
Cyclophosphamide 1.1 g/m2 Brugarolas et al 1978 30 10?
Table 1.3 Single agent chemotherapy of non-small cell lung
cancer
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small cell carcinoma, with or without additional local therapy.
Although chemotherapy has had a significant impact on response
rates and survival in small cell carcinoma, long-term survivors
and cures remain infrequent. Despite improvements in response
rates in non small cell carcinoma, the toxicity of the
presently available chemotherapeutic regimens preclude the
recommendation of their widespread use in clinical practice at
this time. The precise role for combined modality treatment in
these diseases remains undefined at present.
Despite these treatments, the majority of patients with
lung cancer die within a year of diagnosis. In view of the
relatively high incidence of disseminated disease at present¬
ation, advances in systemic therapy would appear to offer the





A number of experimental models have been developed in an
attempt to investigate tumour biology, biochemistry and drug
sensitivity. These include the development of cell culture
techniques allowing for _in vitro correlations with the patient
response, and also many improvements in immunosuppressive
techniques allowing for the growth of human tumours in animal
models.
2.2 Tissue Culture
For many years attempts have been made to culture
malignant cells. In 1907 Harrison successfully explanted small
fragments of tissue from the medullary tube region of frog
embryos into clots of frog lymph, and Carrel (1912), using a
surgically sterile technique maintained one cell strain in
tissue culture for 3^ years.
The establishment of malignant tumour lines in culture
proved difficult, however, as reviewed in 1973 by Giard et al,
showing only 6% success with 200 tumour samples. A number of
16
tumour lines were established however, including lung cancer
lines (Gailleau 1960; Reed 1962; Giard et al, 1973)-
Over the last 10 years a wide variety of tumour types have
been established as cell lines, although some histological
types have proven difficult to culture. A large number of cell
types can be grown in tissue culture medium, such as Roswell
Park Memorial Institute (RPMI) 1640 and Hams F12 medium, when
supplemented with foetal calf serum. These media contain a
wide variety of constituents, including essential amino acids.
Recently it has become apparent that some cell lines grow more
successfully in media supplemented with growth factors (Simms
et al, 1980), often with no requirement for serum. A serum-
free medium has been defined for the growth of small cell lung
cancer. This consists of RPMI 1640 medium supplemented with
hydrocortisone, insulin, transferrin, oestradiol and selenium -
Hites medium (Simms et al, 1980). Similarly, a serum-free
medium has been defined for the optimal growth of breast cancer
cells (Calvo et al, 1984) and for non-small cell lung cancer,
which has been designated ACL 3 (Brower et al, 1986). The
latter comprises RPMI 1640 medium supplemented with hydro¬
cortisone, insulin, transferrin, selenium, epidermal growth
factor, ethanolamine, tri-iodothyronine, bovine serum albumin,
glutamine, sodium pyruvate and hepes buffer.
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With the use of selective media, a wide range of tumour
cell types can now be grown sucessfully in culture. This
allows for the production of large quantities of tumour tissue
for the investigation of tumour cell biology and biochemistry,
in addition to chemosensitivity and radiosensitivity studies.
Improvements in chemosensitivity and radio-sensitivity testing
have been aided by developments in cloning techniques using
malignant cells, and these will be dealt with more fully in
Chapter 2.3.
There are many criticisms of the experimental use of cell
culture techniques to study the characteristics of human
tumours. There are many differences between cells in culture
and human solid tumours. Cultured cells are often growing in
monolayers or as small floating aggregates, with few hypoxic
cells, in contrast to the clinical situation. Likewise, drug
access is not a problem in culture, although in large tumour
masses drug accumulation can be impaired. To address this
problem, a number of variations to basic culture techniques
have enabled workers to study the effects of cytotoxic drug
treatment on 3~dimensional tumour models.
18
2.3 3~Dircensional Tumour Models
2.3a Millipore diffusion chambers
Millipore diffusion chambers can be used to culture tumour
cells from which they can be harvested and directly innoculated
intraperitoneally into a normal mouse host. Immune-suppressed
animals are not required with this technique. Tumour cells can
therefore be grown and treated in an animal host allowing the
normal metabolism of cytotoxic drugs, avoiding effects of host
immunity on tumour cell growth. Selby and Thomas (1980)
reported on the use of these chambers for the clonal growth of
malignant cells. Drug sensitivity testing using this system
correlates well with human xenograft data. The model is highly
labour intensive, however, which may preclude widespread
experimental use.
2.3b Multicellular spheroids
Using the method of Yuhas et al (1977), a variety of human
tumours have been shown to form multicellular spheroids.
Spheroids can be difficult to produce from primary tumours,
however, with an intermediate phase in cell culture or xeno¬
grafts often necessary (Yuhas, 1977). Tumour spheroids exhibit
a number of features similar to solid tumour growth, including
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hypoxic cells (Purand 1976), presence of diffusion gradients
(Sutherland et al, 1979) and the ability to recover from
potentially lethal damage (Twentyman 1980). The chemothera-
peutic response of these spheroids generally correlates with
clinical response and with results obtained from xenograft
experiments (Jones et al, 1982).
2.3c Collagen matrix assay
This assay offers an alternative three dimensional system
to the use of multicellular spheroids. Tumour or xenograft
material can be grown as aggregates on a collagen matrix (Yang,
et al, 1979). This assay system has also been adapted by
Lawler et al (1983) using a mouse mammary tumour model,
obtaining a high rate of growth. Briefly, this method uses a
collagen gel base on which fragments of tumour are grown, and
secured with further collagen gel. Tissue culture medium is
added to this and the cells cultured as normal.
As with the spheroid system, measurement of response is
highly labour intensive. Analysis of response is similarly
achieved, either by external assesment of tumour growth, or by
clonogenic cell survival.
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The collagen matrix assay certainly appears to be a more
permissive environment for the growth of breast carcinoma
cells, but it remains to be seen whether similar results can be
achieved with other cell types. However, as with spheroids, it
is unlikely to be used widely as it is highly labour intensive.
2. *4 In vitro chemosensitivity assays
Modifications of cell culture methods, in particular
cloning techniques, have made it possible to study the chemo¬
sensitivity and radio-sensitivity of human tumour cell lines
(Puck and Marcus, 1955). Cloning in a semi-solid support such
as agar was accomplished in the 1950's and 1960*s utilising a
wide variety of animal tumours. Bradley and Metcalf (1955)
then developed colony forming assays for haematopoietic cell
progenitors. Over the past 10 years a number of modifications
have been made to this method, including the addition of a
number of growth factors both by Hamburger and Salmon (1977)
and Courtenay and Mills (1978) enabling the growth of human
tumour clonogenic cells from primary neoplastic tissue.
Predictive drug testing has frequently been performed on
individual patients' tumours. A number of techniques have been
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utilised although the clonogenic assay has been most widely
used and generally its results are considered the standard by
which other assays are compared.
Human tumours of a single histological type appear to have
a pattern of response in vitro similar to their known clinical
behaviour (Von Hoff, 1981). In addition, comparisons of in
vitro responses have correlated well with subsequent clinical
response in matched patients (Salmon et al, 1980). Good
correlation has likewise been observed between clinical
response and i_n vitro chemosensitivity testing using the
Courtenay assay in melanoma (Tveit et al, 1980).
There are, however, a number of problems relating to the
use of soft agar cloning in chemosensitivity testing. Firstly
for the assay to be valid, a good single cell suspension has to
be achieved, which can be difficult with certain tumour cell
types. By producing a single cell suspension, normal cell to
cell interactions are lost, which may be important in the
response of these cells to chemotherapy and radiotherapy.
Technically, there are problems with this assay, such as
clumping artifacts which can potentially give false negative
results. Often 2 to 3 weeks are necessary before an assay can
be evaluated, and even then colonies can be difficult to count.
Large numbers of cells are required for the assay, often
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resulting in a limited number of drugs being tested with some
tumours not evaluable at all. The main problem relates the low
plating efficiency of many of these tumours, particularly
primary tumours which commonly give plating efficiencies of
approximately 1-5$ using the Courtenay assay, and 0.001 - 1$
with the Salmon technique (Courtenay et al 1978). Obviously a
limited number of cells survive to produce colonies, and it
remains questionable whether these clonogenic cells are
representative of the tumour with regard to chemosensitivity,
and whether they are in fact the true stem cell population.
In view of the many difficulties, particularly relating to
the time consuming nature of clonogenic assays, a number of
alternative assay methods have been described. These include
assays of DNA precursor incorporation, (Bender et al, 1976)
assays of membrane function, (Weisenthal et al, 1983) and also
of cellular metabolism, (Black and Speer, 1954). Not surpris¬
ingly, many drawbacks have been encountered using these
techniques, as with the clonogenic assay. The dye exclusion
assay described by Weisenthal et al, (1983) is interesting, in
that a high proportion of patients specimens can be analysed,
using a limited number of cells, enabling a wide range of drugs
to be tested. The assay is completed in 4 days, a distinct
advantage over the clonogenic assay. However, there are
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similar problems of clumping in the assay making results often
difficult to interpret. Despite this, further comparative
studies are warranted. Recently, an assay has been described
which is based on the cellular reduction of a tetrazolium salt
to a coloured formazan dye (Mossman, 1983). Formazan crystal
formation is proportional to cell number and these crystals can
be solubilised and measured using a spectrophotometer. This
assay can be semi-automated using 96 well plates and a scanning
multiwell spectrophotometer (ELISA reader). Comparable
results have been obtained between this method, the clonogenic
assay and the dye exclusion assay in the assessment of chemo-
sensitivity (Carmichael et al, 1986) and radiosensitivity
(Carmichael et al, 1986) of tumour cell lines.
In conclusion, the majority of human tumours can now be
grown in culture, although on occasions defined media with
specific additives are required for optimal growth. Despite
the many problems associated with clonogenic assays, these
remain the standard by which new chemosensitivity assays are
compared, In vitro drug testing appears to give good predict¬
ability for clinical response, although limited data are
available from single agents tested both in vivo and in vitro.
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There are difficulties in the definition of sensitivity using
these assays, however, with dosage and duration of exposure to
drugs critical (Bateman, 1979).
Further clinical correlations are required for assessment
of the validity of _in vitro drug testing, particularly in
patients treated with single agent therapy. Similarly, further
evaluation is necessary using the 3~dimensional model systems
(multicellular spheroids and collagen matrix assay) to assess
their value, particularly in the study of drug resistance.
2.5 Animal tumour models
Various animal models have been used over the past 30
years in the development and testing of new anti-cancer agents.
They have given vital information regarding the cytotoxicity
and side-effects of these drugs. By far the largest drug
development programme was set up at the National Cancer
Institute in Bethesda, Maryland in 1955 for the systematic
screening of a wide variety of natural and synthetic substances
to assess their cytotoxic potential. These compounds were
tested against a range of transplantable rodent tumours which
had arisen either spontaneously, or through viral, or chemical
induction.
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Each of these tumours had a different range of
sensitivity, enabling the discovery of a wide variety of
potentially valuable cytotoxic compounds. The variation in
sensitivity of these tumours bears some relationship to their
growth rate, which is a function of the growth fraction (the
number of cells in mitotic cycle - rate of cell loss: Steel
1977), with high growth fraction tumours generally more
sensitive to chemotherapeutic agents.
2.5a Rodent tumours
A wide variety of rodent tumours are used in drug testing.
The National Cancer Institute drug screening programme
involved the use of a number of these, including L1210
leukaemia, P388 lymphocytic leukaemia, B16 melanoma and Lewis
lung carcinoma. The leukaemias are both rapidly growing with a
high growth fraction and were both instrumental in the
discovery of a wide range of anti-cancer drugs. BCNU and
cytosine arabinoside were found to be active using the L1210
system, and were later shown to have similar activity against
P388. P388 leukaemia was, however, more sensitive to the vinca
alkaloids and in addition, activity was noted with mithramycin
in contrast to L1210.
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B16 melanoma and Lewis lung carcinoma are more slowly
growing with lower growth fractions than the rodent leukaemias
(Zubrod, 1972). Although sensitive to the nitrosoureas they
were found to be relatively resistant to anti-metabolites
(Schepartz, 1977).
Animals used for cytotoxicity testing can also give vital
information regarding drug toxicity. Although the maximum
tolerated dose for each drug is evaluated in normal mice, it is
also important to assess drug-related lethality when used in
tumour-bearing animals. Drug toxicity and pharmacokinetics in
tumour-bearing mice are often totally different to normal
animals. This is related to a number of factors including
decreased hepatic microsomal drug metabolising enzyme activity
(Kato et al, 1982), and altered haematological indices (Piazza
et al, 1981). These differences may lead to wide variations in
lethality between normal and tumoui—bearing mice with
subsequent loss of tumour-bearing animals.
There are many other rodent tumours used experimentally.
However relatively few active drugs have been 'discovered'
using these models in the last 10 years, particularly for the
treatment of human solid tumours. Therefore, there is now a




Despite the use of rodent tumours with variable growth
rates there are still marked differences in sensitivity between
these and human solid tumours. This has resulted in failure of
recognition of a number of agents with clinical activity, such
as hexamethylmelamine (Griswold et al, 1963).
Many people have attempted therefore to heterotransplant a
wide variety of human tumours into experimental animals.
Initial attempts were unsuccessful, exemplified by Pezrilhe in
1793 xenografting a breast carcinoma into a dog (reported by
Woglam in 1913) and by Leidy in 1851 transplanting breast
carcinoma in frogs, although in the latter case vascularisation
of the tumour was noted. Sailer (1900) considered human tumour
heterotransplantation impossible without modification of the
host animals and this has led to the use of various techniques
to avoid the immunological rejection of the foreign tumour
material. These techniques are listed below and will be
discussed further in this chapter:-
(a) Immune privileged sites
(b) Skin islands
(c) Millipore diffusion chambers
(d) Immature hosts
(e) Immune suppressed animals
28
(f) Immune deprived animals
(g) Congenitally immune deficient animals
2.6a Immune privileged sites
(i) Anterior chamber of the eye
This work was developed by Greene (1938, 19*10, 1952) who
established a number of tumours using this model, although
other workers were less successful (Russell and Johnson
1963). However, there are significant disadvantages in using
this system, with a slow tumour growth rate, poor take rate and
with a strictly limited time for maximal tumour growth.
(ii) Brain
Several difficulties are encountered when heterotrans-
planting to the brains of laboratory animals, but despite this
a number of workers have been successful such as Greene (1951),
Lumb (195*1), Chesterman (1955), Epstein et al (1976) and Gazdar
et al, (1982). However, the tumours are difficult to measure
and premature host death common (Giovanella and Fogh 1978).
Serial transplantation difficult with either of these models.
(iii) Hamster cheek pouch
Billingham et al (1960) and Cohen (1961) showed that
grafts survived for long periods in the hamster cheek pouch in
contrast to sites elsewhere in the trunk of the hamster. A
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number of workers have since been able to heterotransplant
human tumour at this site (Galton et al 1963; Yohn et al 1965;
Goldenberg and Witte 1967; Smith 1969; Williams et al 1971;
Adams et al 1972; Cobb 197*1). Others have further immuno-
suppressed the animals by means of cortisone, cyclophosphamide
or neonatal thymectomy (Handler et al 1956; Patterson et al
1957; Burt et al 1966; Goldenburg and Witte 1967; Kaufman and
Lichtenauer 1967, 1968). Take rates are higher using this model
with direct measurements possible, giving a more reliable
assessment of growth and response to treatment.
There are limitations to this model, however, as hybrid¬
ization between tumour and host cells has been shown by
chromosome banding techniques (Lampert et al, 1968; Goldenberg
et al, 1971, Adams et al 1972, Goldenberg et al, 197*0 .
Unfortunately, there are marked differences in the handling of
certain drugs by hamsters particularly podophyllotoxins
(Goldenberg and Witte, 1967) which limits the usefulness of
this model.
2.6b Skin islands
It was noted in 1968 that skin allografts inlaid in skin
discs could be sustained for long periods attached to a single
vascular pedicle (Barker and Billingham 1968). Ziegler et al
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(1972, 1973) studied skin islands in rats as a potential site
of tumour transplantation but despite the fact that syngeneic
and allogeneic tumours grew well in this system, skin
xenografts survived only a few days.
2.6c Millipore diffusion chambers
Human tumour cells were found to grow well in these
diffusion chambers when implanted intraperitoneally into
xenogeneic mice (Heckman 1967). More recently the system has
been adapted by various workers to grow human tumours in soft
agar, with the additional benefit of transplantability to an
animal model if necessary (Smith et al 1976, Selby and Thomas,
1980). Chemosensitivity testing can be done either _in vitro or
in vivo using this model.
2.6d Immature hosts
Immature immune-incompetent hosts have been used by
numerous workers to grow human tumours. However, all of these
models have a strictly limited timespan for observation of
tumour growth to occur, and therefore chemotherapeutic experi¬
ments and serial transplantation are difficult to carry out
(Vogel and Berry 1975). The chorioallantoic membrane has been
used widely for this purpose (Murphy 1912; Hurst et al 1939;
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Sommers et al 1952; Kaufman et al 1956; Leighton 1967).
Neonatal rats have been shown to produce tumours following
injection of cells from a cancer cell line (Kutner and Southam
1960), although less success was obtained with the use of fresh
tumour material (Southam 1966). Neonatal hamsters have also
been used with variable results. However the effectiveness of
immature model systems is hampered both by developing immunity
causing tumour regression, and on occasions rapid death of the
animals (Giovanella and Fogh 1978).
2.6e Immunosuppression
Adult animals with a normal immune system can be immuno-
suppressed either with ionising radiation or with drugs. Murphy
in 1926 showed that x-rays could temporarily eradicate lymphoid
tissues allowing him to produce Ehrlich carcinoma transplants
in rats. In 1951 Toulan showed that human tumour xenografts
could be grown for a short period in x-irradiated animals and
in the following year (Toulan 1952) reported increased survival
of these xenografts when newly weaned rats were used. He later
combined x-irradiation with cortisone pretreatment in these
newly weaned rats reporting a 90$ take rate (Toulan 1953).
However, serial transplantation was difficult with only 0.5$ of
1000 specimens producing tumour lines (Toulan 1958). Steroids
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alone have been used to immunosuppress animals with variable
success. In 1951 Billingham et al reported prolonged survival
of skin homografts following cortisone therapy. In contrast,
initial reports suggested that inhibition of tumour growth was
occuring (Sugiura et al 1950; Higgins and Bennett, 1952).
Foley (1952) showed that the effect of cortisone was variable
with different tumours and in different strains of animal.
Variability of growth with different tumour types can be
pronounced with teratomas, gastrointestinal
tumours, melanomas and cervical cancers (Patterson 1968;
Williams et al 1971) producing higher take rates than bladder
carcinoma (Handler et al 1956).
Floersheim (1982) showed that an immunosuppressive
protocol of procarbazine, cyclophosphamide and anti-thymocyte
serum allowed adequate tumour growth when compared with nude
mice, but that cyclosporin A was relatively ineffective. This
is in contrast to the report by Deeg et al (1982) who showed
that cyclosporin A was effective as an immunosuppressive
allowing for the growth of allogeneic tumours in dogs.
In conclusion, a number of methods of temporary immuno¬
suppression have been used to allow the progressive growth of
human tumours. These have had variable success, though serial
transplantability is rare. One of the main problems with
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temporary methods is that the treatment has to be continuous if
immunosuppression is to be maintained for the duration of the
experiment. The agents used may significantly affect the
tumour with respect to growth characteristics and biochemistry
More important, when cytotoxic drugs are used to immuno-
suppresses animals they could potentially induce cross-
resistance in the tumour thereby altering the chemosensitivity
profile of that tumour.
2.6f Immune deprived animals
It is well known that the thymus is vital to cell mediated
immunity and is important in the normal development of the
paracortical region of lymph nodes. Selective depletion of
this area is produced by neonatal thymectomy, with repletion
following an intravenous injection of syngeneic thymic cells
(Parrot, de Souza and East 1966). In 1962 Miller showed
permanent impairment of immunity following thymectomy and
x-irradiation and later Davies et al (1966) reported on the
major role played by T-lymphocytes in xenograft rejection.
Reduction of the T-lymphocyte population can be achieved
surgically (Davies and Lewis 1967, 1968)or by the admini¬
stration of anti-lymphocyte serum (Lance and Medawar 1968) or
anti-thymocyte serum (Woodruff and Anderson 1963).
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The combination of thymectomy with either anti-lymphocyte
or anti-thymocyte serum has been shown by a number of authors
to be more effective than single modality treatment (Davies
and Lewis 1967, Phillips and Gazet 1968, Cobb 1972). Mitchell
et al (1974) combined thymectomy with low dose x-irradiation
(600 cGy) in an attempt to grow human myeloma cells with limited
success. A major improvement was reported by Davies et al
(1969) who showed that ths combination of thymectomy, lethal
x-irradiation and syngeneic bone marrow reconstitution allowed
for the progressive growth of human tumours which could destroy
the host. This was confirmed by Cobb and Mitchley (1974) who
showed that progressive tumour growth was obtained in 25? of
xenografts using this method of immunosuppression. The
addition of anti-thymocyte serum did not improve tumour take
rates (Detre and Gazet 1973) although Berenbaum et £l (1974)
reported that 75% of tumours survived, or grew progressively
from a series of 116 tumours transplanted into thymectomised,
irradiated, mice treated with anti-lymphocyte serum.
In 1978 Steel et al showed that the practice of injecting
5 x 106 bone marrow cells for reconstitution was inappro¬
priately high. He achieved improved tumour take rates with
injections of 2 x 1 C)5 bone marrow cells with no increase in
morbidity of the animals. At the same time, he reported that
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the use of cytosine arabinoside injected intraperitoneally at a
dose of 200 mg/kg 1-3 days before x-irradiation, protected
against the lethal effects of the latter, enabling the bone
marrow reconstitution to be omitted entirely. The take rates
in these cytosine arabinoside treated animals were higher than
with bone marrow reconstituted or with nude mice.
2.6g Congenitally immune deficient animals
(i ) Nude mice
The first hairless mutant mouse was discovered in Scotland
in 1962 (Flanagan 1966) and was found to be athymic by
Pantelouris (1968). Total absence of mature T cells was noted
with normal B cell function. The initial infective problems of
these mice were overcome by the use of strict pathogen free
environments (Giovanella and Stehlin 1973). Nude mice are now
available from a wide range of genetic backgrounds. The immune
systems of these mice vary, with differences in tumour recep¬
tivity often observed. In particular, differences have been
noted in natural-killer cell activity between strains, and also
between different laboratories using the same strains. Natural
killer cells are thought by many to play a significant role in
tumour rejection although Fodstad et al (1984) showed lack of
correlation between natural killer cell activity and tumour
36
growth control. Other factors are also important however,
including host macrophage function as reported by Jacubovich et
al (1984). Both nude mice (Gillis et al 1979) and thymec-
tomised irradiated animals (Duprez et al 1984) have been shown
to have normal T lymphocyte precursors but have defective
lymphokine production.
Colonic tumours were first grown in 1969 (Rygaard and
Povlsen) and subsequently numerous human tumour xenografts were
successfully grown (Povlsen and Rygaard 1971; Epstein and
Kaplan 1974; Giovanella et al 1974). However some cell types,
including carcinoid tumours and seminoma, remain difficult to
grow as xenografts.
(ii) Lasat mice
Resting (1980) reported on the discovery of an athymic,
asplenic Lasat mouse. In these mice, tumour take rates were
higher and the latent period prior to tumour growth shorter
than with conventional nude mice, but infective problems were
much greater, as may have been predicted.
(iii) Beige nude mice
There are now strains of mice available, termed beige
mice, which are immunodeficient with regard to natural killer
cell activity. From these animals a strain of nude mouse has
been derived which has the characteristics of both strains
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(Fodstad et al 1984). This, so called beige nude mouse,
therefore has the immunological characteristics of a neonatal
nude mouse, and is potentially a highly receptive host. As
with lasat mice, however, infective problems may preclude its
widespread use.
2.7 Conclusion
The vast majority of human cancers can now be grown either
in cell culture or as xenografts in a wide variety of hosts.
The choice of optimal model is dependent on the aims of the
particular study. Cell culture techniques provide a rapid
means of producing large numbers of tumour cells, and would
seem ideal for use in drug screening projects. Three
dimensional assay systems, such as multi-cellular spheroids,
and collagen matrix assays address the problem of drug access
and hypoxic areas of tumours, but the problems of cytotoxic
drug pharmacokinetics remain. Human xenografts in immune-
deficient animals are an improvement in this regard, although




VALIDITY OF HUMAN TUMOUR XENOGRAFT MODELS
3.1 Introduction
With the wide range of immunosuppressed animal models now
available, the vast majority or human cancers have been
established as xenografts. Most of this work has been carried
out in nude mice, of varying generic backgrounds, although
some centres have used thymectomised, cytosine arabinoside
primed, irradiated mice as described by Steel et al (1978).
3.2 Receptivity of xenografts
Comparisons of take rates between diferent human xenograft
models have proven difficult, as the criteria for a positive
take have varied between centres. In some models the continued
presence of tumour material was sufficient for a positive take,
(Berenbaum et al 1974), but it has since transpired that
xenografted cells, in the absence of progressive growth, may
not be serially transplantable (Sharkey et al 1978). It is
now generally accepted that criteria for a positive take
include progressive growth, maintenance of human characteris¬
tics and serial transplantability.
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Wide variation in take rate occurs with different histo¬
logical categories of tumours, with colorectal carcinomas,
melanomas and lung cancers giving the best figures. Reports by
Povlsen and Rygaard (1976) and Sharkey et al (1978) revealed
impressively high take rates using melanoma and colorectal
tumour samples. These figures have been confirmed by
numerous other authors.
The first report of successful growth of bronchial
carcinoma xenografts was by Greene (1952) who reported 13/13
positive takes using both the anterior chamber of the eye and
guinea pig brain as models. Primary tumour samples were used
in 3 cases, the remaining samples were obtained from secondary
deposits. However, no information was given in this study
regarding the number of transplants required from each
specimen to produce a successful take. Excellent results were
also reported by Shimosato et al (1976) and Sharkey et al
(1978), with bronchial carcinoma generally transplanting well
in the majority of model systems. Early reports showed high
take rates of both squamous and small cell carcinomas, with
little information on other histological categories. Shorthouse
(Ch.M. thesis 1981) reported on the results of 49 lung cancer
biopsy transplants, with a 1Q% success rate in establishment of
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xenograft lines. However, a large number of these specimens
were from metastatic deposits, with large cell and adeno¬
carcinoma specimens giving the highest take rates.
In contrast, other tumours have been more difficult to
establish. In breast carcinoma Povlsen and Rygaard (1976) were
unsuccessful with 5 transplants and Sharkey et al (1978)
achieved only 16? of positive takes from 87 specimens, with
serial transplantability in only 7%. Giovanella et al (1978)
were more successful with 67/127 (53%) positive takes, although
no information was given regarding the number of grafts from
each specimen showing progressive growth. However serial
transplantation was achieved in 6/8 tumour lines attempted, far
superior to results obtained by any other group.
Ovarian carcinoma has proven difficult to establish
(Povlsen and Rygaard 1976; Sharkey et al 1978) although
Kullander et al (1978) were more successful. Similar problems
have been encountered in attempting to establish lymphomas and
leukaemias (Povlsen and Rygaard 1974; Cobb 1974). Intracranial
inoculation has improved these results (Epstein et al 1974,
1976) and recently a carcinoid tumour has been established for
the first time in the anterior chamber of the eye (Nilsson et
al 1984).
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Despite the frequency of success with germ cell tumours,
seminoma has proven very difficult to establish. Raghavan et
al (1980) did report on the growth of a xenograft from a
patient thought to have a seminoma, although the xenograft was
shown to have germ cell features. There is no report on the
establishment of a pure seminoma xenograft at present.
In summary, a large number of xenografted tumours have
been established using various model systems. Take rates in
the hamster cheek pouch and anterior chamber of the eye have
been excellent but progressive growth is obviously limited and
serial passage difficult. Of the models allowing for progres¬
sive growth, nude mice and TAR (thymectomy, cytosine arab-
inoside pretreatment and total body irradiation) mice give
impressive take rates. Total body irradiation has been shown
to temporarily impair natural killer cell function (Hastings -
personal communication) with TAR mice giving marginally better
take rates than nude mice (Rostom et al 1978). However, a
significant number of these mice regain some or all of their
immunity 4-6 weeks after total body irradiation. Although
optimal for the establishment of many xenograft lines these TAR
mice may be be less than ideal for longer term chemotherapy
studies (Steel 1978). The establishment of some histological
subtypes remains difficult, although with the use of lasat and
beige nude mice these problems may well be overcome.
3.3 Factors Influencing the Successful Establishment of
Xenografts
Successful takes are more common in tumours with a rapid
doubling time, although it has to be stressed that this does
not necessarily relate directly to the differentiation of the
tumour. In fact, some non-transplantable tumours have been
poorly differentiated (Houghton and Taylor 1978). Biopsies
from metastatic deposits give higher take rates than primary
tumour specimens (Sharkey et al 1978) and this may account in
part for the very high take rate reported by Shorthouse (1981).
Steel (1978) reported increased take rates on tumours first
established in cell culture in agreement with other workers
(Fogh et al 1977).
The strain of mouse can affect the take rate (Hanna et al
1982 ) as can the sex, with increased take rate in female
animals (Pettengill et al 1980), both thought to be related to
immunological factors. The site of implantation of the tumour
fragment affected the take rate, with increased success
observed when specimens were transplanted anteriorly on the
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flank compared with posteriolateral implantation (Kyriazis and
Kyriazis 1980; Dipersio 1981; Auerbach and Auberbach 1982). The
enhanced growth observed with anterior implantation is thought
to be related to improved vascularisation and decreased
necrosis of the tumour. In addition, regional lymph node
metastases were more frequent with anterior implantation.
Similarly, Levy et al (1982) showed that the characteristics of
the MCF-7 mammary adenocarcinoma cell line varied according to
the site of inoculation.
In summary the tumour take rate is determined by a number
of factors which can be loosly grouped into tumour related and
host related. The tumour-related factors are the cell type,
whether it is a primary or metastatic tumour sample, and its
doubling time. Host-related factors consist of the strain of
animal used, method of immunosuppression and site of implant¬
ation of the tumour.
3.4 Growth Kinetics
The growth kinetics of tumours can affect their response
to cytotoxic drugs (Steel 1978). Cell proliferation in murine
tumour systems is more rapid than in human solid tumours, with
a significant difference in the duration of DNA synthesis
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(Steel 1977). This may make a difference in the response of
these tumours to certain anti-cancer drugs, particularly phase
specific agents.
Similar growth kinetics have been observed in human solid
tumours and in human xenografts. The labelling index in
gastrointestinal tumour xenografts (Schmidt et al 1977) has
been shown to be similar to previous reports on these neoplasms
in patients. However, despite the similarity in labelling
indices, tumour doubling times are significantly shorter in
xenografts. This may be related to a number of factors,
including decreased cell loss in xenografts (Lammerton and
Steel 1975). Xenografted tumours are generally smaller and
thus may have improved vascularisation in comparison with
primary tumours and this may be important in the relative
growth rates of these tumours. In addition, with successive
passaging of xenografts, the more rapidly proliferating clones
may be selected, which could alter their growth
characteristics.
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3.5 Maintenance of Human Characteristics
If human xenografts are to be used widely in the study of
human cancer, the characteristics of the original tumour have
to be maintained. This has been extensively studied by
numerous authors showing that this is indeed the case for a
number of parameters, as is shown in the following sections.
3.5a Histopathology
In all models, maintenance of the histopathological
features of the original human tumour are seen irrespective of
the number of passages undergone (Povlson and Rygaard 1971;
Houghton and Taylor 1978). However there is greater diversity
of opinion regarding changes in differentiation of xenografted
tumours. Sordat et al (1974) reported no change in different¬
iation of transplanted tumours, but many other authors have
reported either increased or loss of differentiation. Selby et
al (1979) showed loss of differentiation in a testicular
teratoma xenograft using immunoperoxidase staining for B-HCG.
Giovanella et al (1978) likewise oberved loss of different¬
iation in a melanoma xenograft, whereas Sharkey et al (1978)
showed increased differentiation in 25% of transplanted
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tumours. Shorthouse (1981) reported frequent loss of differ¬
entiation although increased differentiation was noted in 6% of
xenografted tumours.
3.5b Electron Microscopy
Similar electron microscopic features have been identified
in xenografts when compared with original tumours, including
the presence of keratin filaments and desmosomes in squamous
cell carcinoma, neurosecretory granules in small cell lung
cancer (Kameya et al 1977) and melanin granules and rnelano-
somes as described by Selby et al (1979) in melanoma.
3.5c Histocytochemistry
In general the histocytochemical features of the donor
tumour are maintained in xenografts. Houghton and Taylor
(1978) showed no change in the epithelial mucin pattern of
xenografts and Selby et al (1979) reported maintainance of
pigmentation in 80? of melanoma xenografts, although in 2 loss
of pigmentation occured with loss of differentiation of the
tumour. The latter finding was also reported by Shimosato et
al in (1976) and Giovanella et al (1978).
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3.5d Chromosomes
Many authors have shown that human karyotypes are main¬
tained in xenografted tissue. When working with human xeno¬
grafts it is important to establish frequently that the tumours
have a human karyotype as spontaneous murine tumours have been
known to arise in conjunction with xenograft tissue (Houghton
and Taylor 1978; Goldenberg and Pavia 1982; Staab et al 1983).
Maintenance of human characteristics has been shown by Whang-
Peng et al (1982) who described a cytogenetic abnormality in
small cell lung cancer, a 3 P deletion, which was shown to
persist following multiple passages in tissue culture. However,
chromosomal changes have been noted on passaging using banding
techniques (Reeves and Houghton 1978).
3.5e Functional activity
It has been shown that species specific isoenzymes such as
lactate dehydrogenase and glucose-6-phosphate dehydrogenase,
maintain human patterns in xenografts (Houghton and Taylor
1978). Similarly the key APUD enzyme, L-dopa decarboxylase, has
been demonstrated in both clinical specimens and in small cell
carcinoma cell lines (Carney et al 1983). However, aryl-
sulphatases have been shown to vary in transplanted tumours
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compared with surgical specimens, although this may be related
to alterations in the interstitial supportive tissue of these
xenografts (Gasa 1981).
Surface antigens such as carcinoembryonic antigen and
alphafoetoprotein which are associated with a variety of
tumours in man, have been shown to persist in human xenografts.
Carcinoembryonic antigen has been associated with colonic
carcinoma in particular for many years and was noted in
xenografts by Sordat et al in 1974. This finding has since
been confirmed by many authors, with Miwa et al (1977) showing
localisation of carcinoembryonic antigen by by immunocyto-
chemical techniques. Alphafoetoprotein has likewise been
detected in teratomas (Raghaven et al 1980) and hepatoma
xenografts (Hirohashi et al 1977) in nude mice. Similarly, in
1974 Mitchell et al induced myeloma in nude mice by the
injection of bone marrow cells from affected patients. The
characteristic immunoglobulin production of the original tumour
was maintained in these animals with overproduction of IgG and
IgA.
The growth of endocrine tissue in nude mide has proven
difficult, but where this has been achieved normal hormone
production has been maintained (Kameya et al 1977). Renal
carcinoma xenografts have been shown to secrete erythropietin
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by a number of workers including Tamaoki in 1977. Ectopic
hormone production, which is a feature of some human malignant
neoplasms, has also been detected in nude mice bearing these
tumours. Human chorionic gonadotrophin is often produced by
testicular germ cell tumours and Selby et al (1979) illustrated
the continued production of this hormone by immunohistochemical
techniques and radioimmunoassay over a number of passages in
xenografted mice. However, after 5 passages the production of
hormone decreased, and this was associated with progressive
loss of differentiation of the tumour.
Bronchial carcinomas are associated with a wide variety of
ectopic hormone producing syndromes. Biochemical evidence for
excessive production of these hormones is present in approxi¬
mately 25t of small cell carcinoma patients, although the
incidence of clinical syndromes is less than 10% (Greco 1981).
A large number of hormones are produced by lung tumours
including anti-diuretic hormone, adenocorticotrophic hormone,
melanocytic-stimulating hormone and calcitonin (Becker et al
1983). These have all been shown to persist in xenografts
(Kameya et al 1977; Shin et al 1977) and cell lines (Sorenson
et al 1982). Recently, other tumour markers have been observed
in small cell carcinomas, these include L-dopa decarboxylase
(Baylin et al 1980), bombesin (Sorenson et al 1982; Moody et
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al 1581, 1983), neuron-specific enolase (Marangos et al 1982)
and the BB isoenzyme of creatine kinase (Carney et al 1985).
These are relatively specific to this tumour type and have been
shown to persist in cell culture (Sorenson et al 1982).
Ectopic parathormone production has also been detected in lung
cancer patients but as yet has not been identified in xeno-
grafted animals, although hypercalcaemia has been observed
(Ohsawa et al 1977).
Of interest is the hormone-dependency of some tumours
which can be grown in immunosuppressed animals. Breast
carcinoma is the commonest of these and, likewise has been
shown to be hormone dependent in some xenograft models
(Hirohashi et al 1977; Levy et _al 1982).
3.6 Metastatic disease
Initial reports suggested metastatic disease was a rare
occurence in human tumour xenograft models (Giovanella et al
1972; Detre and Gazet 1973; Sharkey et al 1978). With the
passage of time, however, the number of reports of metastatic
disease in xenografted animals has steadily increased. A
number of important factors have come to light regarding this
phenomenon.
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The biology of the tumour cells implanted may well be
important. It has been shown that there is enhanced metastatic
potential in murine tumour cells obtained from metastatic sites
when compared with the primary tumour samples (Talmadge and
Fidler 1982; Poste et al 1982). A study reported by Kerbel et
al (1984) showed similar findings using a human melanoma cell
line transplanted into nude mice. In addition, it has become
apparent that xenografts derived from established cell lines
will frequently metastasise with systemic spread noted in both
thymectomised, irradiated mice and in nude mice (Giovanella
et al 1974; Franks et al 1975; Kier and Schroeder 1982). A new
osteosarcoma strain has emerged that has a high metastatic
potential (Kuroki 1984) and recently additional metastatic
models have been observed. Gazdar (personal communication) has
developed 2 metastatic models in nude mice, one a large cell
carcinoma of bronchus and the other a pulmonary adenocarcinoma.
Both tumours were originally established as cell lines, then
inoculated intra-peritoneally into nuce mice. The metastases
appeared in multiple sites, including kidney, liver, heart,
lungs and brain, similar to the pattern of distribution
expected clinically.
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Improved techniques of immunosuppression have also
increased the incidence of metastases. Regional invasion is
frequent in thymectomised, cytosine arabinoside pretreated,
irradiated mice (Steel et al 1978) although metastases are
more frequently seen with the use of neonatal nude mice (Sordat
et al 1977). Natural killer cell activity is virtually absent
in the neonatal animal, and this may well account for the
difference in metastatic potential. Variations in natural
killer cell activity may, likewise, explain strain dependent
differences in metastatic potential of nude mice although
others dispute this (Fodstad et al 1984). Reid et al (1981)
showed that treatment with mouse interferon decreased natural
killer cell activity allowing metastases to occur. The
injection of xenogeneic human T-lymphocytes into tumoui—bearing
nude mice has also been shown to increase the incidence of
metastases (Graham 1982), although the reason for this remains
undefined.
On a more practical basis, one also has to consider the
duration of survival of the host following transplantation, as
premature death may preclude the appearance of micrometastases
(Steel and Peckham 1980).
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3.7 Cachexia
The cause of cachexia in humans remains in doubt, although
abnormalities in glucose metabolism have been implicated.
Other authors have suggested alterations in lipid metabolism
involving "toxohormones" are related (Masuno et al 1981)
although this remains speculative.
Despite frequent, and often marked weight loss in patients
suffering from particular cancers, cachexia is rare in experi¬
mental animal models, even when the xenografts become very
large (Povlsen and Rygaard 1971; Giovanella et al 1974).
However, there are some reports of tumours causing weight loss,
such as the murine sarcoma MCG101 (Eden et al 1983) in addition
to human xenografts originating from a melanoma (Kondo et jal
1977), and a hyperneophroma (Strain et al 1980).
Cachexia could be caused by soluble human proteins, and
lack of cachexia in mice may not necessarily infer loss of
functional activity in xenografts, but may merely reflect lack
of species cross-reactivity to these substances. However, it
is likely that cachexia may be related to the production of
cachetin. Cachetin, or tumour necrosis factor (Beutler and
Cerami 1986), is produced by 'host' macrophages, with survival
of 'host' macrophages limited following transplantation. In
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addition, the immune reaction is different in these mice, with
their macrophages not stimulated t produce this 'hormone'.
3.8 Chemotherapeutic response in xenografts
It is now generally accepted that the chemotherapeutic
response in xenografts is similar to that of the tumour of
origin.
In 1974 Ziegler showed complete regression in a Burkitts
lymphoma xenograft treated with cyclophosphamide, similar to
the expected clinical response. Kopper and Steel (1975) and
Mitchley et al (1975) found similar correlation between
clinical and xenograft response using a variety of tumour
types.
However, it is known that there is variability in clinical
response of any particular histological type of tumour to
cytotoxic drugs. Similar variability was noted in xenografts
by Osieka et al (1977) and Nowak et al (1978).
Of even more interest, is whether the xenograft maintains
the same pattern of sensitivity, and therefore could predict
the chemotherapeutic response of the 'source' tumour. A number
of studies have addressed this problem, not without difficulty.
Burt et al (1966) showed similarity of response in a bladder
xenograft when compared with the donor patient, whereas other
55
authors have reported conflicting results. Hertz (1967) found
poor correlation in methotrexate sensitivity comparing the
response of choriocarcinoma in the patient and the xenograft
growing in the hamster cheek pouch. However it should be
emphasised that a relatively high dose of methotrexate was
used in the animal, which was inappropriately sensitive,
although this explanation does not account for the poor
correlation for vinblastine sensitivity. This study, (Hertz,
1967), was far from ideal, however, as all patients had been
treated before xenograft material was obtained, and the
chemosensitivity tests were carried out after multiple tumour
passages.
Berenbaum et al (1974) experienced great difficulty in
establishing tumours using mice prepared by thymectomy,
irradiation and with anti-lymphocyte serum. Chemosensitivity
tests were performed in only 4/104 tumours using histological
damage as the end-point of assessment. Variable growth was
obtained in these xenografts however, and therefore quantit¬
ation of the results was impossible. No direct patient-
xenograft comparisons were achieved. However, in 1977
Giovanella et al reported good correlation with clinical
response using breast carcinoma xenografts growing in nude
mice with growth delay used as the end point of assessment.
Similar to Hertz (1967) xenografts were shown to be marginally
more sensitive. Hayashi et al (1978) and Nowak et al (1978),
using choriocarcinoma and colorectal xenografts respectively,
have likewise claimed good correlation with clinical response.
Shorthouse (1980) reporting an excellent study, showed
good correlation of response in 14 lung cancer xenografts when
compared with clinical response in the respective donors. Five
small cell carcinoma xenografts were established from previ¬
ously untreated patients, all of whom had achieved complete
remissions. All 5 xenografts completely regressed with
identical therapy.
One other patient with small cell carcinoma had been
treated prior to the establishment of the xenograft. This
patient did not respond clinically and the xenograft was
likewise resistant to chemotherapy. In the 8 non-small cell
carcinomas, the poor patient reponse correlated very well with
minimal response in the xenograft.
3.9 Conclusions
In general, human xenografts growing in immunosuppressed
animal hosts retain human tumour cell characteristics.
However, they do have shorter doubling times with a tendency to
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lose differentiation over successive passages. The majority of
cell types can now be successfully established as xenografts
with these xenografts exhibiting a similar chemotherapeutic
profile to the original tumours. Many human characteristics
are maintained, including histological, electron microscopic
and histochemical features. Functional activity is maintained
and patterns of growth, including metastatic spread, have now
been shown to be similar. Therefore human xenografts offer an
excellent _in vivo model for the study of the biology and
biochemistry of human tumours.
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CHAPTER 4
ASSESSMENT OF CHEMOTHERAPEUTIC RESPONSE IN XENOGRAFTS
4.1 Introduction
There have been prolonged debates regarding the validity
of some xenograft models. One of the major problems relates to
the end-point of assessment of response where the following
methods can be used:
(1) Histopathological assesment
(2) Clonogenic cell survival assays
(a) following in vivo drug treatment
(b) following i_n vitro drug treatment
(3) Tumour regression rate
(4) Specific growth delay
4.2 Histopathological Assessment
This was first attempted by Berenbaum et al in 1974. He
encountered many problems as great variability in growth was
noted during the initial man to mouse passage. Of 44 tumours
tested, only 3 showed extensive histological damage after
treatment. Kyriazis et al (1983) carried out a similar
pathological study but divided responses into mild, moderate
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and severe. He showed good correlation between response
determined by growth delay and pathological damage. He claimed
that histopathological assessments were superior to tumour
regression analysis as an indicator of chemosensitivity
particularly when significant necrosis was present in the
tumour.
4.3 Clonogenic Cell Survival Analysis
Variability in host defence mechanisms could have a
significant impact on chemotherapeutic response, particularly
with long term experiments. Thymectomised, irradiated mice
specifically, may regain some immunity 4-6 weeks after
irradiation, with an increase in particular in natural killer
cell activity (Hastings - personal communication). The problem
of returning immunity can be avoided with the use of clonogenic
assays (Courtenay and Mills 1978) to measure response following
in vivo or i_n vitro drug exposure.
4.3a Clonogenic Survival Following In Vivo Treatment
Tumour bearing animals are treated i_n vivo and the tumour
resected 18-24 hours later, allowing full chemotherapeutic
effect. Single cell suspensions are made from the excised
tumour and incubated in soft agar using previously described
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techniques. The proportion of tumour cells producing colonies
from drug treated animals (plating efficiency) is compared with
the plating efficiency from untreated control tumours. The
surviving fraction of treated tumour cells is derived from the
ratio of the respective plating efficiencies (Courtenay and
Mills 1978).
4.3b In Vitro Treatment
Tumours are excised and a single cell suspension obtained.
The cells are then exposed to the drug(s) _in vitro for a
specific period, then plated out and incubated in soft agar.
Bateman et al (1979) reported good correlation between this
method and xenograft growth delay in pancreatic carcinoma.
4.4 Xenograft Regression Rate
The rate of regression of a xenograft can be used as a
assessment of chemotherapeutic response. This has been shown
to be effective clinically in small cell carcinoma (Lenhard et
al 1983) with regression in the first 28 days correlating well
with survival. However, in xenografts regression rate is used
less frequently than growth delay, although it may give
important information in exquisitely sensitive tumours.
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Kyriazis et al (1983) suggested that regression rates should
always be calculated concurrently with histopathological
assessment.
4.5 Specific Growth Delay
This is the parameter most often used in the assessment of
chemosensitivity in xenografts, and the one with which all new
methods of response evaluation must be compared. It is derived
from the tumour doubling (Tp) times of control and treated
xenografts by the following formula:-
Td (treated) - T[) (control) (Kopper 1975)
Specific Growth Delay =
T[) (control)
It is expressed in units of tumour doubling time, with
the most sensitive tumours obviously having the highest value.
This is the most reliable method of assessing chemothera-
peutic response at present, although there can be problems with
its interpretation. Difficulties arise with tumours that
regress completely and with experimental deaths prior to
doubling of tumour volume. Estimation of tumour volume can
also be problematical in view of the error involved in external
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measurement, particularly in small tumours and cavitating
tumours. Despite these problems, good correlation is found
between xenograft growth delay and clinical response
(Shorthouse 1981).
4.6 Conclusion
There are a number of methods by which xenograft response
can be measured. Survival would be the optimal parameter, but
this is highly variable in human tumour models. Growth delay
is, therefore, generally considered the optimal method for
assessment of chemotherapeutic response.
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CHAPTER 5
MODULATION OF CANCER CHEMOTHERAPY
5.1 Introduction
Chemotherapy has been used to treat all types of human
solid tumours with a variable degree of success. Apart from a
few notable exceptions such as testicular teratoma, cure has
remained remarkably elusive, with the narrow therapeutic index
of the presently available cytotoxic drugs a major problem.
The overall effect of chemotherapy remains a delicate balance
between anti-tumour activity and toxicity. A number of factors
may affect the response of tumours to cytotoxic drugs thereby
causing drug resistance, and these can be categorised generally
as host or tumour related:
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5.2 Host Related Resistance Factors
5.2a Host Toxicity
The total dosage of chemotherapy administered to a patient
is often attenuated by drug-related toxicity, particularly to
the bone marrow. Variation in administered drug dosage could
obviously affect the patients' clinical response.
5.2b Variations in Detoxication Systems
The majority of anti-cancer drugs are metabolised as
foreign compounds mainly in the liver, and in the process may
be activated or deactivated. There are a number of
detoxication pathways for the handling of xenobiotics of which
the following are the most relevant to cancer chemotherapy:
(i ) Cytochrome P-450 system
This consists of a heterogenous group of enzymes with
variable substrate specificity, essential in the metabolism of
a wide range of xenobiotics.
(ii) Superoxide Dismutases
Anthracyclines have been associated with the production of
several toxic species, including hydrogen peroxide, hydroxyl
radicals and superoxide radicals (Sies et al 1983). Superoxide
dismutases are involved in the detoxication of superoxide
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radicals to form oxygen and hydrogen peroxide (Wafers and Sies
1983) which can then result in the production of hydroxyl
radicals via Fenton-like reactions. Superoxide dismutases,
catalase and glutathione peroxidase are involved in the
detoxication of these species.
(iii) Glucuronidation
This represents one of the major conjugation reactions
involved in the metabolic conversion of xenobiotics to polar
water soluble metabolites, although glucuronidation may be less
important than the glutathione redox system in the handling of
cytotoxins (see below).
(iv) Glutathione Redox System
This system will be dealt with more comprehensively
because of its importance in the prevention of alkylating agent
toxicity and in view of the experimental data presented later
in this text.
Glutathione is a tripeptide with the amino-acid sequence
of y-glu-cys-gly. Glutathione can either bind directly with
electrophilic compounds to form glutathione conjugates or can
be oxidised at the thiol group of the cysteine residue to form
a disulphide, often denoted as GSSG. Glutathione is a major
constituent of all cells and is normally the predominant
non-protein thiol present. Thiols are in general very reactive
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towards free radicals and are potentially very important in the
prevention of oxidative damage by superoxide and hydroxyl
radicals (Sies et al 1983).
Glutathione and glutathione-dependent enzymes such as
glutathione peroxidase and the glutathione transferases, have
been shown to participate in a large number of intracellular
reactions involving the detoxication of drugs, carcinogens and
their metabolites (Arias 1976; Meister 1981; Larsson 1984).
Various toxins have been shown to deplete intracellular
glutathione (Mitchell et al 1982) and glutathione transferase
levels (Pi Simplicio 1982) in the liver.
The glutathione transferases are a group of multi¬
functional isoenzymes involved in detoxication, with the
capacity to bind an enormous number of hydrophobic compounds
(Jakoby 1978). They are, in addition catalysts, for a wide
variety of reactions involving glutathione, and may also
directly act as scavengers by covalently binding alkylating
radicals.
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5.3 Tumour Related Resistance Factors
5.3a Elevated Enzyme Levels
These can be particularly important in resistance to
anti-metabolites. A good example is methotrexate, where high
levels of dihydrofolate reductase can negate the effects of the
drug. However, many other mechanisms are also important, such
as impairment of polyglutamation.
5.3b Alteration of Membrane Structure
The presence of a 170 kilodalton glycoportein (P-glyco-
protein), first described by Juliano and Ling (1976), has been
shown to be associated with multi-drug resistance. It would
appear to be particularly important in resistance to natural
products such as adriamycin and the vinca alkaloids. This
resistance is partly explained by enhanced drug efflux,
resulting in diminished drug accumulation particularly in the
nucleus of resistant cells.
5.3c Kinetic Variations
Tumours with a low growth fraction are generally
considered to be more resistant to chemotherapy, as many drugs
are cell cycle or phase specific.
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5«4 Approaches to Manipulate Chemotherapy
With greater knowledge of the biochemical effects and
pharmacokinetics of anti-cancer drugs, numerous attempts have
been made to improve their therapeutic index. Arbitrarily, an
improved therapeutic index can be achieved by either increasing
the anti-tumour activity, or by protecting normal tissues from
toxicity.
5.Ma Methods of Increasing Anti-Tumour Activity
Cytotoxic drugs can only be effective if they gain access
to the neoplastic cells. Attempts have been made to improve
drug uptake of neoplastic cells, by combining drugs with agents
that are actively transported into cells. For instance,
melphalan, a widely used alkylating agent, consists of nitrogen
mustard attached to the amino-acid phenylalanine which is
thought to promote incorporation of the drug into the cell by
an active transport mechanism (Vistica et al 1977).
The pharmacokinetics of a drug are obviously affected by
the route of administration. Variations in drug delivery can
cause changes both in anti-tumour activity and in host
toxicity. As an example of this, Evans et al in 1984, showed
that higher doses of cyclophosphamide were tolerated by mice,
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with no loss of anti-tumour activity when the cyclophosphamide
was administered in divided doses in comparison to a single
intra-peritoneal dose.
Many variations in drug administration have been attempted
in order to increase the anti-tumour effect of cytotoxic drugs.
These variations are listed below and discussed individually:
i) timing of drug administration - circadian rhythm
ii) combination with calcium channel blockers
iii) combination with glucocorticoids
iv) combination with electron-affinic radiosensitisers
v) combination with buthionine sulfoximine
vi) combination with biological response modifiers
vii) combination chemotherapy
viii) combined modality therapy
i) Timing of Drug Administration
The timing of administration of cytotoxic drugs may be
important, as their metabolism appears to be affected by a
circadian rhythm. This has been shown with methotrexate,
(English et al 1982) cis-platinum, (Hrushesky et al 1982) and
melphalan (Simpson and Stoney 1977). Both methotrexate and
cis-platinum give maximal toxicity at 0600 hours with minimal
toxicity at midnight, whereas melphalan toxicity was greatest
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at 16.00 hours. However, a recent study by Focan (1979)
stressed that far more tumour cells are in cycle in the early
morning, and that approximately 30? more anti-tumour activity
is found with the use of S-phase specific agents at this time.
Therefore, although interesting, it remains debatable whether
circadian rhythm differences can be utilised for any signif¬
icant clinical benefit.
(ii) Combination with Calcium Channel Blockers
The vinca alkaloids, vincristine, vinblastine and
vindesine are all known to interfere with calcium transport
(Gietzen et al 1980). Tsuruo et al in 1981 first reported
enhanced cytotoxicity both jji vivo and _in vitro with vinca
alkaloids when combined with the calcium channel blocker
verapamil. Tsuruo et al (May 1983) later reported that
verapamil increased the cellular level of vincristine by
blocking drug efflux particularly in resistant cell lines.
He later showed (Tsuruo et al June 1983), that resistance to
vinca alkaloids, or adriamycin which is often found to be
cross-resistant, could be reduced with the use of calcium
influx blockers.
However, a recent report by Rabkin et al (1983) pointed
out that increased mortality could also occur through enhanced
adriamycin cardiotoxicity when combined with verapamil.
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Although there may be a place for the use of calcium channel
blockers, particularly in the treatment of in tumours that have
become resistant to multiple drugs, (Riordan and Ling 1985)a
more detailed assessment of the toxicities associated with
these combinations is warranted.
(iii) Combination with Glucocorticoids
Corticosteroids are active drugs in the treatment of
lymphoid malignancies. In addition, glucocorticoid hormones
have been shown to have significant effects on cytotoxic drug
action. Prednisolone has been shown to enhance the anti-tumour
activity of mustine, chlorambucil, melphalan and cyclophos¬
phamide, with suppression of gastrointestinal toxicity in
combination with the first two agents (Shepherd and Harrap
1982). Similar enhancement of activity has been observed with
combinations of corticosteroids and platinum analogues (Goddard
et al 1982). Prednimustine is a commercially available
combination of chlorambucil and prednisolone which is presently
undergoing clinical trial. However, in view of the mode of
action of this combination, it is possible that scheduling may
significantly affect the synergistic action.
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(iv) Combination with Electron-Affinlc Radiosensitisers
Nitroimidazoles such as misonidazole have been shown to
increase the sensitivity of cells in vitro to the lethal
effects of radiation, heat and many alkylating agents used in
current cancer chemotherapy. Misonidazole has also been
shown to be cytotoxic to hypoxic cells (Varnes et al 1980).
Rose (1980) using the Lewis lung carcinoma model, showed
improvement in the therapeutic index with an i_n vivo combin¬
ation of misonidazole and melphalan. Enhanced activity has
likewise been confirmed with combinations of misonidazole and
other cytotoxic drugs as reported by many authors, including
Sutherland et al (1980), using adriamycin in multicellular
spheroids, and Stratford et al (1980) using cis-platinum.
The mechanisms of chemosensitisation by misonidazole have
not been fully elucidated. Taylor et al (1982) showed that
misonidazole both depleted intracellular glutathione and also
exhibited enhanced cytotoxicity on glutathione depleted cells.
However, using a glutathione depletor diethyl maleate, it was
shown that glutathione depletion was not the only mechanism of
action of misonidazole. It has been shown to enhance binding
of cytotoxic drugs, increase DNA strand breaks and cross links,
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in addition to altering the pharmacokinetics of some drugs
(Tannock 1980). In general, misonidazole interacts best with
bifunctional alkylating agents and nitrosoureas (McNally 1982).
Increased toxicity to the bone marrow and gut were also
observed with combinations of misonidazole and cytotoxic drugs,
requiring dosage modification of the latter (Rose 1980).
However, there is normally a therapeutic gain with large doses
of misonidazole, although it is ineffective at lower doses in
mice (Rose 1980). Unfortunately, in man neurotoxicity is dose
limiting, and it seems unlikely that sufficiently high serum
levels will be achievable clinically (Brown 1984). Other
radiosensitisers of the nitroimidazole class are still under
investigation (Guichard and Malaise 1982; Adams et al 1984)
which may not have dose-limiting neurotoxicity. This subject
was recently excellently reviewed by Brown (1985).
(v) Combination with Buthionine Sulfoximine
Buthionine sulfoximine is one of a group of drugs that
deplete intracellular glutathione (Griffith 1982). It is a
competitive inhibitor of Y glutamyl-cysteine synthetase and has
no other documented primary effects on the cell (Griffith and
Meister 1979). It has been shown that buthionine sulfoximine
will deplete glutathione in many cell lines, and when used in
combination with radiation, heat or a number of cytotoxic drugs
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will enhance cell kill (Roizin-Towle et al 1984; Mitchell and
Russo 1983; Russo et al 1984; Russo and Mitchell 1985).
Hamilton (personal communication) showed that buthionine
sulfoximine treatment enhances the cytotoxic activity of
melphalan _in vivo, observing a similar anti-tumour effect with
5 mg melphalan in combination with buthionine sulfoximine to
that normally achievable with 10 mg melphalan alone. No
enhancement of toxicity was observed with the melphalan and
buthionine sulfoximine combination in bone marrow cultures.
Likewise, Russo et al (1986) has shown no enhancement of
haematological toxicity either to the CFU-s population or the
peripheral white cell count with the combination of buthionine
sulfoximine and melphalan. SR 2508, a radiosensitiser under
investigation at present, has been shown to be glutathione-
dependent, with a 3~fold increase in radiosensitivity when used
in combination with buthionine sulfoximine (Mitchell et al
1986).
Further studies with buthionine sulfoximine would seem
indicated at this stage, to assess its potential to enhance the
effects of radiation therapy and chemotherapy.
(vi) Combination with Biological Response Modifiers
A wide range of compounds have been used as biological
response modifiers, but the most significant recent develop¬
ments have been the production of large quantities of human
interferons and interleukins, which now can be used either
singly or in combination with cytotoxic drugs.
Interferons consist of a family of proteins having
anti-viral, anti-polyreactive and immunomodulatory activities.
Using recombinant DNA technology it has been possible to purify
these in large quantities. Although human recombinant subtypes
have maintained species specificity, some constructed hybrid
proteins have gained the ability to cross-react with other
species (Brunda and Rosenbaum 1984).
Interferons have many actions, including a direct inhib¬
ition of cell multiplication, modulation of the host immune
system (Billiau 1981; Spina et al 1983) and alteration of cell
surface antigens such as 6 microglobulin in small cell lung
cancer (Funa et al 1986). Various interferons have been
assessed using human xenografts as a model. Human fibroblast
interferon has been shown to suppress the growth of human
gliomas, melanomas and one lung cancer line when injected
directly into the tumour, but no effect was seen with more
distal injections (Ida et al 1982). Human leukocyte interferon
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was shown to inhibit the growth of a human osteosarcoma
xenograft in nude mice when injected intraperitoneally, 50,000
IU daily (Masuda et al 1983) and similarly, human lympho-
blastoid interferon has been shown to inhibit the growth of
human breast tumours in nude mice (Balkwill et al 1982).
In patients the results have been less successful,
although there are some reports of activity in hairy cell
leukaemia, nodular lymphoma, mycosis fungoides, breast cancer
and melanoma (Quesada et al 1984). Stoopler et al (1980) found
no activity in non-small cell lung cancer, and a similar result
was reported by Jones et al (1983) using human lymphoblastoid
interferon in small cell lung cancer. In addition to the
disappointing clinical results, treatment was highly toxic,
with anorexia, nausea and flu-like symptoms frequent.
More recently, attention has turned to the combination of
human interferons with cytotoxic drugs. Inoue and Tan (1983)
reported enhancement of actinomycin D and cis-platinum effects
by human g-interferon and Balkwill and Moodie (1984) recently
described potentiation of the cytotoxicity of sublethal doses
of cyclophosphamide and adriamycin on human breast cancer
xenografts using human lymphoblastoid interferon. In
Balkwill's study mice were treated with 200,000 IU interferon
daily which equilibrates to 20 x 10^ u/m2 daily in man using
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the calculations of Freireich et al (1966). This dosage is
likely to be unacceptable to many patients, and further
assessment is required of a more realistic schedule.
There is evidence that interferon may interfere with species
specific drug metabolising enzymes (Singh et al 1982; Balkwill
et al 1984), which will have to be taken into consideration in
the construction of any clinical phase II studies using human
interferons in combination with cytotoxic drugs. Decreased drug
metabolising activity has been observed in tumour bearing
animals (Kato et al 1982), and it would be of interest to
assess the effect of interferon on this parameter, as altered
drug metabolism could obviously influence the activity of a
number of cytotoxic drugs.
(vii) Combination Chemotherapy
Very few human tumours are controlled with single agent
chemotherapy and with the widespread use of drug combinations
there are numerous ways in which interactions, both synergistic
and antagonistic, can occur. For example, if drugs are
administered simultaneously there may be competition both for
protein binding sites and drug metabolising pathways. For
instance, misonidazole has been shown to alter the pharmaco¬
kinetics of nitrosoureas, alkylating agents (Tannock 1980),
and 5-flurouracil (McDermott et al 1983), thereby increasing
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the activity of these drugs. However, interactions can be
antagonistic as reported by Tattersall et al (1973) using
methotrexate and 5-fluorouracil both in vitro and _in vivo.
It is known that the activity of a number of anti-cancer
drugs can be affected by the phase distribution of cells in
cycle. As several drugs have been shown to alter the phase
distribution of cells as shown by continuous-flow eyto-
photometry (Revazova et al 1981; Yokomori et al 1983), there is
potential for enhancing cytotoxicity of some drug combinations
by scheduling techniques. This has been successful in cell
culture with increased vincristine sensitivity following
partial synchronisation with hydroxyurea (Mujagic et al 1983).
Clinically, drug scheduling has likewise been shown to be
effective with enhanced activity of vinblastine and cyclophos¬
phamide following methotrexate and 5-fluorouracil (Focan
1979). However, although studies have shown beneficial effects
of drug scheduling, the precise role for this modification of
treatment remains unclear.
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(viii) Combination of Modalities
Combined modality treatment offers significant advantages
over combination chemotherapy in that the dose-limiting
toxicities of different modalities often vary, with modific¬
ation of treatment doses minimal. However, assessment of the
value of these combinations remains preliminary.
(a) Surgery and Chemotherapy
In ovarian carcinoma surgical debulking in the ptreatment
of stage III disease prior to chemotherapy has been shown to be
beneficial. However the precise role of the combination of
these modalities in lung cancer remains unclear although a
combination of surgery and chemotherapy is occasionally used in
patients found at thoracotomy to have small cell carcinoma.
(b) Radiotherapy and Chemotherapy
The combination of radiotherapy and chemotherapy can
potentially improve treatment in a number of ways. Combination
of these modalities tends to improve long-term survival rates
although toxicity is increased (Salazar and Creech 1980). They
are mutually supportive, in that chemotherapy is useful in
treating disseminated disease but is often inadequate with
bulky local disease in contrast to radiotherapy. In addition,
enhancement of therapeutic effect can be stimulated in a number
of ways (Steel and Peckham 1979):-
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(1) modification of radiation damage
(2) inhibition of DNA repair
(3) cell synchronisation
(*4) re-oxygenation following chemotherapy
(5) improved drug access following radiotherapy
(6) tumour shrinkage by radiotherapy leading to increased cell
proliferation
(7) tumour shrinkage by chemotherapy leading to smaller field
sizes, allowing an increase in the maximum radiation dose
to the tumour.
5. *Jb Protection of Normal Tissues
The protective mechanisms can be divided into 2 main
groups; exogenously administered agents and endogenous
protective compounds:
(i) Exogenous Protection
(a) Mesna - sodium 2-mercaptoethane sulphate
Following an intravenous injection, mesna is oxidised to
an inactive disulphide, and is subsequently regenerated in the
kidney, and accumulates in the bladder. In its original form,
mesna binds electrophilic reactive molecules including
acrolein, a toxic product of cyclophosphamide and ifosfamide
metabolism. The deactivation of acrolein prevents haemorrhagic
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cystitis which can be dose-limiting. Mesna has also been shown
to protect against cis-platinum related GI toxicity (Allan et
al 1986). Of importance, it was shown that mesna did not
affect the anti-tumour activity of cis-platinum using mouse
L1210 leukaemia as a model (Allan et al 1986).
(b) WR-2721 - S-2(3~aminopropylamino) ethylphosphorothioic acid
Thiol groups have been shown for years to decrease the
toxicity of alkylating agents, however therapeutic gain is only
achieved if there is a differential response between host and
tumour tissues. WR-2721 is reported to enter normal tissues by
facilitated diffusion and tumour cells by passive diffusion,
with intracellular reduction to the active sulphydryl compound
(Yuhas 1980). This mechanism is disputed by Millar et al
(1982), although a differential effect between normal and
tumour tissue was noted using mesna in combination with
melphalan against melanoma xenografts. Millar proposed
vascularity as the main cause of the differential effect.
Yuhas (1980) confirmed the differential protective effect in
vivo using a combination of WR-2721 and cis-platinum.
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(c) Sodium diethyldithiocarbamate
This thiol has been shown to protect rats from
cis-platinum renal toxicity. Renal function is preferentially
protected, but there is also a significant decrease in
gastrointestinal toxicity (Elliot et al 1983).
(d) Folinic acid
Methotrexate acts by inhibiting the enzyme dihydrofolate
reductase, thereby preventing the production of the cofactor
tetrahydrofolate which is essential in nucleic acid synthesis.
Methotrexate toxicity is affected both by the dosage
administered and the duration of infusion. Large doses of
methotrexate can now be given as tetrahydrofolinic acid can be




It is widely accepted that enzyme induction can occur in
the liver. This has frequently been shown with the cyto¬
chrome P-450 system and with enzymes involved in conjugation.
The cytochrome P-450 system can be induced _in vivo with
phenobarbital or 3-methylcholanthrene. However, effect of
enzyme induction can be variable as metabolism of drugs via the
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cytochrome P-450 system can result in activation of some agents
and deactivation of others. Alternatively acrolein, a toxic
metabolite of cyclophosphamide, has been shown to deplete
cytochrome P-450 levels. As cyclophosphamide requires micro¬
somal activation, acrolein could theoretically impair cyclo¬
phosphamide activity.
(b) Priming phenomenon
It is now well established that normal tissue toxicity of
alkylating agents can be attenuated by the prior administration
of a low dose of an alkylating agent (Millar et al 1976; 1978;
1980; 1981), allowing approximately 50$ more drug to be
administered.
This is not a new concept. In 1958 Smith showed that
administration of a stathmokinetic agent, a colchicine
derivative, protected against the lethal effects of
x-irradiation given 48 hours later. He later reported on the
protection afforded by vinblastine and vincristine on survival
and haematopoiesis in irradiated mice (Smith and Wilson 1967).
In 1968 Jeney and Connors reported decreased toxicity of
merophan after pre-treatment with sub-toxic doses of the same
compound. Millar and McElwain (1978) reported on a number of
combinations of cytotoxic drugs with less than expected
toxicity on normal tissues. They showed that cyclophosphamide
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could protect against the lethal effects of busulphan or
x-irradiation when given at different times prior to the
administration of these toxic agents. This protective,
'priming', effect has been observed in the bone marrow, gut and
urothelium (Millar and McElwain 1978). Haematopoetic stem
cells have been shown to recover more rapidly in the pre-
treated animals (Millar and McElwain 1978). The underlying
mechanism of 'priming' remains unclear however, and although
different tissues can be 'primed', the optimal time between
priming and challenging with toxic doses for each tissue varies
(Phelps and Blackett 1979). Particularly interesting is the
fact that no experimental tumours have shown a priming effect,
and, therefore, a therapeutic gain is possible. Priming doses
of cyclophosphamide have been used clinically prior to high
dose chemotherapy with cyclophosphamide or melphalan, with or
without autologous bone marrow transplantation.
In summary, there are a number of ways in which we can
potentially increase the therapeutic activity of the presently
available anti cancer drugs. Although some of these methods
are employed clinically at present, the majority require
further evaluation, particularly with respect to their
influence on anti-tumour activity.
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SECTION 2 - METHODS
CHAPTER 6
MATERIALS AND METHODS - Human Tumour Xenograft Studies
6.1 Introduction
The main aim in this study was to establish a variety of
human lung cancer xenografts in an immunodeficient animal
model. As it was important to carry out chemosensitivity tests
on these xenografts, the choice of animal model was limited to
those allowing progressive tumour growth. Animals suppressed
by chemotherapeutic drugs were not used, in view of the
potential problems relating to chemotherapeutic cross-
resistance. The choice, therefore, lay between nude mice and
the immune-deprived TAR (thymectomy, cytosine arabinoside
treated, irradiated) mice, (see Table 6.1). As specific
pathogen free facilities were not available in the animal unit
at that time, TAR mice were used. Tumour explants were
implanted subcutaneously into the flanks, and thereafter
passaged at regular intervals. Chemotherapeutic responses in
xenografts were assessed in vivo using growth delay as the
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end-point. Histopathology was carried out on each tumour line
at each passage with chromosomal analysis carried out following
a minimum of 5 passages.
6.2 Source of Tumour Samples
Tumour material was obtained from two main sources.
Patients from the Northern General Hospital with suspected
bronchial carcinoma who were undergoing rigid bronchoscopy and
biopsy for diagnostic purposes comprised one group, and the
other consisted of patients at the City Hosptial who were
having surgical resections of previously diagnosed lesions. All
specimens apart from one were obtained from these sources, with
the last specimen obtained from a patient at the Western
General Hospital. This was a skin nodule biopsy from a patient
with recurrent small cell carcinoma of the lung, who was
admitted for further chemotherapy.
The vast majority of specimens were therefore obtained
from primary tumours. Surgical resection specimens were
collected by the author directly from the operating theatre.
Resected specimens were immediately stored on ice and then
taken to the University Pathology Department. With a minimum
of delay, sections of tumour tissue were taken for transplant¬
ation preferably from relatively non-necrotic areas, with a
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biopsy from adjacent tissue for histological confirmation of
malignancy. The xenograft specimen was immediately placed in
Roswell Park Memorial Institute (RPMI) medium with added
penicillin and streptomycin, and kept on ice. The second
specimen was fixed in formal saline prior to histological
staining. Bronchoscopy specimens were obtained directly from
theatre and immediately divided in two parts, one being placed
in RPMI medium as above and kept at 4°C, with the other half
being fixed in formal saline for histology.
Specimens were transported by taxi where necessary
assuring a minimal delay prior to implantation. The majority
of samples were implanted within 4 hours.
6.3 Preparations of Biopsy Specimens
Specimens were prepared for implantation in the animal
unit using sterile techniques under a laminar flow hood.
Biopsy material was placed in a sterile Petri dish, in cold
RPMI medium. As far as possible, all non-tumour and necrotic
material was removed, and the remaining apparently viable
tumour was dissected using cross-scalpels into approximately
8 mm3 cubes ready for implantation.
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6. i) Preparation of Immune-Deprived Animals
Both male and female CBA/lac mice were used during this
study. They were obtained from the University Animal Unit,
George Square for the first 6 months of the study, but
thereafter were supplied from a breeding colony at the Western
General Hospital Animal Unit.
Thymectomy was carried out on newly weaned mice 21-28 days
old, by the method described by Shorthouse (1981 ChM thesis) as
shown in Table 6.1. Animals were anaesthetised using ether
(May & Baker) for approximately 45 seconds. They were then
laid in the supine position with each limb stretched by means
of a bulldog clip and elastic band, and secured with a pin
into cork matting. The neck was extended by means of a paper
clip and elastic band which was likewise attached to the cork
mat, with a cotton wool bolster placed between the scapulae.
The skin was cleaned with methylated spirit, and a 1 cm
vertical incision was made in the skin of the neck exposing the
strap muscles of the neck. A midline line incision was then
made in the upper sternum and the strap muscles divided by
blunt dissection, thereby allowing access to the thoracic
cavity. Both lobes of the thymus were then aspirated using
suction apparatus, the salivary glands apposed and the skin
closed by means of a surgical clip. The procedure lasted
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CBA mice (3 - 4 weeks of age)
1) Neonatal thymectomy
I
3 - 6 weeks
1




3) Total body irradiation 735 cGy (x-ray 250 kV source)
4) Prophylactic antibiotics for 14 days after irradiation
5) Tumour transplantation days 1 - 8 or days 15-22 after
irradiation
Table 6.1 Preparation of immune-deprived animals for xenograft
studies
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approximately 90 seconds enabling 100 thymectomies to be
completed at one session. Animals recovered within 2 minutes
of the procedure with acute deaths accounting for approximately
5% of animals.
All immune-deprived animals were caged in a separate room
and kept in a controlled environment with 12 hours light. They
were given acidified water ad libitum to minimise the
possibility of pseudomonas infection. Between 3-6 weeks
following thymectomy animals were prepared for whole body
irradiation. They were given a 'priming' dose of cytosine
arabinoside (200 mg/kg) intraperitoneally 48 hours before
irradiation, a procedure that has previously been shown to
protect both the gastrointestinal tract and bone marrow from
the lethal effects of radiation (Millar et al 1978).
X-irradiation was administered via a 250 KV, 15 mA source,
using a Thaurus filter giving approximately 37 rads/minute.
Mice were held in perspex chambers 30 cm from the x-ray source
and were given 735 rads ± 5% total body irradiation. Allowing
for the dose modification factor for x-rays, this corresponds
well with the 900 rads given by Shorthouse (1981), using a 60co
source.
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Following irradiation, animals were commenced on anti¬
biotic therapy of neomycin and terramycin administered in the
drinking water for 14 days. This was to prevent septicaemia
from commensal gut flora. Irradiation was tolerated well by
the animals with few deaths, although transient diarrhoea was
noted 7-10 days after treatment. Acute deaths within 28 days
of thymectomy resulted in the loss of approximately 10% of
animals.
6.5 Tumour Implantation
Implantation of tumour fragments was carried out either in
the first 7 days after irradiation or between 14-28 days
following this procedure. Implantation between 7-14 days after
irradiation resulted in increased mortality. For all of the
chemotherapy studies, tumours were implanted the day following
irradiation.
For tumour implantation animals were anaesthetised in
ether then laid on their ventral surface. The skin was cleaned
with methylated spirit and a 1 cm horizontal incision made in
the mid-dorsal region. Using blunt forceps subcutaneous tracks
were fashioned up the anterolateral aspect of the flanks and
8 mm3 tumour fragments were implanted at this site. The skin
was closed using a surgical clip, and the mouse identified
using numbered ear tags 1-3,000 (Hauptner).
As stated previously the animals were housed in a room
designated for the sole use of immune-deprived animals. As
described by Shorthouse (1981), specific pathogen free
facilities were deemed unnecessary.
6.6 Tumour Passage
Following progressive growth of tumour xenografts to
greater than 1 cm mean diameter, they were then suitable for
transplantation to a subsequent generation. The host animals
were sacrificed by cervical dislocation and the tumour(s)
removed aseptically. These were then dissected, removing all
necrotic material, and 8 mm3 fragments produced using a
cross-scalpel technique. These fragments were kept in ice-cold
RPMI medium prior to subsequent implantation into freshly
prepared immune-deprived animals. Sections of untreated
tumour were taken for histological analysis at each passage
with all of the above procedures carried out in a laminar flow
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6.7 Tumour Storage
Wherever possible tumour samples were stored from the
original passage and each subsequent passage. Tumours were
dissected as described previously into 8 mm3 cubes, 10 of which
were placed into vials containing 1 ml freezing mixture, which
was composed of 10? dimethyl sulphoxide in new born calf serum.
The vials were then placed in a -40°C freezer for 6 hours prior
to transfer into liquid nitrogen.
When specimens were required for implantation they were
removed from liquid nitrogen and rapidly thawed. The freezing
mixture was aspirated and the tumour fragments washed
repeatedly in RPMI medium with added penicillin and
streptomycin. The fragments were then kept on ice until
implantation which was carried out with minimal delay.
6.8 Tumour Measurement
Following implantation the animals were left undisturbed
until removal of the surgical clip at 14 days. Tumour measure¬
ments were commenced 14 days after transplantation. The skin
was shaved over the tumour area and perpendicular measurements
were made using calipers, with the mean of 3 recordings for
each measurement. Tumour volume was estimated using the
formula ir/6 Dd2, where D = longest diameter and d = shortest
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diameter, assuming the tumour to be ellipsoid. To assess the
accuracy of these measurements a number of tumours from one
cell line were excised and weighed following measurement,
showing close correlation between actual and estimated tumour
volumes, except at small tumour volumes.
6.9 Tumour and Implant Take Rates
The tumour take rate relates to the number of original
tumours which showed progressive growth and subsequent trans-
plantability, thus enabling the establishment of xenograft
lines. For a positive tumour take, animals were observed for a
minimum of 3 months, following which they were sacrificed
should there be no evidence of progressive tumour growth.
The implant take rate refers to the proportion of tumour
implants that progressively grew in excess of 0.3 cm3. This
was assessed in all tumour samples following initial
implantation and with each subsequent passage.
6.10 Growth Rate
Tumours were assessed for growth twice weekly from 14 days
after implantation. Tumours were measured as described using
the formula ir/6 Dd2 to estimate tumour volume. Following an
initial lag period, progressive growth followed at a linear
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rate. With each tumour xenograft line, the time taken for
xenografts to double in volume from 0.2 cm3 to 0.4 cm3 (tumour
doubling time-Tp) was estimated to determine the growth rate.
Tumour doubling time was estimated for all xenografts reaching
this size, and mean values for each tumour line at every
passage were determined.
6.11 Specific Growth Delay
In all chemotherapy studies this parameter was used as the
end point of assessment. It is calculated from the respective
doubling times of control and treated animals by the following
formula:-
_ ... .. . , Tn (treated) - Tn (control) ,v .Specific growth delay = (Kopper &
T[) control Steel 1975)
The doubling times (TD) of each treatment group are based
on the time taken for each xenograft to double its original
volume. From these results mean doubling times were calculated
for each group. The specific growth delay is expressed in




End organ or specific drug toxicities can vary between
species and also between strains of the same species. There¬
fore for all drugs used in the chemotherapeutic studies, an
assessment of toxicity was made. A dose response curve was
constructed for each drug from which a maximum tolerated dose
could be calculated. The maximum tolerated dose used was
marginally lower than the LD10, which is the dose of drug
causing death in 10% of animals over a 30 day observation
period. Normally, non-tumour-bearing immune-deprived animals
were used for these toxicity studies.
In tumour bearing animals impairment of drug metabolising
enzyme activity has been identified, therefore 90% of the LD-|0
was used as the maximum tolerated dose in all experiments. This
enabled the drugs to be effectively ranked based on their
anti-tumour activity.
6.13 Chemotherapy Experiments
Following the establishment and characterisation of each
xenograft line, a number of chemotherapeutic studies were
carried out with xenografts in the 3rd to 7th passage.
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For these experiments all animals, preferably of the same
sex, were irradiated on the same day and transplanted 24 hours
later. When a sufficient number of tumours had grown to
volumes of 0.2 cm3 to 0.7 cm3, they were divided into groups,
stratified both for the sex of animals and for tumour size.
Chemotherapy was then administered, based on the maximum
tolerated dose, on a milligram per kilogram basis. The drugs
were dissolved in water for injection, or normal saline, at a
concentration enabling their administration in a volume of
0.1 ml per 10 g mouse body weight, and were all given intra-
peritoneally.
It was intended to have 10 tumours in each treatment
group, but in view of the variability in take rates and growth
rates, this was not always possible. Early treatment-related
deaths were excluded from analysis, but in animals where
regrowth or progressive growth was observed at the time of
death, extrapolation of the growth curve was occasionally
performed to estimate the tumour doubling time. Where
permanent tumour regression occured, mean growth delay could
not be estimated and in this situation median growth delay was
considered appropriate (Nowak et al 1978).
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6.14 Preparation of Single Cell Suspensions
The tumours were excised using an aseptic technique, and
placed immediately in ice-cold RPMI medium with added anti¬
biotics and transferred directly to the laboratory. They were
dissected in a sterile Petri dish, in a sterile tissue culture
hood, using a crossed-scalpel technique and rinsed 3 times in
phosphate buffered saline. Enzymatic disaggregation was
performed using collagenase 2 mg/ml in Ham's medium for 30
mintues at 37°C. The solution was centrifuged at 450 g, the
supernatant discarded and the cell pellet resuspended in
phosphate buffered saline with added trypsin (0.05?). The
trypsin was removed after 5 minutes, the pellett resuspended in
Ham's medium for 5 minutes and then into Ham's medium with
added serum. The solution was then filtered through a sterile
polyster mesh of pore size 25 ym.
A sample of the filtered solution was taken and 6 drops of
trypan blue added to differentiate dead from live cells and a
cell count performed manually using a heamocytometer chamber.
This technique for the production of a single cell




Using a single cell suspension, metaphase spreads were
produced by first incubating in colchicine 0.4 pg/ml in Ham's
medium for 2 hours at 37°C. The solution was then centrifuged,
the supernatant discarded and then resuspended in hypotonic
potassium chloride solution for 8 minutes. Following this the
cells were fixed by slowly adding a solution containing 3=1
methanol acetic acid. This solution was kept at 4°C for a
minimum of 30 minutes, and was repeated on 3 occasions.
Drops of the suspension were heat dried on clean glass
slides and Giemsa stained. Intact metaphase spreads were
photographed and chromosomes counted where possible. This was
done with the help of Sandra Lawrie (ICRF Medical Oncology
Laboratory).
6.16 Cell Culture
Appropriate cell dilutions were made for each cell line in
order that equal numbers of viable cells could be added to each
tube. The cells were plated in 0.3? agar medium with added rat
erythrocytes, foetal calf serum and Ham's F12 medium (Courtenay
and Mills, 1978). One ml agar cultures were gassed with 5I O2,
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5% CO2 and 90% N2 gas mixture. The plating efficiency, which
is defined as the proportion of cells which proliferate and
form colonies, was determined for each sample.
6.17 Histopathological Techniques
Sections of original tumour tissue and specimens from
xenograft tumours at each passage were assessed using standard
histological techniques. All histopathology and electron
microscopy work was done with the assistance of the Pathology
Department, Western General Hospital. All samples were fixed
in formalin, embedded in paraffin wax and sectioned at 4 pm.
Sections were floated onto microscope slides, deparaffinised in
xylene, treated with ethanol to remove xylene and brought to
water. All specimens were examined using standard haematoxylin
and eosin stain, with periodic-acid schift stain for the non-
small cell carcinomas to distinguish adenocarcinomas.
6.17a Haematoxylin and Eosin (H & E)
Sections were stained in standard Ham's haematoxylin for
2 minutes then blued in lithium carbonate. Following washing
plates were placed in Putt's eosin for 2 minutes, then dehyd¬
rated, cleared and mounted in DPX.
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6.17b Periodic-acid Schiff (PAS)
Sections were stained in 1$ aqueous periodic acid for 5
minutes and washed in water. They were then placed in Schiff
reagent for 15 minutes, and washed in water for 30 minutes.
The nuclei were stained in haematoxylin for 2 minutes, blued in
lithium carbonate and washed in water. Sections were then
dehydrated, cleared and mounted in DPX.
6.18 Electron Microscopy
Wherever possible, specimens of original tumour tissue and
freshly excised xenograft tissue were dissected into small
fragments and fixed in 5% glutaraldehyde in 0.1 M sodium
cacodylate buffer (pH 7.2) and kept at 4°C. They were washed
overnight in sodium cacodylate with 0.3 M sucrose, then fixed
in 0.05 M sodium cacodylate and 1$ osium tetroxide for 1 hour
at 4°C. The sections were then dehydrated and embedded in
araldite. Sections of 30-50 nm were cut on a Reichert Om U2
ultratome stretched with chloroform and collected on uncoated
copper grids. Grids were stained with uranyl acetate and lead
citrate, 20 minutes in each solution, and then photographed.
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CHAPTER 7
MATERIALS AND METHODS - BIOCHEMICAL STUDIES
7.1 Introduction
The second aim of this study was to investigate bio¬
chemical sequelae of cytotoxic drug administration, in
particular the drug 'priming' phenomenon. In view of the
association of glutathione and related enzymes in the detoxic-
ation of alkylating agents, it was decided to concentrate on
this area with particular reference to the effect of cyclophos¬
phamide on tumour cells and bone marrow cells. Commercially
available male CBA mice from a solitary source were used for
these experiments. This work was done in collaboration with
Dr David Adams and Dr Roland Wolf, ICRF Medical Oncology Unit,
Edinburgh.
7.2 Preparation of Animals
Male CBA mice 8-12 weeks of age, 22-30 g in weight, were
used in these experiments. All cytotoxic drugs were
administered intraperitoneally and x-irradiation was performed
using the 250 kV source described previously.
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7.3 Preparation of Tissue Samples
The effectiveness of cytotoxic chemotherapy is often a
balance between anti-tumour activity and toxicity. In view of
this a number of tissues were examined to investigate the
biochemical effects of cytotoxins with all animals sacrificed
by cervical dislocation.
7.3a Tumour Tissue
Xenograft tumours were rapidly excised and all obvious
necrotic debris removed. Individual samples were immediately
placed in ice-cold phosphate buffer, and finely minced using a
crossed scalpel technique. The phosphate buffer used for all
these assays comprised of a 20 mM sodium phosphate buffer with
0.005 M ethylenediamminetetracetic acid (pH 7.7). They were
then disaggregated using a polytron homogeniser, each under¬
going 3 homogenisations of 10 seconds, taking appropriate
precautions to keep the specimen cold and to minimise the
possibility of aerosol spray contamination of the experimenter.
Following this, the specimen was centrifuged at 40,000 g at 4°C
for 60 minutes and the supernatant collected. This was then
analysed immediately for reduced glutathione content or stored
at -80°C for enzyme studies.
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7.3b Liver
The livers were removed and immediately placed in ice-cold
phosphate buffer. They were later removed from the buffer,
filter paper dried and weighed. Following this phosphate
buffer was added, 3 ml per mg wet weight of liver, and the
livers were scissor-minced. They were homogenised using a
Silverson Heavy Duty laboratory mixer emulsifier, then centri-
fuged at 30,000 g and the supernatant used for glutathione and
glutathione transferase assays. All samples were stored at
-80°C.
7.3c Bone Marrow
Animals were stretched out on their dorsal surface with
the femurs of both hind limbs exposed. The bones were divided
using scalpels and the marrow obtained by pushing through
ice-cold phosphate buffer using a 23 gauge needle. Cells were
disaggregated by passing through needles of increasing gauge
using 1.5 ml buffer. 1.5 ml buffer was used for 6 femurs,
giving a cell yield of approximately 5 x 107/ml. Cell counts
were carried out using a haemocytometer taking 2 measurements
for each sample. Cells were disrupted by sonication for 5




The bladders were removed, washed and then placed in
ice-cold phosphate buffer. They were then divided by crossed-
scalpels, resuspended in 5 ml phosphate buffer and disrupted
using a Polytron homogeniser as previously described. The
samples were then centrifuged at 30,000 g at 4°C for 30 minutes
and the supernatant collected for assay purposes.
7.4 Fluorescence Activated Cell Sorter (FACS)
Bone marrow and peripheral blood samples were sorted into
constituent cell populations using a Becton-Dickinson FACS IV.
These studies were carried out in collaboration with
Dr John Ansell, Zooology Department, Edinburgh University,
using equipment kindly supported by the Cancer Research
Campaign. Peripheral blood and bone marrow specimens were
separated using forward and 90° scatter with four distinct




4) anomalous population - including blast cells and monocytes
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The purity of these cell populations had previously been
confirmed histologically, having been shown to be greater than
80? pure.
7.5 Preparation of Granulocytes
Granulocytes were obtained for assay from three sources,
bone marrow, peripheral blood and the peritoneum.
7.5a Bone marrow
Samples were obtained as previously described. Bone
marrow cells were suspended in ice-cold phosphate buffered
saline containing 0.5? bovine serum albumin, azide and heparin.
They were then separated into the 4 constituent cell popul¬
ations using a fluorescence activated cell sorter by means of
forward and 90° scatter (Watt et al 1980).
7.5b Peripheral Blood
Animals were sacrificed in ether (May and Baker), placed
on their dorsal surface and the inferior vena cava exposed.
Using a 25 gauge needle approximately 0.5 ml blood was obtained
from each animal. 1.5 ml blood was diluted in 20 ml ice-cold
phosphate buffer containing azide, bovine serum albumin and
heparin. This was spun at 1150 g for 10 minutes at i4°C.
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Erythrocytes were lysed using a distilled water shock technique
adding 9 ml water to the resultant cell pellet. Hypotonicity
was reversed using 1 ml of 10 times concentrated Eagles medium
without added glutamine, and the solution was brought to 20 ml
with phosphate buffer. The cell suspension was centrifuged at
1^00 rpm for 10 minutes through 2 ml 10? foetal calf serum to
remove red cell debris. The resultant cell pellet was resus-
pended in a few drops of phosphate buffer and separated by
means of the FACS.
7.5c Peritoneal Granulocytes
Peritoneal granulocytes were obtained using casein
stimulation as previously described (Watt et al 1979). Animals
were injected intraperitoneally with 2 ml of 0.2? (w/v) calcium
caseinate and sacrificed 3 hours later using ether anaesthesia.
5 ml of ice-cold isotonic saline was injected intraperitoneally
using a 25 gauge needle, then 10 minutes later the abdomen was
lavaged using a Pasteur pipette, and the suspension washed in
phosphate buffered saline three times at . The cells were
resuspended in 10 ml 0.168 N ammonium chloride and left
standing on ice for 10 minutes to lyse contaminating red blood
cells. These cells were then later resuspended in 0.5 ml
phosphate buffered saline containing bovine serum albumin 1?
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W/V) and counted using a haemocytometer. The purity of all the
above samples was assessed histopathologically using Giemsa
stained preparations, and were found to be greater than 80$
pure.
7.6 Glutathione Assays
Reduced glutathione was measured using two techniques.
7.6a Fluorimetric Assay
A fluorimetric assay using O-phthalaldehyde was used to
determine glutathione levels as described by Hissin and Hilf
(1976). O-phthalaldehyde 0.1 ml (1 mg/ml Sigma Chemicals Ltd)
in absolute methanol was added to 1.89 ml phosphate buffer
(20 mM sodium phosphate with 0.005 M ethylenediamminetetracetic
acid [EDTA], pH 7.7).
Test solutions were prepared by mixing equivalent amounts
of 10$ TCA (trichloroacetic acid) and tissue homogenates and
spinning at 2,000 g for 5 minutes in an Eppendorf centrifuge.
Duplicate supernatant test solutions of 0.01 ml were added to
the mixture of O-phthalaldehyde solution 0.1 ml (1 mg/ml Sigma
Chemicals) and 1.89 ml phosphate buffer, as previously
described. The resultant solution was mixed thoroughly and
left to incubate at room temperature for 15 minutes. It was
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then transferred to a quartz cuvette and fluorescence detei—
mined using a Perkin Elmer LS-3 fluorescence spectrometer
(excitation/emission: 350/420 nm). These values were compared
with glutathione control solutions and negative controls. The
second method involved the measurement of cycle reduction of
glutathione using glutathione reductase and NADPH as described
by Tietze (1969).
7.6b Cycling Dependent Glutathione Assay
Glutathione was estimated using a modification of the
assay assessing cyclic reduction of Elman's reagent using NADPH
(Sigma Chemicals Ltd) and glutathione reductase, as described
by Tietze (1969). 1.6 ml of 200 mM sodium phosphate buffer
with 10 mM EDTA, pH 7.3 as added to both test and standard
cuvettes. 60 pi of glutathione reductase 0.5 mg/ml (Boehringer
Mannheim Ltd) was added to each cuvette with 100 pi of DTNB
Elman's Reagent - 5 mg/ml). Test samples were diluted in 0.6?
sulphosalicylic acid and 200 pi was added to the test cuvette,
with 200 pi 0.6 sulphosalicyclic acid added to the standard.
The reaction was started by adding 40 pi NADPH (9 mg/ml) to
each cuvette, with the samples read, following thorough mixing,
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in a Hitachi 100-80 A spectrophotometer at a wavelength of
412 nm. Samples were assayed over 3 minutes and compared with
glutathione standards.
7.7 Oxidised Glutathione
As glutathione is a labile compound that can be rapidly
oxidised to its disulphide, estimations of the disulphide
were occasionally made to assess the degree of autoxidation of
samples. Reduction of the disulphates was achieved with
glutathione reductase (1 mg/ml) and NADPH (9 mg/ml).
Following incubation with these compounds, glutathione levels
were determined fluorimetrically. Oxidised glutathione
(disulphide) levels were estimated by subtracting glutathione
levels in the untreated samples from levels measured in samples
treated with glutathione reductase and NADPH.
7.8 Glutathione-Transferases
Glutathione transferase levels were measured using 1-chloro-
2,4-dinitrobenzene (CDNB) as substrate (Habig et al 1974).
The CDNB solution was prepared by adding 1 mM CDNB in 2%
ethanol to an 0.1 M sodium phosphate buffer, pH 6.5. CDNB was
added drop by drop to the buffer and heated to 50°C. A 20 mM
glutathione test solution was also required.
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One ml CDNB plus 0.05 ml phosphate buffer comprised the
reference solution and when compared with 1 ml CDNB plus
0.05 ml glutathione test solution, gave the background value.
Test samples were prepared in an identical manner to the
glutathione assay samples and variable volumes of the resultant
solution (0.01-0.05 ml) were added in an attempt to observe
significant activity. An ideal sample comprised of 0.01 ml of
1 mg/ml cytosol. Samples were measured at 25°C using a
Pye-Unicam SP8-500 uv/vis spectrophotometer at 340 nm. Protein
estimations were carried out on the samples (Lowry et al 1951)
and values expressed as enzyme activity = mol CDNB/minute/
milligram cytosolic protein, except in the case of bone marrow
samples where enzyme activity was expressed in terms of cell
number.
7.9 Glutathione Quench Curves
Interference with the glutathione assay could be caused by
a number of tissue components (Mokrasch and Teschke 1984), and
it was therefore important to assess the degree of quenching in
all tissues.
A minimum of three samples from each tissue were assayed
for glutathione as previously described. Known amounts of
gluathione (25-800 mM) were added to identical tissue samples
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and glutathione measured. Glutathione levels measured before
and after the addition of known amounts of glutathione were
compared and quench curves generated. Quench curves were
constructed for liver, tumour and bladder tissues in addition
to bone marrow cells and peripheral blood cells.
7.10 Protein Measurements
All protein samples were analysed using the method
described by Lowry et al (1951).
7.11 Interleukin Preparations
7.11a Interleukin I
Crude human interleukin I was isolated from human mono¬
cytes stimulated with concanavalin A. Activity was shown by
pyrogen tests on CBA mice with no evidence of endotoxin
contamination as shown by the Limulus amebocyte lysate test.
The supernatant was concentrated by and stored at -80°C.




WEHI-3B, a mouse myelomonocytic cell line, is known to
produce a number of substances including interleukin 3.
Interluekin 3 is produced in relatively large amounts and can
be isolated and purified from the supernatant of confluent
cells (Ihle et al 1982; 1983). Crude conditioned media
supernatant was used in this study, with no attempt made to
purify or concentrate the substances. Similarly the Limulus
amebocyte lysate test for endotoxins was not carried out.
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SECTION 3 EXPERIMENTAL RESULTS
CHAPTER 8
GROWTH CHARACTERISTICS OF HUMAN LUNG CANCER XENOGRAFTS
8.1 Introduction
The main purpose of this study was to establish a valid
tumour model for the study of drug sensitivity in human lung
cancer. This included the study of methods to improve the
therapeutic index of the presently available cytotoxic drugs.
To address both these aims, it was decided to establish a
human xenograft model. As 'specific pathogen free' facilities
were not available at that time, TAR (thymectomy, cytosine
arabinoside pretreatment and total body irradiation) mice were
used.
8.2 Xenograft Take Rate
Fifty-six specimens were obtained in all, the details
listed in Table 8.1, with 51 of these containing tumour tissue.
Progressive growth and serial transplantation were achieved in
16 xenografts giving a take rate of 31.3?. Successful tumour
takes were achieved in squamous carcinoma 9/20 (45?), adeno¬
carcinoma 5/16 (31?) and small cell carcinoma 1/6 (17?).
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All biopsies

































(b) Bronchoscopy specimens - total 12
- no tumour 4
- viable tumour 8
- squamous 4
- adenocarcinoma 1
- small cell 1



















(c) Sub-cutaneous metastasis - small cell 1
Table 8.1 Establishment (tumour take rate) of human xenograft
lines in immune-deprived CBA mice. Take rates of
biopsies obtained from various sources.
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Tumours with features of both squamous and adenocarcinoma were
implanted on 3 occasions with 1 successful tumour take (33?).
Differences in take rates between histological categories were
not statistically significant although numbers were small. All
biopsies were from primary tumours except 2 samples, one a
subcutaneous biopsy from a small cell carcinoma which was
successfully grown, and the other a hilar lymph node biopsy
from a squamous carcinoma which did not grow. Despite the
limited amount of tissue, when viable tumour was obtained at
bronchoscopy a take rate of 25? was achieved, similar to that
observed with thoracotomy specimens (31?).
Sixteen xenograft lines were established, 9 squamous
carcinoma, 5 adenocarcinoma, 1 small cell carcinoma and 1
adenosquamous tumour.
8.2 Tumour Implant Take Rates
In the original man to mouse passage of squamous carcinoma
26/180 (14.4%) of implants progressively grew in comparison to
10/159 (6.3?) in adenocarcinoma and 1/52 (2?) of small cell
carcinoma implants. 5/30 adenosquamous carcinoma implants
grew, but there were insufficient numbers in the other histo¬
logical categories to analyse. Implant take rates are illust¬
rated in Table 8.2. Once xenografts became established the
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Squamous Carcinoma
Xenograft Take Rate Xenograft Take Rate
CX 104 1/10 CX 108 5/10
CX 109 8/10 CX 112 1/10
CX 121 2/10 CX 133 3/8
CX 140 2/6 NX 002 3/10
NX 004 1/5 1 1 biopsies no growth 0/101
Implant take rate 26/180 = 14.4%
Adenocarcinoma
CX 105 2/10 CX 117 4/1 1
CX 1 18 2/10 CX 131 1/10
CX 132 1/8 11 biopsies no growth 0/110
Implant rake rate 10/159 = 6.3%
Adenosquamous Carcinoma
CX 143 5/10 2 biopsies :no growth 0/20
Implant take rate 5/30 = 16.6%
Small Cell Carcinoma
wx 310 1/10 5 biopsies ino growth 0/42
Implant take rate 1.52 = 2%
Table 8.2 Implant take rate in the first man to mouse passage,
of various histological subtypes of human lung
cancer. All tumours grown in immune-deprived CBA
mice.
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Implant Take Rate (%)
Xenograft Histological Passage
Line Type 1 2 3 4 5
NX 002 30 50 64 63 60
CX 108 50 33 14 28
cx 109 Squamous 80 58 76 80 69
cx 133 38 21 55 63
33 31 35 46 63
cx 117 Adenocarcinoma 36 23 40 63 62
CX 143 Adenosquamous 50 62 55 70 61
wx 310 Small cell 10 23 41 50
Totals 31/ 1 18/ 286/ 650/ 1433/ 326/ 1 30/
75 289 621 1077 685 464 17*4
443 . 3% 40.8$ 46i 60. 45S 63.2% 70.25% 75%
Table 8.3 Implant take rate of human lung cancer xenografts in serial
mouse to mouse passages in immune-deprived CBA mice.
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implant take rate generally improved, as shown in Table 8.3,
with implant take rates significantly better in passages 4-6
compared with passages 1-3 (p < 0.001 X2). in total 1408/2328
(60.5%) squamous carcinoma implants showed progressive growth,
in comparison to 344/680 (50.6%) of adenocarcinomas and 109/261
(41.8%) of small cell carcinomas. This gave an overall implant
take rate of 57% (1861/3269).
8.3 Effect of Delayed Implantation on Xenograft Take Rates
Using a well established xenograft (NX 002) at its fifth
passage, the effect of delay on tumour implantation was
assessed. Seventy mice were transplantated unilaterally at
designated times following total body irradiation. All mice
were transplanted on the same day and the results are illust¬
rated in Table 8.4.
The best results are achieved by transplantating on Day 1
or Day 15 following total body irradiation. Successful tumour
growth was also achieved with transplantation on Day 8, but the
mice were less able to tolerate the procedure at this stage,
resulting in a greater loss of animals. Radiation-related
gastrointestinal toxicity was maximal at this time which may




Day after total body
irradiation 1 8 15 22 29 36 43
Progressive growth 6 5 7 3 5 2 1
No growth/regression 4 3 3 7 5 7 8
Host death 0 2 0 0 0 1 1
Table 8.4 Effect of timing of tumour implantation on implant
take rates of human lung xenografts, using the
squamous lung cancer xenograft NX002 at the 5th
passage in immune deprived CBA mice.
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8.4 Effect of Liquid Nitrogen Storage on Xenograft Take Rates
Whenever possible tumour material from each passage was
stored in liquid nitrogen at -1960c. When specimens were
recovered from liquid nitrogen implant take rates were very-
poor however, similar to the results achieved with the initial
man to mouse passage. Therefore, this procedure was
satisfactory for the maintenance of xenograft lines but the
implant take rate was inadequate for the planning of chemo¬
therapy experiments.
8.5 Tumour Regression
It is known that a proportion of immune-deprived mice will
regain some or all of their immunity within 6 weeks of total
body irradiation. With returning immunity, stasis or even
regression of tumour growth can be problematical. The incid¬
ence of tumour regression was assessed in all xenograft lines
during the fourth passage, and was found to be extremely
variable:-
cx 109 0% CX 1 43 10?
NX 002 3% CX 133 15?
CX 1 40 6? wx 310 15?
CX 117 7.8? CX 108 20?
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Histopathological classification had no apparent effect on the
incidence of tumour regression although regression was more
common in slowly growing tumours.
8.6 Incidence of Single and Double Takes in Xenografts
To assess the importance of returning host immunity on
xenograft take rates, an analysis of implant take rate was
carried out. All animals were implanted bilaterally and were
categorised with respect to the number of implants showing
progressive growth.
The distribution of implant takes was investigated in
three separate tumours at the same passage. The tumours were
histologically different and were analysed independently. The
results are illustrated in Table 8.5, showing a tendency for
each mouse to either accept or reject both implants in all
three tumour groups. The results were analysed using the X2
goodness of fit test applied to a binominal distribution. These
differences were highly significant (p < 0.001), showing that







(take probability 0.4) 2
X2ldf = 21.52 p<0.001
Observed no. Expected no.











NX 002/4 0 31 14.99
Squamous 1 35 66.70
(take probability 0.69) 2 90 74.27
X2ldf = 35.48 p<0.001
Table 8.5 Effect of host immunity on xenograft implant take
rates. Incidence of progressive growth in one or
both tumour implants using human non-small cell




The pattern of xenograft growth is divided into a "lag
phase" and a "growth phase". Growth rates can vary widely
between xenografts and even within a xenograft line at the same
passage, as illustrated in Figure 8.1.
8.7a Lag Phase
The lage phase encompasses initial cell death following
transplantation, clearing of stromal debris and then tumour
cell proliferation, until macroscopic growth is evident when
the growth phase begins. The division of growth into two phases
is somewhat arbitrary, and therefore in this study the lag
phase was defined as the period lapsing until tumour volume
reached 0.05 cm2.
The lag phase was evaluated for all xenograft lines at
every passage. The mean lag period for all xenografted tumours
in the original man to mouse passage was 48.37 days (range
25-95 days) with no significant difference between squamous
carcinomas (45.5 days) and adenocarcinoma xenografts (55.2
days). Variation in duration of the lag phase was seen between
xenografts of the same histological type, between passages of
the same xenograft and even within the same passage. Mean
values for lag periods of tumours used in chemotherapy experi¬
ments are illustrated in Table 8.6.
200 180 160 140 120 100









1 2 3 4
NX 002 LP 42 57 38 37.9 32.5
Td 16.5 10.6 12.65 12.7 12.9
CX 108 LP 36.8 34.3 54 42
TD 11.9 13.7 10.5 18.8
CX 109 LP 25 32 44.5 32.3 21
Td 18.6 7.0 12.26 12.72 11.0
CX 121 LP 92.5 71.3 54
td 1 4.2 15.5 18.7
CX 133 LP 32 35.4 46.4 35.35
td 1 4.0 14.15 14.18 13.49
CX 1 AO LP 28.5 53.8 80.8 14.2 46.3
td 12.65 11.2 11 .75 12.67 17.2
CX 117 LP 39.3 87 37 29.6 34.1
(adeno- TD 11 .25 10.7 00CO• 10.9 11 .04
carcinoma)
CX 143 LP 56.8 46.3 34.5 37.8
(adeno- Tp 19.13 18.66 15.64 1 6.83 11.9
squamous)
WX 130 LP 38 70 52.3 45. 4
(small Tq 14.9 17.2 14.25 18.1
22.1
cell)
Table 8.6 Mean lag periods (LP) and tumour volume doubling
times (Td) in days of human lung cancer xenografts measured
over successive passages in immune-deprived CBA mice. All
xenografts are squamous carcinomas unless otherwise indicated.
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8.7b Growth Phase
Growth in the majority of implants followed an exponential
pattern. However stasis and regression of tumour growth did
occasionally occur, this being more common in particular
xenograft lines. This tends to suggest that in addition to
returning host immunity there may be tumour related factors
affecting xenograft take rate. Tumour volume doubling times
varied from 11.25 days to 23.1 days in the original man to
mouse passage, with similar variations amongst squamous and
adenocarcinoma lines. Mean tumour doubling times for xeno¬
grafts used in chemotherapy studies are shown in Table 8.6.
However, it has to be appreciated that numbers in these groups
were very small, with only one tumour to measure on occasions.
Marginally less variation in volume doubling is seen in
subsequent passages, both within the same tumour line and
between xenografts of particular histological categories.
In the original man to mouse passage the mean volume
doubling time for squamous carcinomas was 15.53 ± 5.02 with a
similar value 15.61 ± 1.86 days in adenocarcinoma. At the
third passage when tumours were relatively well established,
the figures were 13-71 ± 1.86 days in squamous and 11.83 ± 1.93
days in adenocarcinoma xenografts.
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Apart from a minimal general increase in growth rate,
there was no obvious growth trend in individual xenograft
lines, with some increasing growth rate with passage, some
remaining static and others decreasing growth rate. The lag
period varied from passage to passage but likewise, with no
obvious trend. The lag period in these experiments did not
decrease with increasing passage as has previously been
reported. In addition, no correlation was noted between
duration of the lag phase and tumour volume doubling time in
the original man to mouse passage (r = 0.28).
8.8 Potential Error in Estimation of Xenograft Volume
Using the xenograft line NX002, a squamous carcinoma at
the sixth passage, evaluation of the accuracy of caliper
measurements in the estimation actual tumour volume was made.
Twenty-four tumours were measured immediately prior to
sacrifice and tumour volume estimated using the formula tt Dd2/6
where D is the longest diameter and d the diameter perpen¬
dicular to this. This assumes the tumour to be ellipsoid.
The tumours which were of variable size were then excised,
weighed and a graph constructed of estimated volume against
actual tumour weight. A linear relationship was obtained above
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0.2 cm3 but below this the estimated volume was inappropriately
high, with overlying skin thickness probably playing an
important role in this measurement error.
8.9 Animal Deaths
8.9a Deaths Following Immune-deprivation
In all, approximately 10? of immune-deprived animals died
prior to tumour transplantation. Acute deaths following
thymectomy accounted for 5?, with an additional 3? of
irradiated animals dying by day 14, the majority between days
7-10, thought to be due to radiation related gastrointestinal
toxicity. Another 2? of animals progressively lost weight,
although it was impossible to ascertain whether this related to
the wasting syndrome associated with thymectomy, or chronic gut
toxicity. Of the animals surviving immune-deprivation and
successful transplantation, between 5-10? were unsuitable for
chemotherapy studies as they had failed to gain sufficient
weight. As stated previously, of the animals surviving these
procedures, 57? would successfully grow tumours.
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8.9b Unexpected Deaths
On one occasion halfway through the project, a large number
of animals became unwell, developing a wasting syndrome. Ten
sick animals were sacrificed and underwent post-mortem examin¬
ation. Macroscopically no abnormality was detected. Histo¬
logically the livers showed small zones of necrosis surrounded
by mixed inflammatory cells, although the appearance of most of
the organ was entirely normal. The spleens and kidneys were
all normal. A periarteritis was noted in the lungs with oedema
in the alveoli but no other abnormalities were detected in the
lungs or other organs. Culture specimens were sent from all
organs but no organisms were grown. Specimens were examined
for common pyogenic organisms, anaerobic bacteria and tubercle
bacilli with no growth. As pasturella infection had previously
been a problem in the animal unit, specimens were examined
specifically for this pathogen, but no organisms were detected
and likewise, fungi were not isolated. In addition no viral
particles were seen on electron microscopic examination of
several organs. The CBA breeding colony was assessed for
common murine viruses such as Sendai and Mouse Hepatitis Virus
but these tests were all negative.
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The illness affected both immune-deprived non-tumour
bearing and tumour bearing animals, which were all housed in
the one room. The breeding stock were not affected by the
illness and there was no excess of neonatal deaths at that
time.
At this stage there were a number of possibilities for
these unexpected deaths, the most likely being infective,
either atypical bacterial or viral. Another possibility was
that the animals were receiving a higher dose of radiation than
intented, but the dose-meter on the x-ray source was checked and
found to be working normally. As there were large numbers of
ill animals it was decided to sacrifice all, apart from a
select few tumour bearing animals from each tumour line. These
animals were treated with claforan (Roussel Ltd) and metro¬
nidazole (May & Baker Ltd) intraperitoneally 3 times daily for
1 week and arrangements were made to obtain mice from an
outside source. The author is greatly indebted to
Dr Gordon Steel at the Institute of Cancer Research, Sutton for
kindly supplying 50 male, thymectomised CBA mice. These
animals were kept in quarantine, irradiated and then 5 animals
were transplanted with each of 10 xenograft lines. Each tumour
was implanted bilaterally into 5 mice, and 9 xenograft lines
were successfully salvaged. CX 104 a moderately differentiated
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squamous carcinoma failed to take, however. Another 6 tumour
lines were lost as there were no healthy animals suitable for
transplantation. Following this procedure all of the original
stock mice were sacrificed, resulting in the loss of 1057 mice,
453 of which were tumour bearing, 310 transplanted but non-
tumour bearing and the remainder awaiting transplantation.
Over the next 2 months the mice were closely scrutinised
but showed no evidence of the wasting disease. Another worry
was that the infection could be transmitted by the tumour
fragments, and also that any infiltration of the tumour itself
by the infective agent could affect the physical character¬
istics of the tumour. Over the past 15 months however there
has been no recurrence of this wasting disease, and the
xenograft lines have remained remarkably consistent with
respect to growth characteristics.
8.10 Conclusions
The success rate in establishing xenograft lines was
disappointing (31$) in comparison with other studies on lung
cancer, particularly Shorthouse (1981), who used a similar
tumour model, and reported a 78$ take rate in tumour specimens
from 49 patients.
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There are a number of possible explantations for this
discrepancy. Most important, the delay in tumour implantation
was often much longer than desired in this study, in particular
there was a delay of up to 1 hour on occasions before samples
were transferred to a suitable medium, with implantation taking
up to 4 hours on occasions. This compares very unfavourably
with Shorthouse (1981), where all samples were transplanted
within 2 hours, therefore viability of the samples used in this
study may have been impaired. In addition, the majority of
specimens obtained for this study were from primary tumours,
whereas a large number of samples obtained by Shorthouse (1981)
were from metastatic sites, the latter known to be associated
with a higher take rate. Other factors, such as the level of
natural killer cell activity in these animals was considered as
a cause for the low take rate, but was considered unlikely as
overall implant take rates were similar to those reported by
Shorthouse (1981). Initial inexperience in the technique of
thymectomy was also considered as a possible explanation for
the poor take rate but was discounted as similar tumour take
rates were obtained throughout in the study.
Implant take rates in squamous carcinoma and adenocar¬
cinoma were similar, although only 1 adenocarcinoma line was
passaged through many generations. Small cell carcinoma did
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not take well, with numbers in the other histological cate¬
gories too small for analysis. Implant take rates signific¬
antly improved in established lines, with the best results
achieved by implantation in the first 7 days after irradiation,
as previously reported (Shorthouse 1981). Storage of tumour
tissue in liquid nitrogen was sufficient to maintain xenograft
lines although implant take rates were poor. The disap¬
pointing take rates were probably due to the amount of necrotic
material present in lung cancer xenografts, as 70% bladder
cancer xenografts were successfully grown in these animals from
samples stored in liquid nitrogen (tissue kindly supplied by
Dr John Hay).
Tumour regressions were occasionally encountered, being
variable between xenograft lines. Tumour related factors were
certainly important, but returning host immunity was also a
factor as regressions were more common in the slowly growing
tumours. In addition by the analysis of the frequency of
single and double implant takes in these animals, it was shown
that host immunity was a statistically significant factor in
determining the likelihood of successful transplantation.
Growth patterns in the xenograft were similar to prev¬
iously reported studies, with a variable lag phase followed by
an exponential growth phase. Duration of the lag phase varied
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widely between and within tumour lines. However, in contrast
with previous studies (Shorthouse 1981; Mattern et al 1981) the
lag phase did not shorten with progressive passage. Similarly
the growth rate did not progressively increase with passage as
may have been expected from previous studies, although in this
study the selection of tumours for transplantation may have
been different. Tumours of 0.5-1.0 cm3 were used wherever
possible for transplantation, as these tumours had minimal
necrosis. Tumours of variable growth rate were transplanted in
the routine maintenance of xenograft lines to avoid selection
of rapidly proliferating clones. Other studies frequently used
the faster growing xenografts for transplantation, therefore
often selecting the more rapidly growing cells. Every attempt
was made to avoid this in this study.
Estimation of tumour volume by external caliper measure¬
ment was used for the assessment of growth and chemotherapeutic
response. Analysis of tumour weight and estimated tumour
volume showed that external measurement gave a valid estimation
of tumour volume with tumours of greater than 0.2 cm3.
Loss of animals during immune-deprivation was a problem
which obviously would have been diminished with the use of nude
mice. The loss of animals from these procedures was similar to
the experience of Shorthouse (1981). Despite these losses, the
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use of immune-deprived mice was less expensive than a nude
mouse colony would have been. Normally immune-deprived animals
are considered more resiliant to infection than nude mice, but
unfortunately a major problem was encountered in this study. No
cause was found for the many unexpected deaths, and although
infection was the most likely aetiology, multiple attempts to
isolate an organism were unsuccessful. Fortunately, there no
longer appears to be a problem in the mouse colony. Obviously,
infection can be a major stumbling block in any experiment
using immune-deprived animals, and great care should be taken
with these mice to minimise these risks. Following the loss of
these mice, antibiotic therapy in the form of terramycin and
neomycin in acidified drinking water has been instituted for 14
days following total body irradiation to reduce the risk of
endogenous bacteraemias from gut flora.
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CHAPTER 9
MAINTENANCE OF HUMAN CHARACTERISTICS BY XENOGRAFTS
9.1 Introduction
Following the successful establishment of human lung
cancer xenografts it was essential to show that the
characteristics of the original tumour were maintained prior to
chemotherapy studies.
9.2 Histopathology
All tumours were classified according to the WHO histo¬
logical classification (WHO 1981) as illustrated in Table 9.1,
and graded using the Edinburgh Classification (1982) as shown
in Table 9.2. Original sections from thoracotomy specimens
were reviewed by Dr D Lamb (Department of Pathology, University
of Edinburgh). All xenograft biopsies were reviewed and
compared with the histology of the donor patient by Dr M A
Mclntyre (Department of Pathology, University of Edinburgh).
All tumours grew as discrete subcutaneous nodules in the
flanks of the mice as shown in Figure 9.1. Some animals grew 3
or 4 nodules, the additional tumour material growing either
along the implantation track or at the incision site. The
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1. Squamous cell carcinoma
variant (a) spindle cell carcinoma
2. Small cell carcinoma
(a) oat cell carcinoma
(b) intermediate cell type





(d) solid carcinoma with mucus formation
4. Large cell carcinoma
Variants (a) giant cell carcinoma
(b) clear cell carcinoma
5. Adenosquamous carcinoma
6. Carcinoid tumour





Table 9.1 World Health Organisation Classification of Primary
Lung Tumours 2nd Edition (WHO 1981)
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A. Squamous carcinoma
1. Well differentiated - much keratinisation
(up to 50% of islands of tumour).
2. Moderately differentiated - less obvious keratinisation.
3. Poorly differentiated - very occasional squamous pearl
or single cell keratinisation or easily seen prickles.
B. Adenocarcinoma
1. Well differentiated - predominantly formed of obvious
acinar formation some of which may be cribriform.
2. Moderately differentiated - less marked glandular
formation including cribriform pattern and acinar
structures in less than 50% of high power fields.
3. Poorly differentiated - scanty gland spaces, less than 1
in 10 high power fields.
plus
4. Bronchio-alveolar carcinoma.
5. Solid carcinoma with mucus formation.
Table 9.2 Edinburgh Classification (1982). Criteria for the
differentiation of non-small cell lung cancer.
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Figure 9.1 Human lung cancer xenograft growing subcutaneously
in the flank of an immune-deprived CBA mouse.
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majority of tumours had a variable degree of central necrosis
particularly when the tumour volume exceeded 1 cm3, although
two of the xenografts, both moderately differentiated squamous
carcinomas, showed minimal necrosis, the tumours having a solid
glistening white appearance on their cut surface. The small
cell carcinoma xenograft (WX310) had a similar gross morpho¬
logical appearance to that described by Shorthouse (1981),
being invariably fragile and haemorrhagic.
All of the xenografts maintained the general histological
characteristics of the original tumour, with occasional vari¬
ations in differentiation. Examples are shown in Figures 9.2-
9.11. Changes in differentiation from poorly differentiated
to moderately well differentiated were fairly common as was the
reverse. No well differentiated tumours were successfully
grown. Xenograft CX 143, an adenosquamous carcinoma, was
particularly interesting. The original tumour is illustrated
in Figures 9.2 and 9.3, showing poorly differentiated mucin
secreting adenocarcinoma (Figure 9.2) with areas of poorly
differentiated squamous carcinoma (Figure 9.3). Over 6 passages
the general adenosquamous pattern has been maintained as illus¬
trated in Figures 9.4 and 9.5. However at the sixth passage
more differentiation is seen in the squamous pattern, with
similar areas of poorly differentiated adenocarcinoma.
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Figure 9.2 Histological appearance of donor patient tissue
from the human lung cancer xenograft CX 11)3 -
adenosquamous carcinoma showing PAS positive
staining indicating adenocarcinoma, with
glandular formation - poorly differentiated
adenocarcinoma. (PAS; magnification 1)1)0 X approx).
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Figure 9.3 Histological appearance of donor patient tissue
from the human lung cancer xenograft CX 143
-adenosquamous carcinoma. Clusters of poorly
differentiated malignant cells with lack of
glandular formation and no keratin formation.
Appearances of poorly differentiated squamous
carcinoma (H + E stain; magnification 440 X approx).
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Figure 9.4 Human adenosquamous xenograft CX 143 at the 6th
mouse to mouse passage. Minimal glandular
formation with areas of PAS positivity.
Appearances of poorly differentiated adenocarcinoma
(PAS stain; magnification 440 X approx).
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Figure 9.5 Human adenosquamous xenograft CX 143 at the 6th
mouse to mouse passage. Areas of keratin formation
in the absence of glandular formation. Appearances
of moderately differentiated squamous carcinoma
(H+E stain; magnification 440 X approx).
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Figure 9.6 Original biopsy from donor patient of NX 002
xenograft. No evidence of glandular formation with
moderate degree of keratinisation with some
evidence of stratification. Appearances of
moderately differentiated squamous carcinoma.
(H+E stain; magnification 440 X approx).
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Figure 9.7 NX 002 human lung cancer xenograft at the 7th
passage showing similar features to the original
biopsy. (H+E stain; magnification 440 X approx).
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Figure 9.8 Original biopsy from donor patient of CX 117
xenograft. Large oval nuclei with PAS positivity
in the cytoplasm, but with minimal glandular
formation. Vacuolation of the cytoplasm. Appear¬
ances of poorly differentiated adenocarcinoma.
(PAS stain; magnification 280 X approx).
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Figure 9.9 CX 117, a poorly differentiated adenocarcinoma
xenograft at the 6th passage showing similar
histological features to the donor tissue (PAS
stain; magnification 280 X approx).
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Figure 9.10 Original biopsy from the donor patient of WX 310.
Small round cells with irregular darkly staining
nuclei with minimal cytoplasm growing in sheets.
Appearance of anaplastic small cell carcinoma.
(H+E stain; magnification 4*10 X approx).
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Figure 9.11 WX 310 xenograft at the 5th passage showing similar
features to the original biopsy. (H+E stain;
magnification MHO X approx).
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NX 002 a moderately differentiated squamous carcinoma is
illustrated in Figures 9.6 and 9.7 showing no significant
change over 7 passages. Similarly, the appearance of CX 117 a
poorly differentiated adenocarcinoma is essentially unchanged
(Figures 9.8 and 9.9). The histological appearance of the one
established small cell xenograft is shown in Figures 9.10 and
9.11.
Of the 9 tumours which underwent multiple passages, 5
retained similar differentiation characteristics, 3 increased
differentiation (CX 108, CX 112, CX 140) whereas 1 became more
anaplastic initially, although by passage 6 had regained the
appearance of moderately differentiated squamous carcinoma. A
number of reports have shown occasional increased differ¬
entiation of xenografts (Greene 1940; Helson et al 1975;
Sharkey et al 1978) although only 6$ showed increased differ¬
entiation in Shorthouse's study (1981). The 33$ incidence of
increased differentiation in this study is more akin to the
25$ incidence described by Sharkey et al (1978).
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9.2 Electron Microscopy
A number of xenograft lines were examined after a minimum
of 4 passages in an attempt to identify ultrastructural
features which would confirm the tumour cell type. Five tumour
lines were examined, 1 poorly differentiated adenocarcinoma,
1 small cell carcinoma and 3 squamous carcinomas.
The features of the adenocarcinoma xenograft (CX 117) are
shown in Figure 9.12. The cells were large mononuclear cells
with profuse cytoplasm, which contained large granular
structures and rough endoplasmic reticulum. No features of
squamous differentiation were visible.
The ultrastructural appearance of the small cell xenograft
after 5 passages (WX 310) is shown in Figure 9.13. It shows a
large granular nucleus with no evidence of intracytoplasmic
secretory granules. Secretory granules may have been exepcted
as the patient showed clinical evidence of inappropriate
anti-duretic hormone secretion. As electrolyte studies were
not performed on these mice it is not known whether the mice
were affected by a similar syndrome, although ectopic hormone
production has frequently been shown to persist in xenografts
(Ruddon et al 1980; Shorthouse et al 1982). However, there
are limitations to the measurement of ectopic hormone
production as an assessment of tumour burden, particularly when
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Figure 9.12 Electron microscopic appearance of CX 117, an
adenocarcinoma xenograft at the 5th passage.
Typical large mononuclear cells with profuse
cytoplasm containing mitochondria and dilated
endoplasmic reticulum. Large nucleus with




Figure 9.13 Electron microscopic appearance of WX 310, a small
cell carcinoma xenograft after 5 passages. A
large irregular nucleus, without a nucleolus but
with chromatin clumping . Few organelles and no
intracytoplasmic secretory granules. Magnific¬
ation 1 3, ^400 X.
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central necrosis is present (Quayle 1982). The lack of
secretory granules is consistent with the development of the
more resistant variant phenotype (Gazdar 1985). Variant small
cell lines have been shown to lose secretory granules in
addition to exhibiting decreased production of dopa decai—
boxylase and creatinine phosphokinase. These changes are often
associated with amplification and increased expression of the
c-myc and related oncogenes. The variant sub-type is also
associated with a poor prognosis, and is generally associated
with resistance both to cytotoxic drugs and to radiation.
Electron microscopy was performed on three squamous
carcinomas at the fourth passage, namely NX 002, CX 133 and
CX 140. The classical appearances of tonofilaments and
desmosomes were present in all specimens, and examples are
shown in Figures 9.14 and 9.15.
9.3 Chromosome Studies
All tumours were examined at a late stage to ensure that a
human karyotype was maintained (Warenius 1980). Karyotypically
all tumours examined were of human origin with metacentric and
submetacentric and acrocentric chromosomes with a number of these




Figure 9.14 Electron microscopic appearance of moderately
differentiated squamous carcinoma showing
intracytoplasmic keratin filaments -
tonofilaments. Taken from NX002 xenograft at












Figure 9.15 Electron microscopic appearance of moderately-
differentiated squamous carcinoma exhibiting
intercellular bridges - desmosomes and tono-
filaments. Taken from xenograft at 5^,000 X
magnification.
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isolated from any of the tumour samples examined. CX 140, more
extensively studied, was found to have 36 chromosomes and is
illustrated in Figure 9.16.
Relatively few metaphase spreads were examined from other
xenografts but of those examined, chromosome number was
depleted with 36 chromosomes in CX 140, 31 chromosomes in
CX 117 and 28 chromosomes in NX 002. In addition to alteration
of chromosome number, a number of break points were also
visualised.
9.4 Metastases
There was no macroscopic evidence of metastatic disease in
any of the tumour bearing animals examined. With larger
tumours there was evidence of local invasion but no distant
spread was observed. This is consistent with other reported
xenograft series (Detre and Gazet 1973; Giovanella et al 1972,
1973; Sharkey et al 1978; Shorthouse 1981).
9.5 Cachexia
Although weight loss was observed in a number of mice, no
evidence of cachexia was detected in any particular xenograft
line. The finding is in keeping with previous studies (Povlsen
and Rygaard 1971; Giovanella et al 1974). Cachexia has been
Figure 9.16 Metaphase spread of CX 1 MO xenograft (5th passage)
showing typical human chromosomes (n=36) with
metacentrics, submetacentrics and acrocentrics.
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observed in a malignant melanoma xenograft (Kondo et al 1977)
and rarely in other tumours. No cachexia was detected in
Shorthouse's study (1981) using similar tumour bearing animals.
9.6 Conclusion
This study confirms that many human characteristics are
maintained in xenografts when grown in immune-deprived animals.
Their histopathological appearances showed no change in
classification, although alteration in differentiation was
frequently noted. Increased and decreased differentiation of
xenografts were encountered, as has previously been described.
Ultrastructurally, xenografts were shown to exhibit the
features of their particular histological type, even after many
passages. Typical features of squamous carcinoma, adeno¬
carcinoma and small cell carcinoma were seen by electron
microscopy after a minimum of i| passages in immune-deprived
mice.
Karyotypically all tumours were of human origin with
typical human chromosomes showing metacentrics, sub¬
metacentrics and acrocentrics. The typical murine karyotype
(n = *42) contains exclusively acrocentric chromosomes, and no
murine karyotype was observed in these samples. Chromosome
number was decreased in all xenograft lines examined, including
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CX no (n = 36); CX 117 (n = 3D and NX 002 (n = 28), although
insufficient metaphase spreads were obtained for definitive
karyotyping or banding studies.
Previously, the lack of metastases in xenografts
questioned the validity of these model systems, although the
short duration of animal survival following tumour trans¬
plantation was considered a possible explanation for this
discrepancy. There is now increasing evidence that metastases
are, in fact, more common than originally thought. The first
metastatic models were seen in osteosarcomas when the tumour
was inoculated intravenously. Over the past year however,
many more models have been described, including a number of
intraperitoneal human tumour models such as ovarian adeno¬
carcinoma (Hamilton et al, 198D, colonic adenocarcinoma and
non-small cell carcinoma (Gazdar - personal communication). In
the latter 2 models, documented histological spread was
detected in numerous sites, including the liver, lungs,
pericardium and brain. The metastases were all detected by
day 52 following tumour transplantation although in these cases
the tumours were initially established as cell lines. The
possibility is raised that the site of tumour inoculation may
be important in the development of metastatic disease in these
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animals. These metastatic models may be a significant advance
in the development of xenografts for further experimental
studies.
In conclusion, xenografts in general maintain the
characteristics of the donor tumour , although minimal
variation in histological differentiation and functional
activity may occur. In addition to their value as models for
chemosensitivity testing, xenografts are also valuable as tools




10.1 Non-small Cell Lung Cancer
In this section details of the clinical studies carried
out in the ICRF Medical Oncology Unit at the Western General
Hospital will be discussed.
10.1a Introduction
The prognosis of unresectable non-small cell lung cancer
remains extremely poor despite encouraging recent results
using a chemotherapy schedule employed by Gralla et al (1981).
A similar combination of drugs was used in this study in an
attempt to confirm the activity and assess the treatment
related toxicity of a cis-platinum-vindesine combination.
10.1b Patients and Methods
Sixty-three patients with histologically proven, inoper¬
able non-small cell carcinoma of the bronchus were treated
between March 1981 and May 1983. All patients had evaluable
disease in previously non-irradiated sites and were of good
performance status; none had received any prior chemotherapy.
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They had normal bone marrow function and no hepatic or renal
disease. All the histology was reviewed by one pathologist
(Dr M A Mclntyre, Pathology Department, Western General
Hospital, Edinburgh). Patient details are summarised in
Table 10.1. Thirty-three patients had extensive disease with
metastatic spread as described in Table 10.2. Patients with
cerebral metastases at presentation were not included although
5 patients subsequently developed evidence of central nervous
system involvement.
Prior to entry into the study all patients had a full
clinical examination, chest x-ray, barium swallow,
diaphragmatic screening and audiometry. Blood tests included
full haematological indices, electrolytes, liver function tests
and creatinine clearance. All patients underwent bronchoscopy
for diagnosis and staging even though in some the diagnosis was
established by lymph node biopsy. Histological details are
shown in Table 10.1. Liver ultrasound and isotope bone scans
were only performed when metastatic disese was suspected
clinically, or because of abnormal biochemical results.
The treatment schedule consisted of vindesine 3 mg/m2
intravenously on days 0,7, 14 and 21 and cis-platinum 100 mg/m2
on Days 0 and 21. The cis-platinum was infused in 500 ml 10$
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Squamous carcinoma 30 (18*)
Adenocarcinoma 15 (21*)




Table 10.1 Details of patients entered into the trial of
cis-platinum and vindesine in the treatment of
non-small cell lung cancer.
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e 10.2 Sites of metastatic disease in patients treated
with cis-platinum and vindesine in the non-small
cell lung cancer study.
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mannitol over 30 minutes following 6 hours pre-hydration with
one litre dextrose/saline. A further 1.5 litres dextrose/
saline was administered in the 18 hours after the cis-platinum
infusion. Cycles of chemotherapy were repeated every i»2 days.
Full haematological and biochemical profiles were carried out
prior to each cycle. In addition a full clinical examination
and radiological assessment was performed, as well as an
appraisal of treatment-related toxicity. Response was assessed
following 3 courses of treatment unless progressive disease or
unacceptable toxicity made earlier cessation of treatment
necessary.
All pre-treatment investigations were repeated at this
stage except bronchoscopy which was restricted to patients in
whom there was a clinical response. Clinical responses were
defined as follows:- complete remission (CR) was the complete
disappearance of all evaluable disease including a negative
bronchoscopy. Partial remission (PR) was defined as greater
than 50$ reduction in measurable tumour diameters, with no new
lesions appearing.
10.1c Results
All 63 patients were evaluable for response. The results
are outlined in Table 10.3. The overall response rate was 33?
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Group No. CR PR OR %
All 63 5 16 21 33
Squamous 43 1 13 14 22
Adenocarcinoma 15 3 12 15 33
Large cell 5 1 1 2 40
Male 43 13 30
Female 20 8 40
Limited disease 30 3 11 14 47
Extensive disease 33 2 5 7 21
Performance status
0 26 11 42
1 24 6 25
2 13 i) 30
Table 10.3 Response of non-small cell lung cancer patients to
cis-platinum and vindesine in combination.
CR » complete response; PR = partial response;
OR = objective response
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with 5 patients (8?) achieving a complete remission. Similar
response rates were noted for all cell types. Patients with
limited disease on entry responded significantly better than
those with extensive disease (Chi squared analysis p<0.05).
There was no significant sex difference and performance status
on entry into the study had no relationship to response.
Median duration of response was 1 months (range 2-15
months), although 2 patients remain in remission following
observation periods of 6 and 8 months respectively.
Median survival of responding patients was 11 months
compared with 4.8 months for non-responding and 6.5 months in
the overall group. Survival curves are shown in Figure 10.1.
Ten patients remain alive 6-25+ months after entry into the
study.
All 63 patients were evaluated for toxicity, and the
results are listed in Table 10.1 using WHO criteria.
Side-effects were common and often severe. Alopecia was
universal and gastrointestinal toxicity severe, although in 40%
vomiting was controlled with high dose metoclopramide (Allan et
al 1981). Haematological toxicity was moderate, although blood
transfusion was required in 20 patients following at least 2
cycles of treatment. Peripheral neuropathy was common, and
although occasionally severe, was reversible. High tone
03691258 TIME(months)
Figure10.1Cis-platinuma dvindesinethtreatmentofnon-smallc ll gancer. Survivalofpatientsbyrespon etchem therapy.
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Alopecia







Grade 1 15 24*






Grade 2 33 52*
Grade 3 711*
RCB
Grade 2 20 32*
Table 10.4 Toxicity of vindesine and cis-platinum in combin¬
ation in the treatment of non-small cell lung
cancer. All toxicities graded according to WHO
criteria.
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hearing loss was detected in 16 patients and was symptomatic in
10 cases. Renal impairment was not a clinical problem although
it was demonstrated in 2 patients biochemically. Regardless of
response, performance status deteriorated in 20 patients with
improvement in only ^ cases.
10.1d Discussion
Until recently the results of chemotherapy in non-small
cell lung cancer were extremely disappointing. Single agents
demonstrated minimal activity and little improvement was seen
with combination chemotherapy (Livingston et al 1977). One of
the best studied regimes was a 5 drug combination (BACON)
reported by Livingston et al in 1976. Despite encouraging
initial responses seen initially with this combination, these
were not confirmed when larger numbers of patients were
treated, with only a 20$ response rate in 116 patients, in whom
considerable toxicity was observed.
Recent reports by Gralla and co-workers (Gralla et al
1981; Kelsen et al 1982; Itrl et al 1983) have shown response
rates of 30-50$ with combinations of vindesine and cis-
platinum. One study compared the effects of low dose cis-
platinum (60 mg/m2 every 6 weeks) with high dose (120 mg/m2
every 14 weeks), when used in combination with vindesine. The
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vindesine was administered at a dosage of 3 mg/m2 weekly for 6
weeks, then alternate weekly. Response rates were similar in
both groups but duration of response was significantly longer
with the higher cis-platinum dose regimen. The addition of
cyclophosphamide, adriamycin or bleomycin to the high dose
cis-platinum regimes failed to improve on these response rates
however.
A similar response rate of 33? was achieved in 63 patients
of good performance status. The patients studied included more
patients with squamous carcinoma than in Gralla's group 1981,
but these results, in agreement with his, show no difference in
response rates in different histological categories as shown in
Figure 10.2.
In contrast, however, duration of response and survival
was disappointingly short in this study compared with those
reported by Gralla. Despite a relatively large dose of
cis-platinum 100 mg/m2 3 weekly x 6, the median duration of
response was only 4 months. However, treatment was
discontinued at 18 weeks, whereas in Gralla's study drugs were
continued until disease progression or unacceptable toxicity
supervened. Median survival of responders was 14 months, with
a 1 year survival of 67?. Non-responders had a median survival
Figure10.2Effectofh stologyns rvivalpatientswithnon-smallc llu cancertre tedwithis-pla inumvind sineicombination.
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of 4.8 months, with a 1 year survival of 15%, whilst in the
whole group of 63 patients the corresponding figures were 6.5
months and 29% respectively.
The toxicity of this drug combination was considerable,
with deterioration in performance status common following
treatment. Alopecia and gastrointestinal toxicity were almost
universal, the latter being controlled in only 40% with high
dose metoclopramide (Allan et al, 1984). Weight loss was
almost invariable with a mean loss of 4.1 kg.
This study confirms the activity of vindesine and cis-
platinum in combination in the treatment of non-small cell
carcinoma of the bronchus. However, in view of the relatively
short duration of response and considerable toxicity, this
regimen is likely only to be of benefit to a selected few
patients.
10.2 Small Cell Lung Cancer
10.2a Introduction
For many years it has been accepted that small cell
carcinoma is a chemosensitive disease, with combination
chemotherapy more effective than single agent treatment.
Results of the many chemotherapy studies reported in this
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disease are well summarised in 2 excellent reviews (Bunn & Ihde
1981; Ihde & Bunn 1982). Unfortunately the majority of the
published trials report uncontrolled studies, although it is
accepted that controlled studies are difficult in a disease
offering median survival of only 6-17 weeks in untreated
patients. The object of this study was to assess the activity
of combination chemotherapy using methotrexate, cyclophos¬
phamide and the nitrosourea, CCNU, in patients with small cell
lung cancer and to compare these results retrospectively with
results observed in a similar patient population treated
between 1972 and 1978
10.2b Patient3 and Methods
(i ) Patients treated between 1971-1978
This group comprised of 193 patients with small cell lung
cancer who were admitted to hospitals in the North Lothian
District of the Lothian Health Board. The names of these
patients were obtained from the National Cancer Registry. The
case records of 13 patients were unobtainable, and in a further
10 the histological diagnosis could not be confirmed,
leaving 110 assessable patients. Treatment comprised of
radiotherapy alone in 37 patients, radiotherapy and single
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agent chemotherapy (cyclophosphamide) in 9, cyclophosphamide
alone in 9 and surgical resection in 11 patients. The
remaining 75 patients were treated symptomatically.
(ii) Patients treated between 1979-1981
All patients less than 80 years of age with histologically
confirmed small cell lung cancer were entered in the study, if
their performance status was less than 1 (Eastern Co-operative
Oncology Group Scale). Of 108 patients presenting over this
time period with small cell lung cancer, 13 were excluded on
the grounds of age, performance status or questionable
histology. A further 12 patients had no evaluable disease
leaving 83 patients who were entered on study. Patients were
staged by clinical examination, chest x-rays, barium swallow,
diaphragmatic screening, full blood count and assessment of
electrolytes, urea, liver function tests and serum calcium.
Isotope scans of liver, bone or brain, liver ultrasound or bone
marrow aspiration were only performed if there was overt
clinical suspicion of metastatic disease involving any of these
sites. Results were analysed using the conventional categories
of limited and extensive disease, the former referring to
disease apparently limited to the lung, mediastinum or
ipsilateral supraclavicular nodes. The patients all received
the following chemotherapeutic regime:
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Methotrexate 200 mg/m2 given as a 21 hour infusion
followed by 18 hours folinic acid rescue
(9 mg/m2 6 hourly)
Cyclophosphamide 1 g/m2 i.v.
Both drugs were given every 3 weeks for 1 courses. In
addition, CCNU was administered orally at a dosage of 100 mg/m2
with course 1 and 50 mg/m2 with course 3.
At 12 weeks all patients were assessed for response, using
standard criteria.
Patients achieving a complete or partial response were
then randomised to receive no immediate treatment or to receive
6 months maintenance therapy with vincristine (1.1 mg/m2
intravenously days 1 and 8) plus procarbazine (100 mg/m2
orally days 1-11), alternating each month with methotrexate
(10 mg/m2) and cyclophosphamide (500 mg/m2) both given intra¬
venously on days 1 and 8.
10.2c Results
Patient details of both groups are illustrated in Table
10.5. Ninety-six of the patients in the 1971 group were male
(69?) and 11 female. Their median age was 65 years (range 39-83).
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Table 10.5 Characteristics of patients presenting with small
cell lung cancer in the North Lothian District,
Lothian Health Board, 1971-1981
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Disease was apparently confined to the lung in 21?,
mediastinal or local invasion of ribs in 27? and widely
metastatic in 52%. Patient treated between 1979-1981 comprised
of 50 men (60.2?) and 33 women, with a median age of 60 years
(range 28-75). Forty-five patients (54?) had limited disease
and 38 (46?) extensive disease at presentation. Performance
status (P.S.) was assessed in the 1979-1981 patient group only,
with 21 having a P.S. of 0, 35 P.S. of 1, 22 P.S. of 2 and 5 a
P.S. of 3-
Patients treated with chemotherapy between 1979 and 1981
were assessed for response at 12 weeks from the start of
treatment. Fifty-eight per cent of patients had achieved an
objective response (partial or complete remission) at this
stage). Following bronchoscopy 25? of patients were considered
to be in complete remission. Survival of all groups is shown
in Figure 10.3. Median survival was 2 months in the patients
treated between 1971-1978, actively treated patients surviving
a median of 5 months as opposed to 3 weeks for patients
receiving supportive care only. Fifteen per cent of the
actively treated patients survived 1 year and 2 patients
survived more than 3 years (3 years 8 months and 5 years 1




Figure 10.3 Impact of combination chemotherapy on survival of
patients with small cell lung cancer.
M = patients treated with combination chemotherapy
1979-1981 (n = 93); T = actively treated patients
1971-1978 (n = 65); S = supportive care only






Figure 10.Effect of response to chemotherapy on survival of
small cell lung cancer patients treated with
combination chemotherapy; Edinburgh 1979-1981
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with 33$ alive at 1 year and 13? at 2 years. Three patients
remain alive and in remission at 3 years and 9 months, 1 years,
and 1 years 1 months from diagnosis.
Positive factors associated with prolonged survival
included performance status at presentation and response to
chemotherapy. Figure 10.4 illustrates that responding patients
survived longer than patients not achieving a partial response
(p < 0.001). Of patients achieving a complete response, 26$
were alive at 2 years and 11$ at 3 years. The influence of
performance status is illustrated in Figure 10.5, showing that
survival of patients with a performance status of 0-1 was
significantly longer than patients with a performance status of
2-3 (p < 0.001). The survival of patients receiving further
chemotherapy immediately was no different to patients treated
on relapse. Therefore, no apparent benefit was derived from
the use of maintenance chemotherapy, as illustrated in Figure
10.6. Patients relapsing locally with intrathoracic disease
were treated with radiotherapy (1500 cGy in 20 fractions),
whereas patients relapsing systemically were considered for
alternative chemotherapy. Four patients relapsed in the brain,
and were treated with cranial irradiation. Drug toxicity was
observed but was considered tolerable by the majority of












Figure 10.5 Effect of performance status on survival of






















Figure 10.6 Effect of 6 months additional maintenance
chemotherapy on survival of patients with small
cell lung cancer treated with chemotherapy.
M+ = maintenance chemotherapy; M- = observation
alone.
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degree which was reversible with moderate gastrointestinal
toxicity in 29$ (WHO grade 2). Eight patients had haemato-
logical toxicity requiring active intervention but there were
no treatment-related deaths.
10.2d Discussion
Prior to 1979, patients with small cell lung cancer in the
North Lothian District had a median survival of only 8 weeks,
and even selected patients treated with surgery, radiation or
single agent chemotherapy survived a median of only 5 months.
The introduction of combination chemotherapy in 1979 increased
the median survival of patients to 9 months. Despite the
extensive literature on the responsiveness of small cell lung
cancer to chemotherapy, no one regime has emerged as standard
therapy. The results reported in this study are very similar
to many other trials using different drug combinations.
Maintenance therapy had no apparent benefit, similar to results
published from other studies exploring the same concept
(Vincent et al 1980; Daniels et al 1980; Young et al 1981).
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Combination chemotherapy has certainly improved prognosis
for the majority of patients with small cell lung cancer with
long-term survival possible (Johnson et al 1985). However,
despite this, the majority of patients relapse and their
disease is then frequently resistant to further therapy.
10.3 Summary
There remains a wide variation in the response of the
different histological categories of lung cancer. Small cell
carcinoma remains the most chemosensitive of the cell types,
although long-term survival and cure remain remarkable elusive.
More recently attempts have been made to increase the cure rate
with the use of induction regimes similar to the one used in
this study, followed by high dose chemotherapy and autologous
bone marrow transplantation. The results of these studies are
awaited with interest but even if successful these regimes are
likely to be of value to a limited number of patients, and
further developments in the therapy of this disease are
necessary.
Unresectable non-small cell carcinoma of the lung remains
a common and difficult problem. Response rates to chemotherapy
are lower, and the duration of these responses are disap¬
pointingly short. Combinations of cis-platinum and vindesine
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have given the best results with chemotherapy but severe
toxicity precludes the widespread use of these combinations.
The development of new platinum analogues may reduce the
toxicity of these combinations but are unlikely to dramatically
improve the response rate in these tumours. New drugs are
required and greater understanding of the mechanism of inherent
resistance in these tumours may help in the development of a
more effective therapeutic approach.
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CHAPTER 11
CHEMOTHERAPY STUDIES IN XENOGRAFTS
11.1 Introduction
Prior to commencing chemotherapy studies in xenografts,
experiments were performed to identify maximal tolerated doses
of each individual drug. Drug toxicity was primarily assessed
by animal survival experiments although limited studies were
carried out to determine degrees of haematological and renal
toxicity.
11.2a Drug Toxicity Studies
All drugs used in growth delay chemotherapy experiments
underwent acute toxicity studies to determine their maximum
tolerated dose. Using a minimum of 8 animals per group,
survival curves were constructed for each agent. From these
survival curves, the LDiq's (dosage of drug in mice causing 10$
lethality at 30 days) were calculated for each drug. The
survival curve for cis-platinum is illustrated in Figure 11.1.
The maximum tolerated dose of drugs can vary in immuno-
suppressed animals as is shown with cis-platinum (Figure 11.1),
and therefore, wherever possible immune-suppressed or immune-
deprived animals were used. A dosage of drug slightly less
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Fig. 11.1 Determination of LD-|0 of cis-platinum in CBA mice:
•—•normal CBA ■—■ immunosuppresed.
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than the LD^g was used as the maximum tolerated dose with the
survival data for the drugs used in chemotherapy experiments
shown in Table 11.1. The maximum tolerated doses of drugs used
in these experiments were lower than those used by other inves¬
tigators as illustrated in Table 11.2. The reduction in maximum
tolerated doses of these drugs was not entirely related to the
immune status of these animals. Stock CBA mice, although able
to tolerate higher drug doses than immune-deprived animals were
only able to take approximately 10% of the dose tolerated by
similar strains of mice as reported by other laboratories.
11.2b Bone Marrow Toxicity
All agents used in chemotherapy studies were administered
at the maximum tolerated dose to groups of 10 animals, and
white cell counts were measured using a tail vein bleeding
technique. 20 pi of whole blood was collected by capillary
attraction and made up to 10 ml with isotonic saline. Red
cells were lysed using Zaponin (Coulter Products Ltd) and white
cell counts measured using a coulter counter. Each measurement
was the mean of the values from 3 animals and was estimated as
a percentage of control, and the results are illustrated in
Table 11.3.
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Drug Dose (mg/kg) No. of mice Survival %










Etoposide 30 10 10
(VP—16 x 1) 40 10 70
50 10 60
Etoposide (x 3) 15 8 100
20 8 75
25 8 62
JM40 30 10 100
40 10 90
50 10 70








Vincristine x 2 0.6 8 100
0.7 8 62
0.8 8 50
Table 11.1 30 day survival of CBA mice treated with varying
doses of cytotoxic drugs intraperitoneally.
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Maximum Tolerated Doses of Cytotoxic Drugs (mg/kg)






Vincristine 0.8 x 2C 0.6 mg x 2
Cyclophosphamide 200° 150
Ifosfamide 233 x 3C 300 x 1
VP-16 20 x 3° 15 x 3
aSteel G.G. et al. Br J Cancer (1983) _47: 1 — 13
bEvans B.D. et al. Br J Cancer (1982) 4jj: 466-468
°Shorthou3e A.J.. ChM Thesis, University of London 1981
Table 11.2 Maximum tolerated doses of drugs as measured in CBA
mice in 2 different laboratories.
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Time After Injection (days)
Drug 2 4 6 8 10 1 4
Cis-platinum 83 78 78 118 78 102
Vindesine 85 70 81 101 97 123
Cis-platinum + vindesine
(100$ of each drug)
83 36 - - - -
Cis-platinum + vindesine
(.75% of each drug)
87 42 61 102 176 129
JM40 64 45 92 78 130 124
Cyclophosphamide 51 26 70 86 133 94
Ifosfamide 64 36 48 87 135 124
Ifosfamide + mesna 77 33 49 99 1 42 96
Etoposide (35 mg/kg) 88 32 115 154 168 119
Etoposide (15 mg/kg x 3) 91 41 13 107 1 92 113
Table 11.3 White cell counts expressed as a percentage of
control, as measured in CBA mice following maximum
tolerated doses of various drugs.
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Cis-platinum and vindesine had minimal bone marrow
toxicity although enhanced effect was noted with the drug
combination. Complete results are not available for the full
dose cis-platinum and vindesine combination following which all
animals had died by day 6. The platinum analogue JM40 was more
myelotoxic, as was etoposide (VP16). The alkylating agents
cyclophosphamide and ifosfamide were also myelotoxic, although
ifosfamide was more myelotoxic than expected, with urotoxicity
generally considered dose-limiting.
11.2c Renal Toxicity
One of the main problems arising from cis-platinum
administration is renal toxicity. Blood urea estimations were
therefore carried out on groups of 4 mice on alternate days
following the administration of cis-platinum 7 mg/kg, or the
platinum analogue JM40 at a dosage of 40 mg/kg. Animals were
killed by ether anaesthetics and blood obtained from the
inferior vena cava, with two samples pooled together. The
samples were spun at 450 g plasma removed, and specimens
assayed in duplicate. The assays were kindly performed by
Dr D Horn (Department of Clinical Chemistry, Western General
Hospital). The results are shown in Table 11.4. As the LD^jq
of cis-platinum was slightly lower in immune-deprived mice, the










0 2 4 6 8 10 14
9.9 8.4517.9 9.0 18.65 11.65 10.15
9.65 8.9 10.1 10.35 11.15 11.13 10.1
8.6 6.4 20.0 -
Table 11.4 Effect of maximum tolerated doses of platinum
compounds on blood urea measurements in CBA mice.
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was considered. However, no difference was noted histo¬
logically in any of the animals treated with cis-platinum with
or without total body irradiation. Likewise, a few untreated
irradiated mice were sacrificed and blood urea estimations
performed. In none of these mice was the blood urea found to
be elevated.
11.3a Chemotherapeutic Response
Of the 9 xenograft lines available for experimental work,
6 were chosen for chemotherapy studies as they were relatively
non-necrotic and had good implant take rates. All 6 were
non-small cell carcinoma xenograft lines comprising of 1
adenosquamous, 1 adenocarcinoma and if squamous carcinoma lines.
In addition, limited studies were carried out on the 1 small
cell carcinoma xenograft (WX 310). Of the 6 non-small cell
xenografts 5 were derived from patients who underwent thora¬
cotomy at the City Hospital, Edinburgh. The other xenograft
was obtained from a patient investigated at the Northern
General Hospital. This patient later underwent "curative"
resection at the City Hospital and remains disease-free 2 years
later. No direct comparison of patient and xenograft response
was possible as these patients did not receive chemotherapy.
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Treatment
Xenograft Cell Type Vindesine Cis-platinum Combination
Median Growth Delay
NX 002 squamous <0.2 2.0 1.9
CX 109 squamous 0.31 0.73 1 .00
CX 133 squamous 0.26 1.23 0.61
CX 140 squamous <0.2 1 .45 0.77
CX 143 adenosquamous 0.21 0.29 <0.2
CX 117 adenocarcinoma <0.2 0.87 0.74
growth delay 0.2 1.09 0.87
(average)
Table 11.5 Chemotherapeutie response of 6 human non-small cell
lung cancer xenografts to maximum tolerated doses of
vindesine, cis-platinum and a combination of these
drugs (75% of MTD of each drug).
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Treatment
Xenograft Cell Type Vindesine Carboplatin JM4
Median Growth Delay
NX 002 squamous 2.0 0.90 0.33
CX 109 squamous 0.73 0.73 0.36
CX 133 s quamous 1.23 1.16 0.71
CX 1 40 squamous 1.45 — 1 .33
CX 143 adenosquamous 0.29 0.48 0.48
CX 117 adenocarcinoma 0.87 0.95 0.76
growth delay 1 .09 0.84 0.66
(average)
Table 11.6 Chemotherapeutic response of 6 human non-small cell
lung cancer xenografts to maximum tolerated doses
of cis-platinum and 2 platinum analogues.
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Treatment
Xenograft Cell Type Cyclophosphamide Ifosfamide Etoposide
Median Growth Delay
NX 002 squamous 0.36 - 0.2
CX 133 squamous 0.41 0.47 <0.2
CX 140 squamous - 0.58 <0.2
CX 143 mixed 0.63 1.38 0.38
CX 117 adenocarcinoma 0.52 1.40 0.91
growth delay 0.48 0.96 0.36
(average)
Table 11.7 Chemotherapeutic response of 5 human non-small cell
lung cancer xenografts to maximum tolerated doses of
cyclophosphamide, ifosfamide and etoposide.
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The results are presented in groups according to the drug
treatment, and are illustrated in Tables 11.5, 11.6 and 11.7.
The response of the xenografts to cis-platinum, vindesine and a
combination of the 2 drugs was of interest in view of the
clinical trial in non-small cell lung cancer described in
Chapter 10. In view of the severe toxicities often associated
with cis-platinum therapy, an assessment was made of the
activity of the platinum analogues carboplatin and JM10 which
are generally considered les3 toxic. Other agents were tested
to confirm the validity of this model as an indicator of
chemosensitivity and also in view of their potential use in
future chemotherapeutic schedules.
11.3b Xenograft Response to Cis-platinum
The results are listed in Table 11.5. The sensitivity of
these xenografts varied with median growth delays ranging from
0.73 to 2.0 doubling times in squamous carcinoma lines with NX
002, a moderately differentiated squamous carcinoma, the most
sensitive. The adenosquamous carcinoma (CX 113) responded
poorly with a growth delay of only 0.29, with the adeno¬
carcinoma (CX 117) giving a growth delay of 0.87 doubling
times. This gave an average growth delay of 1.09 doubling
times in these xenograft lines.
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11.3c Xenograft Response to Vindesine
The results are listed in Table 11.5. Vindesine showed
minimal activity in these xenografts, with the best response, a
growth delay of 0.31 doubling times, obtained in CX 109, a
moderately differentiated squamous carcinoma xenograft..
11.3d Xenograft Response to Vindesine and Cis-platinum
Combination
The results are shown in Table 11.5. Both drugs were
administered at 75$ of their individual maximum tolerated
doses. Lethality was variable with maximum tolerated doses of
both drugs in combination giving a mortality of approximately
10$. Seventy-five per cent of the maximum tolerated doses of
both drugs given in combination gave variable lethality, on
average 10$. At these doses the combination showed similar
activity to cis-platinum as a single agent being less effective
against the CX 110 xenograft but more active against CX 109.
This combination was ineffective against the adenosquamous line
CX 113, although some activity was detected against the
adenocarcinoma xenograft CX 117.
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11.3e Platinum Analogues
Chemosensitivity studies were performed using both
carboplatin and JM40. The growth delay results were compared
with the activity exhibited by cis-platinum, with the data
illustrated in Table 11.6. Cis-platinum tended to be more
active than carboplatin with this drug marginally more active
than JM40. However, differences were not statistically
significant (Kruskal-Wallis, One Way Analysis of Variance).
11.3f Miscellaneous Agents
Cyclophosphamide was used against 4 tumour lines, two
squamous, 1 adenosquamous and 1 adenocarcinoma, giving an
average growth delay of 0.48 doubling times. Ifosfamide, an
alkylating agent of similar structure but with a different
spectrum of activity and toxicity, was more effective than
cyclophosphamide giving an average growth delay of 0.96 tumour
doubling times in 4 tumours. Ifosfamide was particularly
active in two of the tumours tested, the adenosquamous
carcinoma xenograft CX143 and the adenocarcinoma xenograft
CX117. Etoposide (VP16) gave disappointing results with an
average growth delay of only 0.36 doubling times in 5 xenograft
lines. The results are illustrated in Table 11.7.
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Table 11.8 Chemotherapeutic response of the human squamous
lung cancer xenograft, NX 002, to maximum tolerated doses of a
number of single agents, and a limited number of drug
combinations. Drugs were administered at 75$ of their maximum
tolerated dose in all combination chemotherapy regimes.
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11.3g Combination Chemotherapy
Using the moderately differentiated squamous carcinoma
xenograft NX 002, three drug combinations were tested and the
results are illustrated in Table 11.8. Individual drugs in the
combination chemotherapy regimes were administered at 75? of
their maximal tolerated dose. Cis-platinum was combined with
etoposide giving a disappointing overall result, showing a
growth delay of only 0.75 tumour doubling times using 8 tumours
per group. The combination of carboplatin and vindesine gave a
growth delay of 1.65 doubling times in the same tumour.
Cis-platinum and vindesine was marginally the most effective
combination giving a growth delay of 1.9 doubling times.
However this was no more effective than cis-platinum as a
single agent.
11.3b Small Cell Carcinoma
One small cell xenograft, WX 310, was serially trans¬
plantable. It was tested in one chemotherapy experiment using
cyclophosphamide 150 mg/kg with 10 tumours in each treatment
group. A growth delay of 1.25 doubling times was observed with
cyclophosphamide at this dosage which is less than may have
been expected. Shorthouse (1981) reported growth delays of
greater than 3 doubling times for this drug used as a single
agent against small cell carcinoma xenografts. However, the
donor patient had previously been treated with methotrexate,
cyclophosphamide and CCNU. Originally the patient had achieved
a complete response but on relapse re-treatment was much less
207
successful using the same drugs. As the xenograft line was
established following the failure of re-induction chemotherapy
this may explain the relative resistance of this xenograft to
cyclophosphamide. No further chemotherapy studies were
performed with this xenograft line and as this was the only
small cell xenograft available it was decided to concentrate on
the non-small cell xenografts.
11.4 Discussion
The estimation of maximum tolerated doses for each drug
were somewhat imprecise in view of relatively small animal
numbers used in these experiments. However, it is important
to strike a balance between accuracy of this parameter and the
unnecessary killing of animals. The likelihood of wide
variation from the true maximum tolerated doses are unlikely
using these numbers. Intra-peritoneal injections of vindesine
and vincristine, which can cause a sclerotic reaction at the
injection site, occasionally resulted in random deaths even at
low doses, making estimations of maximum tolerated dose some¬
what imprecise. When drugs were administered in a divided dose
schedule, higher cumulative drug doses were tolerated by the
mice than with single injections. Potentially, there are a
number of possible explanations for the increased drug tolerance
such as changes in the distribution of cells in cell cycle and
alterations in drug metabolising enzyme activity. These
factors will be dealt with in a later section dealing with the
protective effect of 'priming* doses of drugs (Chapter 13).
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However, the lethality of a drug can be related to many other
factors, such as the solvent used for the drug. For example,
the formulation of etoposide includes polysorbate 80, a surface
active agent which has been associated with allergic reactions
(O'Dwyer and Weiss, 1984). Some mice died within 24 hours of
receiving etoposide although it remains pure conjecture whether
an allergic reaction was involved in these deaths.
Myelotoxicity, as measured by peripheral white cell
counts, was minimal with single doses of cis-platinum and
vindesine, but more severe with the alkylating agents and
etoposide. Renal toxicity, as illustrated by the blood urea,
was greater in cis-platinum treated animals than in JM40 or
carboplatin treated, and was also severe in animals treated
with both cis-platinum and vindesine. However, from these
studies the aetiology of the increased lethality from the
combination remains in doubt.
The platinum analogues are interesting compounds, particu¬
larly carboplatin, which has shown significant clinical
activity in a number of studies (Alberts et al, 1985; Muggia et
al, 1985; Smith and Evans 1985), with minimal renal toxicity
and greatly reduced gastrointestinal symptoms. This compound
and another platinum analogue JM9 (CHIP) have been shown to be
the most active of the platinum compounds, so far evaluated,
and it seems likely that one of these two drugs will be used
widely in clinical practice in the near future.
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Clinical response data shows ifosfamide (Morgan et al
1981) and cis-platinum (De Jager et al 1980) having the
greatest single agent activity. Clinical response to vindesine
has been variable, with Gralla et al ( 1979) reporting a 21 %
response rate but this was not confirmed by either Mattson et
al (1980) with a 10% response rate or Elliot et al (1984)
reporting a 0% response rate, with the xenograft response to
vindesine correlating better with the latter two studies.
Cyclophosphamide had minimal activity in xenografts, as
predicted, with etoposide likewise giving disappointing
results. Cis-platinum, carboplatin and ifosfamide were the
most effective agents in the xenografts tested. Cis-platinum
had variable activity in xenografts similar to that observed
clinically.
The results of combination chemotherapy were disappointing
in xenograft experiments with the cis-platinum-vindesine
combination no more active than cis-platinum alone, although it
must be appreciated that with the combination only 75% of the
maximum tolerated doses of both drugs were given. Cis-platinum
with etoposide was less active than the cis-platinum-vindesine
combination using the moderately differentiated squamous
carcinoma xenograft NX 002. In the same tumour, carboplatin
with vindesine showed similar activity to the cis-platinum and
vindesine combination, although again was no more effective
than cis-platinum alone.
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It is appreciated that the use of maximum tolerated doses
of drugs to compare their activity, in this setting, is an
imprecise method of assessing relative chemosensitivity.
However, it is likewise inappropriate to administer the agents
in doses proportionate to those used clinically, as the
handling of cytotoxic drugs can vary widely between species.
Non-small cell lung cancer xenografts therefore exhibit a
similar chemotherapeutic profile to that observed clinically.
As may have been expected, no dramatic responses were seen
although variation in response between xenograft lines of
similar histology was observed. Exquisite drug sensitivity has
been observed in small cell lung cancer xenografts (Shorthouse
1981) but responses of this magnitude were not seen in these
non-small cell lung cancer xenografts.
There is a need for active, new agents, particularly for
the treatment of non-small cell lung cancer, although
variations in scheduling techniques and different combinations
of the presently available drugs may prove beneficial. The
human xenograft model offers a unique opportunity to
investigate both the activity of new chemotherapeutic agents,




INTERFERON AND CYTOTOXIC DRUG COMBINATIONS
12.1 Introduction
As stated in Chapter 5, interest has grown recently in the
potential use of human interferons in cancer therapy. Balkwill
et al (1984) have previously shown potentiation of cyclophos¬
phamide in breast carcinoma xenografts, with other studies also
showing potentiation of cytotoxic drug activity in combination
with interferon (Aapro et al 1983; Inoue and Tan 1983; Welander
et al 1985).
In view of the poor response of non-small cell lung cancer
to chemotherapy, both _in vivo and hi vitro, it was decided to
investigate the effects of combinations of cytotoxic drugs with
human interferon, using the human xenograft model.
12.2 Materials and Methods
12.2a Interferon
Human lymphoblastoid interferon (a2-Namawla) was obtained
as previously described (Fantes et al 1980). It was prepared
and kindly provided by Dr F R Balkwill (Imperial Cancer
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Research Fund, London). It was tested for activity and
aliquoted as previously described (Balkwill et al 1983). This
interferon was shown not to stimulate natural-killer cell
activity in nude mice, this work carried out by Dr Balkwill.
It had a specific activity of 1-2 x 10$ u/mg and was essent¬
ially pure. Animals were injected subcutaneously at the base
of the neck with 2 x 105 U of interferon daily with control
animals receiving subcutaneous saline. This interferon dose
is roughly equivalent to 20 x 106 u/m2 daily in man.
12.2b Cytotoxic drugs
Two drugs were used in combination with interferon.
Cyclophosphamide (Farmitalia Carlo Erba Ltd, St Albans, UK) was
chosen in view of its previously reported potentiation by
interferon (Balkwill et al 1981). Cis-platinum (Bristol-Myers
Ltd, Slough, UK) was used as it was the most active single
agent in these xenografts, and because of previously reported
potentiation by B~interferon (Inoue and Tan 1983). Drugs were
administered intraperitoneally at 20? of their maximum
tolerated dose with a maximum of 5 weekly injections being
given. Total cytotoxic drug dosage in these animals was
roughly equal to the maximum tolerated dose i.e. cis-platinum
7 mg/kg and cyclophosphamide 200 mg/kg.
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12.2c Study Design
Three lung xenograft lines were studied: NX 002, a
moderately differentiated squamous carcinoma, CX 117, an
adenocarcinoma, and CX 113, an adenosquamous carcinoma. All
animals were irradiated on the same day and transplanted with
tumour the following day. When sufficient numbers of tumours
were greater than 0.3 cm3, mice were stratified according to
tumour size then randomly allocated to one of 1 treatment
groups; cytotoxic drug alone, interferon alone, cytotoxic drug
plus interferon in combination, or a control group.
Interferon was administered subcutaneously daily for 35
days, with cytotoxic drugs given intraperitoneally weekly for 5
weeks. Tumour volume was estimated from thrice weekly measure¬
ments performed with calipers.
12.3 Results
Experimental results from each of the xenograft lines are
illustrated in Tables 12.1; 12.2 and 12.3.
12.3a NX 002 - moderately differentiated squamous carcinoma
The results are shown in Table 12.1. The median control
tumour doubling time (Tq) was 16 days, with a mean tumour
volume increase of 136.9$ in control mice over the 35 day
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experiment. Interferon alone and cyclophosphamide were
minimally active with Tp's of 21.5 days, a specific growth
delay of 0.31 doubling times. Cis-platinum treatment resulted
in an increased median tumour doubling time of 35 days; a
growth delay of 1.18 doubling times. The combination of
cyclophosphamide and interferon caused a minimal increase in Tp
to 32 days; specific growth delay of 1.0 doubling times. The
cis-platinum and interferon combination was the most active,
resulting in an increase of median tumour doubling time to 52
days, a growth delay of 2.25 doubling times. Using the
Kruskal-Wallis one way analysis of variance this treatment was
statistically significantly superior to other treatments
(p < 0.05). Using the mean increase in tumour volume at 35
days as the parameter of response, the combination of cis-
platinum and interferon was significantly more active than
other treatment groups (p < 0.005, Kruskal-Wallis one-way
analysis of variance). The tumour volume doubling time was
increased, with less of an increase in mean tumour volume at 35
days in the cyclophosphamide plus interferon group. However,













Control 10 16 - 436.9
Interferon 6 21 .5 0.34 284.4
Cis-platinum
1 .4 mg/kg x 5
6 35 1.18 169.1


















Control 10 16 - 436.9
Interferon 6 21 .5 0.34 284.4
Cyclophosphamide
40 mg/kg x 5
8 21.5 0.34 335.75
IFN +
cyclophosphamide 6 32 1.0 (NS) 220.2 (NS)
Cyclophosphamide 8 0.36
150 mg/kg
Tables 12.1a and 12.1b Effect of human alpha interferon and
cytotoxic drugs administered singly and in combination in the
treatment of the human lung cancer xenograft NX002.
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12.3b CX 143 - Adenosquamous Carcinoma
The results using this xenograft line are shown in Table
12.2. Median control Tq was 16 days, with interferon alone
resulting in minimal growth delay (Tq » 23 days, specific
growth delay 0.44). Cyclophosphamide and cis-platinum were
marginally more active giving specific growth delays of 0.68
and 0.81 doubling times respectively. Interferon combinations
were the most active, with the cis-platinum combination
superior. A median Tq of 41 days was achieved with this
combination compared with 35 days in the cyclophosphamide and
interferon group with specific growth delays of 1.56 and 1.18
doubling times respectively. The cis-platinum and interferon
combination was significantly superior to control or either
agent alone using both specific growth delay (p < 0.05), and 35
day tumour volume increase (p < 0.05) as parameters of response
(Kruskal-Wallis one-way analysis of variance).
12.3c CX 117 ~ Adenocarcinoma
The results are illustrated in Table 12.3. CX 117 was
the most rapidly dividing tumour in this study, with a median
control TD of 13 days. Cyclophosphamide treatment resulted in
an increased median Tp to 19.5 days (specific growth delay 0.5













Control 8 16 - 425.9
Interferon 6 23 0.44 227.0
Cis-platinum
1 .4 mg/kg x 5
6 29 0.81 325.4


















Control 8 16 - 425.9
Interferon 6 23 0.44 227.0
Cyclophosphamide
40 mg/kg x 5
8 27 0.68 325.3
IFN +
cyclophosphamide




Table 12.2a & 12.2b Effect of human a interferon and cytotoxic
drugs administered singly and in combination in the treatment
of the human lung cancer xenograft 0X1*13.
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in Td to 22 days (specific growth delay 0.69 doubling times).
Interferon alone had activity with a Tq of 23 days (specific
growth delay 0.77 doubling times). The cyclophosphamide and
interferon combination was marginally more active than single
agent therapy, with a TD of 27 days (specific growth delay 1.07
doubling times), but these were not statistically significant.
The cis-platinum-interferon combination was by far the most
active, causing an increase in TD to 51 days; a specific growth
delay of 2.92 doubling times (p < 0.01). Similarly, tumour
volume increase at 35 days was limited to 136.8? in this group,
by far the most active of the groups (p < 0.01 , Kruskal-Wallis
one-way analysis of variance).
12.38 Toxicity
No significant difference was noted in the white cell
counts in any of the groups compared to control, using blood
obtained from the tail veins of 3 animals in each group at day 35.
Significant weight loss was not observed in any of the
animals, with no mice losing more than 10? of body weight.
However, control mice did gain more weight than the other














Control 6 13 - 792.6
Interferon 6 23 0.77 303.8
Cis-platinum
1.4 mg/ kg x 5
4 22 0.69 257.4


















Control 6 13 - 792.6
Interferon 6 23 0.77 303.8
Cyclophosphamide
40 mg/kg x 5
6 19.5 0.5 384.2
IFN +




Table 12.3a & 12.3b Effect of human a interferon and cytotoxic
drugs administered both singly and in combination in the
treatment of human lung cancer xenograft CX 117.
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1 2. Discussion
Interferon as a single agent has been shown to have
minimal activity in non-small cell lung cancer (Grundberg et al
1985). Using weekly injections of cis-platinum and cyclophos¬
phamide at 20% of the maximum tolerated dose, minimal effects
on tumour growth were observed, as may have been expected. The
combination of interferon and cyclophosphamide in all 3 lines
showed greater activity than that observed with either agent
alone, although at best showed additive effects. The cis-
platinum-interferon combination was by far the most effective
in all 3 xenograft lines. The combination was particularly
active in the adenocarcinoma line (CX117) • giving a specific
growth delay of 2.92 doubling times. This is in comparison to
growth delays of 0.77 and 0.22 doubling times respectively for
interferon and cis-platinum alone. The response to this
combination is also significantly superior to a maximum
tolerated dose of cis-platinum given as a single intraper¬
itoneal injection, when a growth delay of only 0.87 doubling
times was observed.
It remains pure conjecture as to the mechanism of this
increased cytotoxicity. It has been shown that human lympho-
blastoid interferon does not increase natural killer cell
activity in the host, and it has also been shown that human
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interferon does not affect drug metabolising activity in the
mouse (Balkwill et al). Recently, it was reported that
interferon increased free radical formation i_n vivo, and if
this claim is substantiated it could certainly help to explain
the enhanced toxicities observed with interferons in combin¬
ation with cytotoxic agents such as cyclophosphamide,
adriamycin and cis-platinum. It does not explain the relative
difference in potentiation between cis-platinum and cyclophos¬
phamide combinations. However it would appear from published
reports that the greatest enhancement is observed with the use
of interferon in combination with the most active cytotoxic
drug against that particular tumour.
As previously indicated, there are a number of problems to
be addressed before this therapy can be introduced into the
clinic. Firstly, in this model human interferon has no effect
on any of the host tissues, whereas in patients effects on
numerous tissues could be expected. Mouse interferon has been
shown to affect the activity of drug metabolising enzymes in
mice (Singh et al 1982), with similar effects likely to be
observed in patients when human interferon is used. How much
this will interfere with the beneficial effects of these
combinations remains an open question. However a reasonable
indication could be obtained using this model system with a
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hybrid interferon which expresses inter-species cross-
reactivity. The use of hybrid interferons in this model could
give an indication of the likely clinical effects of altered
drug metabolism on interferon-cytotoxic drug combinations.
Secondly, the schedule used in this study, delivering the
equivalent of 20 mega units per day to humans, would not be
tolerated by many patients and therefore, more realistic
schedules require to be tested in this model. New schedules
require to be assessed both in terms of dosage and frequency
of administration of the interferon. Recently, further work on
this model has been performed by Dr R J Fergusson (ICRF Medical
Oncology Unit) using a much lower dose of interferon. Using
doses of interferon at approximately 10$ of those used in this
study, similar potentiation was observed with combinations of
interferon and cis-platinum, with interferon alone having no
effect on xenograft growth (Fergusson - personal communication).
Thirdly, in view of the toxicity of cis-platinum, it would
seem worthwhile testing more drugs, particularly platinum
analogues, in combination with interferon, in an attempt to
achieve similar results.
Finally, it has to be remembered that the cytotoxic drug
dosages used in this study were much lower than those normally
incorporated into cytotoxic drug combinations. Further studies
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should be done using higher cis-platinum doses in an attempt to
improve the cytotoxicity of this combination. In this study no
significant bone marrow toxicity was observed. Similarly,
weight loss, a good general indicator of toxicity in these
mice, was not seen in treated animals, therefore higher
cytotoxic drug doses may well be tolerated.
In conclusion, the combination of interferon with cyto¬
toxic drugs, particularly cis-platinum, gives a greater
anti-tumour effect than can be achieved with either agent used
singly in the treatment of non-small cell lung cancer xeno¬
grafts. Likewise, this cytotoxicity is greater than that
observed with maximum tolerated doses of these agents given as
a single intra-peritoneal injection. Although further studies
are required, these results are very encouraging and it is
hoped that such combinations may improve on the rather dismal




MODULATION OF CHEMOTHERAPY; - EFFECT OF CALCIUM INFLUX BLOCKERS
13.1 Introduction
As stated in Chapter 5, the use of calcium channel
blockers has been shown to increase the activity of vinca
alkaloids, adriamycin, and the epidophyllotoxin etoposide
(Yalowich and Ross 1984). This increase in activity is more
pronounced in cell lines exhibiting pleiotropic drug
resistance, and is felt to be due to a membrane effect
primarily inhibiting drug efflux from the cell. Vindesine, a
vinca alkaloid, was found to have minimal activity against
these non-small cell lung cancer xenografts. This drug was
therefore combined with verapamil, a calcium channel blocker,
in an attempt to enhance its cytotoxicity.
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13.2 Materials and Methods
13•2a Study design
Two separate experiments were carried out. The first
experiment was designed to assess the cytotoxicity of vindesine
and verapamil in combination, and the second to investigate the
bone marrow toxicity associated with this combination.
13.3 Effect of verapamil on the cytotoxicity of vindesine
The cytotoxicity of vindesine and verapamil in combin¬
ation was assessed using tumour-bearing CBA mice carrying
either NX 002, a moderately differentiated squamous carcinoma
xenograft, or CX 140, a moderately differentiated squamous
carcinoma xenograft. For each xenograft line, the following
groups were studied using a minimum of 5 animals per group:
(a) saline control 0.2 ml/day x 10 i.p.
(b) vindesine 0.2 mg/kg/day x 10 i.p.
(c) verapamil 50 mg/kg/day x 10 i.p.
(d) vindesine 0.2 mg/kg/day x 10 i.p.
+




The control group consisted of 11 tumours with a mean
tumour doubling time of 21.3 days. Groups treated with
verapamil and vindesine alone comprised of 5 tumours per group
with tumour doubling times of 21 days and 21 days respectively.
The goup given the combination of both drugs tolerated
treatment very poorly. All 7 animals, carrying 11 tumours,
died shortly after injections wer discontinued at 7 days with
no animal surviving more than 10 days.
(ii) NX 002
A mean tumour doubling time of 16.6 days was observed in
the control group of 8 tumours. This compared with 18.8 days
in the verapamil treated group of 5 tumours and 21.1 days in an
identical number of vindesine treated animals. Once again, all
animals in the group receiving a combination of both drugs
died, with mice treated with a maximum of 7 days chemotherapy.
13.1 Effect of verapamil on the bone marrow toxicity of vindesine
Bone marrow toxicity of vindesine, verapamil and a
combination of these drugs was assessed using female non-tumour
bearing CBA mice, with 10 animals per group. The same groups
were used as for the previous experiment.
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13.4a Drugs
Vindesine (Eli-Lilly Ltd) was diluted in sterile normal
saline to a concentration of 0.02 mg/ml. CBA mice received
0.1 ml/10 g body weight (0.2 mg/kg) intraperitoneally daily
for 10 days, a maximum dose of 2 mg/kg. Verapamil was
administered at 50 mg/kg, the lowest dose used by Tsuruo et al
(1981; 1983). Verapamil was diluted to a concentration of
2 mg/ml, animals therefore receiving 0.25 ml/10 g body weight,
intraperitoneally.
13.4b Haematological toxicity
White cell counts were carried out every second day, with
blood collected using a tail vein technique. 20 pi of whole
blood was collected in capillary tubes from 3 animals in each
group. The blood was directly added to 9.98 ml normal saline
to which 3 drops Zaponin (Coulter Chemicals Ltd) had been
added. The latter was used to lyse red blood cells, and white
cell counts were then performed using a Coulter Counter.
13.4c Results
White cell counts for all treatment groups, expressed as
a percentage of control, are shown in Table 13.1. In addition,
the effect of cyclophosphamide 150 mg/kg was used as a positive
control. Vindesine alone caused a depletion in the white cell
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count to 52? of control at day 8, with a recovery by day 10.
Verapamil alone caused no significant alteration in the white
cell count. The combination of drugs caused an earlier
depletion in the white cell count but this had fully recovered
by day 10. However, the latter sample consisted of only one
specimen, as there was only one survivor in this group at this
stage.
13.5 Discussion
The combination of vindesine (0.2 mg/kg/day) and
verapamil (50 mg/kg/day) was exceedingly toxic both to
tumoui—bearing and non tumoui—bearing CBA mice. These animals
did not die a haematological death as the white cell count was
normal in these animals at the time of death. Therefore, the
two most likely aetiologies are enhanced neurological
toxicity or enhanced peritoneal toxicity, although neither was
experimentally substantiated.
These results are in keeping with the previous reports
showing no enhancement of adriamycin toxicity on bone marrow
cultures when used in combination with verapamil. Whether
enhancement of vindesine activity can be achieved with smaller
doses of these drugs remains an open question. However, these
studies do suggest that a more detailed assessment of host
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DVA VERAP DVA + VER CYCLO (150 mg/kg)
Day 2 99 106 89 90
Day 1 96 93 18 51
Day 6 81 106 91 26
Day 8 52 86 91 69
Day 10 118 86 110* 86
Day 11 79 106 - 133
Day 16 156 200 -
Day 20 88 81 -
Table 13.1 Effect of verapamil (VER) and vindesine (DVA) on
the white cell count in CBA mice. Verapamil 50 mg/kg i.p.
daily x 10 and vindesine 0.2 mg/kg i.p. daily x 10. White cell
count expressed as a percentage of control with all results a
mean of 3 specimens.
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toxicities is warranted prior to the use of verapamil-cytotoxic
drug combinations in clinical protocols.
Recently, further studies have been performed by the
author to identify the mode of potentiation of calcium channel
blockers in pleiotropically resistant cells. Using two
pleiotropic mutant pairs, the CHO cell lines Aux B-| and its
pleiotropic mutant CHRC5, made resistant to increasing doses of
colchicine, were kindly provided by Dr V Ling (Toronto,
Canada) and 2 MCF-7 cell lines, the wild-type, (WT) and its
pleiotropic mutant ADR10, made resistant to increasing doses of
adriamycin, were kindly provided by Dr K Cowan (National Cancer
Institute, USA). It was found that both pleiotropically
resistant cell lines were collaterally sensitive to the calcium
channel blockers diltiazem and verapamil, compared with
wild-type cells. In addition, an increase was noted in surface
transfer receptor number in both resistant cell lines, although
treatment with calcium channel blockers did not affect the
ratio of surface transfer receptors in resistant and sensitive
cells. Further studies are underway in an attempt to identify




CYCLOPHOSPHAMIDE PRIMING: EFFECT ON ANIMAL SURVIVAL
14.1 Introduction
The results of the biochemical experiments will be
presented in the following chapters. Initially, data are
presented showing the protective effects on survival of small
'priming' doses of cyclophosphamide given prior to a normally
lethal dose of the same compound.
14.2 Materials and Methods
Male CBA mice were used to establish a dose of cyclophos¬
phamide that was lethal to 100^ of animals when administered as
a single intraperitoneal injection. Similar mice were then
used to identify the most effective 'priming' or protective
dose of cyclophosphamide and the optimal day of administration
of this priming dose prior to the lethal dose. For all of




14.3a Identification of a Lethal Dose of Cyclophosphamide
Groups of mice were treated with doses of cyclophos¬
phamide from 250 mg/kg to 500 mg/kg in 50 mg/kg increments. A
single dose of 350 mg/kg was the minimum dose causing death of
all animals and therefore was used for all of the biochemical
experiments. At this cyclophosphamide dose, death is
attributed to either haematological or urotoxicity with
pulmonary toxicity dose-limiting at doses between
400-500 mg/kg. Death occurs much earlier following doses of
cyclophosphamide over 500 mg/kg with cardiac toxicity the most
likely aetiological factor.
14.3b Protective Effect of Cyclophosphamide 'Priming'
Using lethal cyclophosphamide doses of 350 mg/kg and
400 mg/kg, the protective effects of variable 'priming' doses
of the same drug were studied. Survival following a lethal
cyclophosphamide dose was assessed in both pre-treated and
control animals. The results are illustrated in Figure 14.1.
All priming doses were given 5 days prior to the lethal dose in
this part of the experiment. A priming dose of 75 mg/kg
cyclophosphamide was found to be the most effective,
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particularly against a lethal dose of 350 mg/kg, when 90$
survival was achieved. This experiment was repeated 3 times
with identical results.
With regard to the optimal timing of this priming dose of
cyclophosphamide, a similar experiment was carried out using
350 mg/kg as the lethal dose and 75 mg/kg as the priming dose.
The priming dose was administered to groups of mice at
variable times prior to the lethal dose. The results are
illustrated in Figure 1^.2. Maximal protection was observed
5~7 days after the priming dose of cyclophosphamide using these
particular doses.
Discussion
These results confirm previous reports of protection
against the lethal effects of alkylating agents by pre-treat-
ment with the same or similar compounds (Jeney and Connors
1968; Millar et al 1978). The 'priming' phenomenon is not
limited to alkylating agents, however, with the protection
observed against a number of toxic insults. Ozone, for
instance, has been shown to protect against the lethal
pulmonary toxicity of subsequently administered high concent¬
rations of this compound (Chow and Tappel 1972). Likewise,
tolerance to heat can be observed on exposure to thermal stress
(Mitchell and Russo 1983).
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Fig. 14.1 Effect of variable priming doses of cyclophosphamide on 14 day survival
following: Q 350mg/kg and ^ 400 mg/kg in CBA mice.
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Similarly, numerous agents have been shown to protect
against the lethal effects of x-irradiation. Colchicine was
one of the first compounds shown to be protective against
x-irradiation (Smith 1958), followed by the vinca alkaloids
(Smith and Wilson 1967). More recently, Millar (1978) and
colleagues at the Institute of Cancer Research in London have
shown radioprotection by numerous agents including metho¬
trexate, cyclophosphamide and cytosine arabinoside, with the
latter compound extensively studied. If given 2-3 days prior
to irradiation, cytosine arabinoside offers maximal protection
in terms of animal survival. However, by altering the interval
between exposure to the drug and irradiation, maximal
protection can be seen in different tissues, such as the bone
marrow or gastrointestinal tract (Phelps and Blackett 1979).
The mechanism of cytosine arabinoside protection may well
relate to the recruitment of cells into a relatively radio¬
resistant phase of the cell cycle, late S-phase. In agreement
with this hypothesis, a second dose of cytosine arabinoside
administered at the time of maximal radioprotection is highly
toxic, suggesting redistribution of cells in cycle. It seems
likely that the strathmokinetic agents work in a similar way.
In contrast, in the development of thermotolerance,
production of heat shock proteins and elevation in glutathione
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Fig. 14.2 Effect of varying time between priming (75mg/kg) and lethal dose
(350mg/kg) of cyclophosphamide on 14 day survival in CBA mice:
[23 maximal protection.
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levels are considered important (Mitchell and Russo 1983).
However, the mechanism of protection afforded by alkylating
agents against similar compounds and x-irradiation remains
unknown, although a number of typical features have become
apparent. Alkylating agent 'priming' has been shown to
increase the rate of recovery of the CFU-S, CFU-GM and
peripheral granulocyte populations following the subsequently
administered high dose of chemotherapy. However, the enhanced
recovery of blood elements is not due to diminished sensitivity
of the stem cell population to the subsequent toxic insult.
The exact mechanism of protection afforded by alkylating agents




EFFECT OF TOXIC COMPOUNDS ON MOUSE TISSUE GLUTATHIONE AND
GLUTATHIONE TRANSFERASE LEVELS
15.1 Introduction
Glutathione, an intracellular tripeptide, is involved in
cellular defence mechanisms against reactive molecules. Many
xenobiotics have been shown to reduce hepatic glutathione
levels (Pi Simpliclo 1982), and conversely, alterations in
glutathione levels have been shown to affect the response of
cells to cytotoxic drugs (Roizin-Toile et al 1984). Likewise,
glutathione transferases have been shown to be protective to
the liver (Di Simpllcio 1982) and tumour cells in vitro (Batist
et al 1985). In addition, elevations in glutathione and
glutathione-S-transferase levels have been associated with the
development of drug resistance both in vivo (Wolf et al 1985)
and _in vitro (Hamilton et al 1985).
The following experiments were carried out to elicit the
role, if any, of glutathione and glutathione transferase levels
in the protection afforded by low dose alkylating agents. This
work was carried out in collaboration with David Adams and
Roland Wolf in the Imperial Cancer Research Fund laboratories.
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15.2 Cyclophosphamide as a Priming Agent
Methods
Male CBA mice 8-12 weeks of age were used for these
studies. Animals were injected with varying doses of cyclo¬
phosphamide intraperitoneally. They were then sacrificed at
different times and samples prepared for glutathione and
glutathione transferase assays. Hepatic and bone marrow
samples, collected in the manner described in Chapter 7, were
assayed at these time points. Specimens were collected for 10
days following the priming dose with all samples assayed in
triplicate. For these experiments glutathione was measured
using the fluorimetric method described by Hissin and Hilf
(1977) with glutathione transferases measured as described in
Chapter 7 (Habig et al 1976) using 1-chloro-2,4-dinitrobenzene
as substrate.
15.3 Results
15.3a Hepatic Glutathione Levels
The effect of varying doses of cyclophosphamide on
hepatic glutathione levels was assessed. Three cyclophos¬
phamide doses were used, two priming doses 75 mg/kg and
100 mg/kg, in addition to a lethal dose of 500 mg/kg. The
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results are illustrated in Figure 15.1. As is shown initially,
there was a depletion in glutathione levels following all three
doses of cyclophosphamide, with recovery and subsequent minimal
elevation of levels in surviving animals, three days after drug
exposure. Depletion was minimal, with the lower doses (less
than 30? decrease), whereas 500 mg/kg resulted in a 60?
reduction of liver glutathione levels which did not recover
prior to the death of all the animals in that group.
15.3b Hepatic Glutathione Transferase Levels
Aliquots of samples from the above experiments were
assayed for glutathione transferase as described in Chapter 7.
The results were virtually identical to the glutathione data,
showing an initial depletion of transferase levels following
the priming doses with subsequent recovery and minimal over¬
shoot of levels in surviving animals. With the lethal dose,
glutathione transferase levels were depleted to a similar




Fig. 15.1 Effect of varying doses of cyclophosphamide on mouse liver glutathione
levels:•—• 75mg/kg O—0100mg/kg and ■—■ 500mg/kg.
2H2
15.3c Bone Marrow Glutathione Levels Following Cyclophosphamide
Priming
Bone marrow glutathione levels were measured using
samples obtained from the femurs of animals used in the above
study. As can be seen in Figure 15.2 greater variation in bone
marrow glutathione levels was observed, in comparison with
hepatic values. All 3 cyclophosphamide doses caused a
profound fall in bone marrow glutathione levels, dropping to
<30? of control values at 36 hours. Glutathione levels
recovered by day 4 with subsequent overshoot of values to
approximately 180% control by 120 hours in the animals treated
with priming doses. However, in the animals treated with the
lethal dose of cyclophosphamide, levels fell to <5? of control
by 35 hours with minimal recovery prior to death. Of interest,
was a transient fall noted in glutathione levels between days
5-6, noted also for glutathione transferase levels. This would
not appear to be a totally random event, as this experiment was
repeated three times with a similar result obtained on each
occasion. The mechanism behind this remains unexplained,




Fig. 15.2 Effect of varying doses of cyclophosphamide on mouse bone marrow glutathione (GSH-
mol/106cells) expressed as a percentage of control; •—• 75mg/kg0---0 100mg/kg»-'-> 500
mg/kg.
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15.3d Bone Marrow Glutathione Transferase Levels
Glutathione transferases were measured using the same bone
marrow samples. Once again, depletion to 30? of control with
subsequent overshoot of glutathione transferase values was
observed following the priming doses of cyclophosphamide. The
lethal dose of cylophosphamide resulted in depletion of values
to less than 5t of control with no recovery of glutathione
transferase levels noted prior to death of all the animals in
the group.
15.1 Effect of Cyclophosphamide Priming Doses on Tissue
Glutathione Levels Following Subsequent Lethal Dose
Cyclophosphamide Treatment
Methods
Male CBA mice 8-12 weeks of age were used. Animals were
treated with a lethal dose of cyclophosphamide (350 mg/kg) 5
days after pre-treatment with either saline, or cyclophos¬
phamide (75 mg/kg). Bone marrow glutathione and glutathione
transferase levels in treated mice were compared with control
untreated mice at each time point.
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15.5 Results
15.5a Bone Marrow Glutathione Levels
The results are shown in Figure 15.3. Primed animals
once again have elevated bone marrow glutathione levels at day
5. Following the lethal dose, however, levels fall
dramatically in both groups. There was recovery in primed
animals which survived the lethal dose, with overshoot of
glutathione levels to >300$ of control values.
15.5b Bone Marrow Glutathione Transferase Levels
Bone marrow glutathione transferase levels
are illustrated in Figure 15.1, with a similar trend
animals, glutathione transferase levels of approximately 800$
of control were observed following recovery from the 'lethal'
dose.
15.6 Effect of Cyclophosphamide, Cytosine Arabinoside and
X-Irradiation on Mouse Bone Marrow Glutathione and
Glutathione Transferase Levels
Methods
Male CBA mice 8-12 weeks of age were used. Animals were
treated with either cyclophosphamide 75 mg/kg, cytosine
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arabinoside 200 mg/kg (both used as priming doses in mice), or
X-irradiation 200 cGy. Mouse liver and femurs were excised and
specimens processed as previously described.
15.7 Results
15.7a Glutathione Levels
Minimal effect on hepatic glutathione content is observed
following cyclophosphamide, cytosine arabinoside or x-irradi-
ation at these doses with the results shown in Figure 15.5
The results for all 3 treatment modalities on bone marrow
glutathione levels are shown in Figure 15.6. All 3 treatments
caused a fall in bone marrow glutathione levels, with subse¬
quent recovery and overshoot. The timing of the maximal
increase in glutathione levels varied, although the degree of
overshoot was similar.
15.7b Glutathione Transferase Levels
The results are illustrated in Figure 15.7, showing an
identical trend to that shown for glutathione levels, with an
initial depletion, followed by overshoot of glutathione
transferase levels to supranormal levels. Glutathione
transferase values of approximately 200? were observed with
each treatment, although the timing of this increase varied.
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Fig. 15.3 Bone marrow glutathione levels in CBA mice treated with a priming dose of cyclophos¬
phamide (75 mg/kg) followed by a lethal dose (350 mg/kg) five days later.
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Fig. 15.4 Bone marrow glutathione transferase levels in CBA mice treated with a priming dose of
cyclophosphamide (75 mg/kg) followed by a lethal dose (350 mg/kg) five days later.
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15.8 Quenching Effect of Tissue Homogenates
Although non-specific fluorescence of histidine-
containing peptides can interfere with the fluorescent assay
(Mokrasch and Teschke 1984) this is minimal at pH 8.0. Another
problem relates to the non-specific quenching of glutathione by
different tissues. A number of factors are involved in this,
including protein content. This problem was addressed by
adding known amounts of glutathione to extracts from various
tissues with known glutathione content.
15.9 Results
The relative quenching of different tissue homogenates is
shown in Figures 15.8 and 15.9. In these figures the control
curve represents the fluorescence of different amounts of
glutathione. For the tissues, a known concentration of
glutathione is added to each sample so that the increase in
fluorescence of tissue samples should run perpendicular to the
control curve. As can be seen in these two figures, absorbance
is less than expected from the control curves. As can be seen
in Figure 15.8, greatest quenching of glutathione is observed
with liver and tumour tissue. In the tumour tissue proteins
from necrotic cells may be important, due to the formation of
protein-sulfhydryl complexes, thereby reducing the measurable
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Fig. 15.5 Effect of cyclophosphamide, cytosine arabinoside and X-irradiation on mouse liver
glutathione levels (GSH-mol/g wet weight). O—O cyclophosphamide 75mg/kg, O— -O
cytosine arabinoside 200 mg/'kg □ whole body irradiation 200 cGy.
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Fig. 15.6 Effect of cyclophosphamide, cytosine arabinoside and X-irradiation on mouse bone
marrow glutathione levels (GSH-moles/106 cells) expressed as a percentage of control:
O O cyclophosphamide 75 mg/kg; O O cytosine arabinoside 200 mg/kg,0 □
XRT 200 cGy.
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non-protein thiol concentration. Various detoxifying enzymes
from liver tissue, from lysosymes for example, may be an
important cause of degradation of the glutathione. For the
determination of absolute glutathione values in tissue, the
observed values should be corrected using these graphs.
15.10 Discussion
These studies show that exposure of various mouse tissues
to cytotoxic agents or x-irradiation causes depletion of
glutathione and glutathione transferase levels. This is not
entirely unexpected as there is a vast literature on the
effects of toxic chemicals on glutathione levels, particularly
in the liver. In the liver, following non-lethal doses, there
is subsequent recovery of these levels by 72 hours with minimal
overshoot of values above control levels. Recovery was not
observed following lethal doses.
In the bone marrow a different picture emerged with a more
dramatic fall observed in both glutathione and glutathione
transferase levels with subsequent recovery and overshoot of
values to approximately 180$ of control levels. This overshoot
occurred at a different time following exposure to cyclophos¬
phamide than with cytosine arabinoside or x-irradiation.
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Fig. 15.7 Effect of cyclophosphamide, cytosine arabinoside and total body irradiation on mouse
bone marrow glutathione —S—transferase levels (activity = mol DNCB/min/106 cells)




Fig. 15.8 Quenching effect of tissue homogenates on the glutathione assay: •—»control;
■—■ bladder; m—Oliver; * * tumour (NX002).
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Fig. 15.9 Quenching effect of whole blood and bone marrow on the glutathione assay:
■ ■bone marrow; a Awhole blood.
control;
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It is of great interest that in the case of cyclophos¬
phamide this overshoot occurred at the time of maximal
protection against the lethal cyclophosphamide dose. The
elevation in glutathione and glutathione transferase levels
levels following cytosine arabinoside occurs between 72-96
hours after a 200 mg/kg dose with 48-72 hours the time at which
maximal protection is afforded against the lethal effects of
radiation. This was the dosage and schedule of cytosine
arabinoside treatment as used in the preparation of immune-
deprived animals for the xenograft studies.
However, on the negative side, priming with cytosine
arabinoside did not protect against the lethal effects of
cyclophosphamide despite the elevations in glutathione and
glutathione transferase levels. Similarily, no survival
protection was afforded by pretreatment with radiation
(200 cGy) prior to cyclophosphamide lethal dose administration,
given at the time of maximal glutathione elevation. For these
studies CBA mice were primed with either 200 mg/kg cytosine
arabinoside intraperitoneally or with 200 cGy whole body
irradiation. At the time of maximal overshoot in glutathione
levels, 96 hours, the mice were then challenged with a lethal
dose (350 mg/kg of cyclophosphamide) intra-peritoneally. No
survival protection was observed in these studies.
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Cytosine arabinoside treatment blocks cell cycle progres¬
sion. The protection produced by this compound against the
lethal effects of radiation almost certainly results from the
recruitment of cells into late S-phase, a relatively resistant
phase of the cell cycle. Variation in cell cycle distribution
also occurs following x-irradiation and cyclophosphamide
treatment. In fact, the alterations in glutathione levels
observed at these times could be partially explained by cell
cycle recruitment. Harris and Teng (1973) showed variations
in glutathione levels throughout the cell cycle, with late
S-phase cells having the highest glutathione although these
findings have not been reproducible. However, changes in
cell cycle distribution would seem unlikely to fully explain
the alterations in glutathione and glutathione transferase
homeostasis observed in these studies.
Glutathione and glutathione transferase levels, compounds
known to be protective to cells by detoxication mechanisms,
were found to be elevated at the time of maximal protection
against a lethal dose of cyclophosphamide. However, prior to
making any direct correlations, a number of very important
questions required to be addressed. Firstly, the bone marrow
is a dynamic and extremely heterogenous population. Did the
changes in bone marrow glutathione levels merely represent
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alterations in bone marrow cell populations? Certainly Fried
et al (1973) studying the effects of cyclophosphamide on mouse
bone marrow, showed dramatic alterations in overall cellul-
arity, and also an increase in the relative proportions of
granulocyte and granulocyte precursors from 25$ to approxi¬
mately 50$ in treated mice. Secondly, the metabolism of
cyclophosphamide is interesting in that the cytotoxicity and
haematological toxicity are attributed to one metabolite,
phosphoramide mustard, with another metabolite, acrolein,
implicated in the toxicity, particularly to the urogenital
tract.
Therefore, it was of interest to evaluate which metabolite
was responsible for the protective effect on survival provided
by priming doses of cyclophosphamide. In addition, was the
same metabolite responsible for the observed alterations in
glutathione homeostasis?
Thirdly, it has been shown in erythrocytes that there is a
feedback control of glutathione synthesis. It was of interest
to ascertain whether alterations in glutathione and glutathione
transferase levels represented a compensatory synthetic process
or merely preferential survival of cells with higher initial
levels of these two compounds. Finally, it is known that drug
priming can protect the bone marrow, gastrointestinal tract and
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the bladder against subsequent toxic insult. What remains far
from clear is whether tumour tissue can be protected in a
similar manner. Obviously, if a similar phenomenon occurs in
tumour tissue, this would negate the protective effects of
priming on the bone marrow, and would result in an unchanged
therapeutic index of cyclophosphamide. These questions will be
addressed individually in the following chapters.
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CHAPTER 16
EFFECT OF CYTOTOXIC DRUGS ON THE BONE MARROW
16.1 Introduction
The effect of cytotoxic drugs on the bone marrow was
studied both biologically, in terms of overall cellularity, and
biochemically by measurement of glutathione and glutathione
transferase levels in individual bone marrow cell populations.
16.2 Bone Marrow Cell Number
The effect of various toxic agents on bone marrow cell
number was studied.
16.2a Methods
Bone marrow cell counts were carried out during each
glutathione time course experiment with the cells counted using
a haemocytometer. The marrow was obtained from the femurs of 3
mice, with the effect on bone marrow cellularity of cyclophos¬
phamide 75 mg/kg, cytosine arabinoside 200 mg/kg and whole body
irradiation 200 cGy measured over 7 days.
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16.3 Results
Bone marrow cellularity was assessed at different times
following cyclophosphamide 75 mg/kg, cytosine arabinoside
200 mg/kg and x-irradiation 200 cGy with the results illustrated
in Figure 16.1. With all three compounds there was an initial
increase over the first 24 hours, followed by a progressive
fall in cell number, maximal at day 5, with recovery by day 7.
In comparison, acrolein, a metabolite of cyclophosphamide, when
given intra-peritoneally, caused minimal depletion in bone
marrow cellularity as shown in Figure 16.2.
16.4 Discussion
The results from this study confirm a previous report
(Fried et al 1973) showing depletion of nucleated cell number 4
days after 2 mg cyclophosphamide intra-peritoneally. In the
same study, they showed that the relative of proportion
granulocytes and granulocyte precursors in the bone marrow
increased from 25 to 50% following cyclophosphamide. Thus,
from these results, it seems possible that the changes in
glutathione and glutathione transferase levels, observed in
these studies, could be explained by changes in bone marrow
cell populations. Therefore, it was essential to isolate the
individual cell populations for further investigation.
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16.5 Bone Marrow - Individual Cell Populations
As a means of isolating respective cell populations, a
fluorescent activated cell sorter (FACS) was used. Various
cell types from bone marrow and peripheral blood suspensions
were separated using a Becton-Dickinson FACS IV, on the basis
of their differential forward and right angle light scattering
properties (Watt et al 1980; Ritchie et al 1985). The iJ88
nanometre line of an argon ion laser was used for the excit¬
ation of both the forward and right angle scatter signals, with
samples run at approximately 1000 cells per second. This work
was performed in collaboration with Dr John Ansell, Department
of Zoology, University of Edinburgh. Using these techniques,
the bone marrow was divided into it distinct cell populations as
shown in figure 16.3. This figure illustrates the respective
cell populations from a control untreated sample, but following
a cyclophosphamide priming dose there were dramatic changes
observed in these cell populations as shown in figure I6.it. By
gating off appropriate segments, different populations were
sorted, and these were collected in aliquots of 300,000 cells
in ice-cooled Eppendorf centrifuge tubes. During the procedure
all samples were kept at it°C, to minimise autoxidation of
glutathione. Following collection, cells were immediately
centrifuged at 250 g, the supernatant aspirated, and the cell
263
Fig.16.1 Effect of cyclophosphamide, cytosine arabinoside and X-irradiation on mouse bone marrow
cell number: • • cyclophosphamide 75 mg/kg; O--O cytosine arabinoside 200 mg/kg;
•-•-a total body irradiation 200 cGy.
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Fig. 16.2 Effect of Acrolein (6.2mg/kg) on bone marrow cell number.
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pellet frozen in dry ice. Numerous samples of all 4 sub-groups
were collected: granulocytes, lymphocytes, erythrocytes and an
anomalous population consisting mainly of monocytes and stem
cells. The majority of samples were used for biochemical
analyses, although aliquots from each sub-group were histo¬
logically analysed, to confirm purity of the samples.
Glutathione was estimated using O-phthalaldehyde as
previously described (Hissin and Hilf 1976). Glutathione
transferase levels were virtually undectable using 300,000
cells aliquots, therefore 3 samples were pooled and used for
each estimation. All glutathione and glutathione transferase
values were expressed per 10^ cells.
16.6 Results
Glutathione levels in the different bone marrow cell
populations are shown in table 16.1 with comparisons of control
and cyclophosphamide primed samples. For this experiment
animals were treated with 100 mg/kg cyclophosphamide as a
priming dose. Erythrocytes had the lowest glutathione level,
with no difference noted between primed samples and control.
Both the lymphocyte and anomalous cell fractions had higher
levels of glutathione but no significant change in level was
detected following cyclophosphamide priming. The granulocyte
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Right angle light scatter
Figure 16.3 Becton-Dickinson FACS 'dot plots' of mouse bone
marrow from untreated animals. Four populations observed;
















Right angle light scatter
Figure 16.1 Becton-DIckinson FACS 'dot plots' of mouse bone
marrow following treatment with cyclophosphamide 100 mg/kg 5
days previously. Groups A-D as in Figure 16.3
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population had, by far, the highest level of glutathione, with
a significant increase in levels following cyclophosphamide
treatment. Increases of greater than 50? were observed in
repeated experiments with the results of the first 3
experiments illustrated in table 16.1. Glutathione transferase
levels were carried out on the granulocyte samples, with
increases of the same degree detected, as shown in table 16.2.
16.7 Glutathione and Glutathione Transferase in Peripheral
Blood Granulocytes
If glutathione levels in granulocytes prove to be a good
indicator of 'drug priming', it would be extremely valuable if
these measurements could be performed on a peripheral blood
specimen rather than bone marrow specimens. Peripheral blood
specimens were therefore obtained from mice treated in an
identical manner. Animals were given a cyclophosphamide
priming dose of 100 mg/kg with blood collected from the
inferior cava following sacrifice of the animal by ether
anaesthesia. Erythrocytes were lysed using a distilled water
shock technique and remaining cells separated on the FACS as
previously described for the bone marrow cells. Cellular
distribution of peripheral blood samples are shown in figures
16.5 - control sample - and figure 16.6 - cyclophosphamide
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Anom. population 14.5 14.16
Granulocytes i) 36.0 41.33
ii) 25.43 41.23
iii) 25.56 44.5
Table 16.1 Glutathione levels in individual bone marrow cell
populations separated using a Becton-Dickinson FACS. Values
are expressed as emission units per 10& cells in both control
and cyclophosphamide treated cells.
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treated sample. Granulocytic glutathione levels are shown in
table 16.2. Levels of glutathione measured in peripheral blood
samples were lower than those detected in bone marrow granulo¬
cytes, although the degree of overshoot in levels from primed
samples was similar. Unfortunately insufficient cells were
obtained to measure granulocytic glutathione transferase levels
from peripheral blood specimens.
16.8 Glutathione in Peritoneal Granulocytes
Glutathione is a labile compound with autoxidation a
serious problem in measurement. Separation using the FACS can
take a long time, with autoxidation of glutathione potentially
problematical. A method was utilised therefore to obtain large
numbers of granulocytes rapidly for measurement of glutathione
and glutathione transferase levels. Approximately 10? cells
per mouse were obtained using this technique (Watt et al 1979),
with a relatively high purity of granulocytes. Normal CBA mice
were injected with 2 ml of 2% casein intraperitoneally.
Animals were sacrificed 3 hours later and peritoneal lavage
performed using ice-cold phosphate buffered saline. The cells
were spun down at 250 g for 5 minutes and washed 3 times in
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Specimen Control Prime
1) Marrow - (FACS)
27.0 39.0
glutathione
glutathione transferases 0.01M 0.036
2) Peripheral blood - (FACS)
glutathione 22.77 32.5
3) Peritoneal - (Casein stimulated)
glutathione 38.M 62.33
glutathione transferases 0.020 0.029
Table 16.2 Effect of cyclophosphamide 100 mg/kg on murine
granulocytic glutathione and glutathione transferase levels.
Glutathione expressed as emission units per 10^ cells, and
glutathione transferase levels expressed as absorption per
9 x 10^ cells.
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Right angle light scatter
Figure 16.5 Becton-Dickinson FACS 'dot plots' of mouse
peripheral blood from control animal3. Group B - lymphocytes,
Group D - granulocytes.
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Right angle light scatter
Figure 16.6 Becton-Dickinson FACS 'dot plots' of mouse
peripheral blood from animals treated with cyclophosphamide 5
days previously.
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ice-cold 0.168 M ammonium chloride. Cells were allowed to
stand for 10 minutes in ammonium chloride to lyse erythrocytes.
Samples were centrifuged at 250 g for 5 minutes, the
resultant pellet resuspended in the phosphate buffer used for
glutathione estimations, and the cells counted using a haemo-
cytometer. The results are illustrated in table 16.2.
Glutathione and glutathione transferase levels were higher
using this technique, but whether this relates to the more
rapid collection of these cells with minimal autoxidation of
glutathione, or to the casein stimulation itself remains a
matter of speculation. Despite this, increases in glutathione
and glutathione transferase levels were detected in cyclophos¬
phamide treated animals. These increases were proportionately
similar to those observed using granulocytes obtained by FACS
separation.
16.9 Conclusions
Several methods have been described to separate been
marrow and peripheral blood specimens into their constituent
cell types. This was achieved in these studies, with a high
degree of purity, in that greater than 80^ purity of cell type
was estimated by histological examination of these samples.
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On separating the bone marrow into 4 sub-populations, it
was found that the highest glutathione and glutathione
transferase levels were found in the granulocyte population.
This is in keeping with previous reports on glutathione levels
in haematopoetic cells. Following a cyclophosphamide priming
dose, elevation of bone marrow glutathione levels can be
attributed both to an increase of cells (granulocyte and
granulocyte precursor cells) having high initial glutathione
levels, and also to a true increase in glutathione levels in
these cells. This is of great interest as it is the enhanced
recovery of the granulocytic population which is the
predominant factor associated with improved survival in primed
animals.
Higher levels of glutathione were detected in the
peritoneal casein stimulated granulocytes although it remains
unresolved whether this increase relates to the casein stimul¬
ation itself, or whether this is merely a more valid represent¬
ation of granulocytic glutathione levels. FACS separation can
take up to 30 minutes to collect 300,000 cells, dependent on
the cell concentration and it is possible that this delay
results in the autoxidation of glutathione, with subsequent
loss of activity. It is certainly suggestive, as peripheral
blood granulocytes, which take the longest to collect, have the
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lowest glutathione levels. Despite the loss of overall
activity in peripheral blood samples, relatively similar
increases in glutathione levels were detected in cyclophos¬
phamide treated cells.
The measurement of glutathione or glutathione transferase
levels in peripheral blood this could be of great importance
clinically should drug priming and high dose chemotherapy
become more widely used. Potentially, there could be a
relatively simple assay on peripheral blood specimens from drug
•primed' patients to predict whether they are maximally
protected against the toxic effects of high dose chemotherapy.
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CHAPTER 17
EFFECT OF INTERLEUKINS ON DRUG PRIMING
17.1 Introduction
Over the past 30 years considerable interest has focussed
on host response to infection. Phagocytic cells have been
shown to secrete soluble products which have distinct bio¬
logical properties. The term interleukin-1 (IL-1) is now used
to describe a single molecule or family of molecules having
these properties, including lymphocyte activating factor,
endogenous pyrogen and leukocyte endogenous mediator. IL-1 has
been shown to stimulate a granulocytic reaction iri vivo, due to
accelerated release of mature neutrophils from the bone marrow
(Craddock et al 1956). Similarly, increased colony
stimulating activity is noted with IL-1 whilst interleukin-3
(IL-3) has been shown to enhance differentiation of
granulocytes.
One constant finding with the priming phenomenon is the
more rapid recovery of peripheral blood elements, particularly
granulocytes, in pre-treated animals. In view of the
biological activities of these interleukins, it was considered
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appropriate to assess whether IL-1 or IL-3 could protect mice
by enhancing bone marrow recovery following a lethal dose of
cyclophosphamide.
17.2 Materials and Methods
17.2a Animals
Male CBA mice 8-12 weeks of age were used in this study.
Interleukins were injected subcutaneously at the appropriate
times with saline being given to control animals.
17.2b Interleukins
Crude human IL-1 was obtained as described in Chapter
7.11 from concavalin A stimulated human monocytes. This was
kindly provided by Dr Gordon Duff, Department of Rheumatology,
Northern General Hospital, Edinburgh. Human IL-1 was used, as
this substance has previously been shown to possess inter¬
species cross-reactivity. It was shown to be active in these
animals by pyrogen testing.
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WEHI-3B cells were used as a source of IL~3, as
previously described (Ihle et al 1983)> from conditioned media.
This was kindly provided by Dr V. van Heynigen, Medical
Research Council, Clinical Population & Cytogenetics Unit,
Western General Hospital, Edinburgh
17.2c Experimental Design
For all experiments a minimum of 8 animals were used in
each group. All interleukins were assessed for protection
against a lethal dose of cyclophosphamide (350 mg/kg).
Four experiments were carried out using crude human IL-1.
Various schedules for administration of the IL-1 were ass-
sessed. Timing of administration ranged from 18 hours before
the cyclophosphamide injection to 18 hours after injection.
Interleukin 3 was administered 3 times daily for 1-3 days prior
to cyclophosphamide or for 21-18 hours after the cyclophos¬
phamide injection.
17.3 Results
The results of these experiments are illustrated in
Tables 17.1 and 17.2. Duration of survival was unaffected by
any of the interleukin schedules used in these experiments, and
there were no long-term survivors in any experiment.
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17.4 Discussion
The protection afforded to animals treated with a priming
dose of cyclophosphamide is attributed, at least in part, to a
more rapid recovery of peripheral granulocytes. Interleukins
have been shown to increase peripheral granulocyte numbers, and
in particular, the crude human IL-1 used in this study has
been shown to produce a pyrexia and a granulocytic reaction, in
the CBA mice used in this study some 12 hours following IL-1
administration.
Although it is accepted that by no means all potentially
beneficial schedules were studied, this experiment suggests,
that the enhanced granulocytic proliferation detected in primed
animals is a secondary phenomenon and not the primary aetiology
of this protection.
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IL-1 0.25 mis s/c Time 0 hrs 9.0
IL-1 0.25 mis s/c Time -12 hrs 7.125
IL-1 0.25 mis s/c Time -24 hrs 7.25
Control 8.9
IL-1 0.25 mis s/c X 2 Time -24 hrs 7.5
IL-1 0.25 mis s/c X 2 Time -48 hrs 6.5
IL-1 0.25 mis s/c X 2 Time -24 hrs 9.6
IL-1 0.25 mis s/c X 2 Time -48 hrs 7.0
Control 9.4
IL-1 0.25 mis s/c X 2 Time + 24 hrs 10.1




Table 17.1 Effect of crude human IL-1 on the survival of CBA
mice following a lethal dose of cyclophosphamide (350 mg/kg).
282






IL-3 0.25 mis tds for 1 day -2M hrs 10
IL-3 0.25 mis tds for 2 days -M8 hrs 7 NS
IL-3 0.25 mis tds for 3 days -72 hrs 11
2 Control 8.9
IL-3 0.25 mis bd for 1 day +2H hrs 9.8 NS
IL-3 0.25 mis bd for 2 days + iJ8hrs 7.25
Table 17.2 Effect of conditioned media from WeH, 3b cells IL-3 on the




EFFECT OF ACROLEIN ON PROTECTION AFFORDED BY LOW DOSE CYCLOPHOSPHAMIDE
18.1 Introduction
Cyclophosphamide is activated in the liver to ^-hydroxy-
cyclophosphamide. Thereafter, it is further metabolised with
the most active cytotoxic metabolite considered to be phosphor-
amide mustard. With the production of this metabolite,
equimolar amounts of the toxic metabolite acrolein are
produced, the latter responsible for the bladder toxicity
associated with cyclophosphamide. Acrolein is a highly
reactive molecule which has a high affinity for glutathione,
and its toxicity can be prevented by treatment with sulfhydryl
containing compounds such as mesna and N-acetyl-cysteine.
It was, therefore, of great interest to ascertain whether
acrolein or phosphoramide mustard was responsible for the
increase in glutathione levels observed following drug priming,
and similarly, which metabolite was responsible for the
protective effect on survival following the lethal cyclophos¬
phamide dose.
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18.2 Protective Effect of Acrolein Pretreatment
18.2a Materials and Methods
Groups of 10 male CBA mice were used for lethality
studies, as previously described. A lethal dose of cyclophos¬
phamide was used (350 mg/kg), with or without acrolein pre¬
treatment, at a dose of either 3.1 mg/kg or 6.2 mg/kg, with
acrolein given intraperitoneally 5 days before cyclophos¬
phamide. An acrolein dose of 7.1 mg/kg was lethal to 50? of
the mice but no animals died following doses of 3.1 mg/kg or
6.2 mg/kg.
18.2b Results
The effect of acrolein pre-treatment on animal survival
following a lethal dose of cyclophosphamide is shown in figure
18.1. Acrolein 3.1 mg/kg was inactive, but significant
protection was afforded by the higher dose of 6.2 mg/kg
(p < 0.05). However, neither dose was as effective as 75 mg/kg
cyclophosphamide.
285
18.3 Effect of Acrolein on Glutathione and Glutathione
Transferase Levels
18.3a Materials and Methods
Glutathione and glutathione transferase levels were
measured in murine tissues following the administration of
acrolein 6.2 mg/kg. The experiment was performed in an
identical fashion to the cyclophosphamide time course
experiment described in Chapter 15. Animals were sacrificed
and tissues excised at the following time points; 13 hours, 24
hours, 48 hours, 72 hours, 96 hours, 120 hours and 144 hours.
At these time points, livers, femurs and bladders were excised
from these animals and collected in groups of 3. Liver and
bone marrow samples were prepared as previously described
(Chapter 7). Complete bladders were excised, scissor minced in
ice-cold phosphate buffer and then homogenised using a Polytron
homogeniser. Specimens were then centrifuged at 30,000 g for
30 minutes at 40c with the cytosolic fraction used for
glutathione and glutathione transferase assays.
The effect of acrolein 6.2 mg/kg on glutathione and
glutathione transferases levels was assessed in control and
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Figure 18.1 Effect of acrolein as a priming agent given 5 days before a lethal dose of
cyclophosphamide (350mg/kg) in CBA mice: control; Acrolein 3.1
mg/kg: Acrolein 6.2 mg/kg.
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(i) Control - saline 0.2 ml i.p.
(ii) Acrolein - 6.2 mg/kg i.p.
(iii) Cyclophosphamide 75 mg/kg i.p. 5 days before acrolein
6.2 mg/kg i.p.
(iv) Cyclophosphamide 75 mg/kg i.p., 5 days before saline
0.2 ml i.p.
18.3b Results
Figure 18.2 shows the effect of acrolein 6.2 mg/kg on
bone marrow glutathione levels. It can be seen that the
glutathione level is initially depleted, with recovery and
subsequent overshoot by day 5, similar to the results obtained
following a cyclophosphamide priming dose as described in
Chapter 15. Cyclophosphamide priming prevented the initial
depletion of glutathione seen with acrolein alone. Cyclophos¬
phamide priming, in addition to N-acetylcysteine and mesna
treatment, all impaired the subsequent overshoot of glutathione
levels observed in bone marrow samples treated with acrolein
alone. . Similar trends were observed with glutathione
transferase levels, the results being illustrated in figure
18.3. Single agent treatment with N-acetyl-cysteine or mesna,
did not significantly affect glutathione or glutathione
transferase levels in these animals.
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N-acetyl cysteine and mesna were both administered on two
occasions at doses of 200 mg/kg. N-acetyl cysteine was given
30 minutes before and 30 minutes after acrolein treatment,
whereas mesna was given 30 minutes before and 6 hours after
acrolein. Both of these compounds prevented the initial
depletion of glutathione and glutathione transferase levels in
acrolein treated mice, and likewise the subsequent overshoot in
values was impaired.
18.4 Conclusions
Although the protective effect of acrolein was inferior
to cyclophosphamide at priming concentrations, it remains very
interesting that this toxic compound can protect at all. In
addition, it is possible that greater protection could have
been achieved with a different dosage, or perhaps with a slow
infusion of acrolein. Certainly, the acrolein produced in the
metabolism of cyclophosphamide is assimilated less rapidly.
Bladder glutathione levels are shown in figure 18.4. An
increase in glutathione level is noted at day 6, following
acrolein treatment although this was the only time point at
which a significant elevation was observed. A similar increase
was seen in glutathione transferase levels, although great
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Time (Hours)
Fig. 18.2 Effect of acrolein treatment on bone marrow glutathione content in CBA
mice:*—• cyclophosphamide 75mg/kg + acrolein 6.2mg/kg o——o cyclophosphamide
75mg/kg (-5 days) ■—■ Acrolein 6.2 mg/kg.
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Time (Hours)
Fig. 18.3 Effect of acrolein treatment on bone marrow glutathione-S-transferase activity
in CBA mice:#—©cyclophosphamide 75mg/kg -5 days + acrolein 6.2mg/kg o O
cyclophosphamide 75mg/kg -5 days ■—■ acrolein 6.2mg/kg.
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experiment has been repeated and a qualitatively similar result
achieved. Improvements are necessary in the preparation of
bladder samples for this assay, before reliable results can be
achieved or any worthwhile conclusions drawn. However consid¬
eration has to be given to the noxious nature of acrolein which
precludes the frequent repetition of this experiment.
Changes in bone marrow glutathione and glutathione
transferase levels are seen following acrolein therapy. These
changes are virtually identical to those seen after cyclophos¬
phamide priming, both in terms of degree and timing of the
response. It seems likely that the change in glutathione level
observed following cyclophosphamide treatment relates, at least
in part, to acrolein production in view of the high affinity of
this compound for glutathione. It would have been interesting
to confirm this hypothesis by performing a similar experiment
with phosphoramide mustard, but unfortunately this compound is
extremely unstable.
Elevations in bladder glutathione and glutathione trans¬
ferase levels were seen on day 6 following acrolein treatment,
but this experiment should be repeated when techniques have
been improved for the preparation of bladder specimens. Any
changes in bladder glutathione or glutathione transferase
levels would be of great interest in view of the observed
292
Fig. 18A Effect of acrolein treatment on bladder glutathione content in CBA mice:
• »acrolein 6.2mg/kg •—•cyclophosphamide 75mg/kg-5 days + acrolein
6.2 mg/kg.
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improvement in the pathological appearances of bladder tissue
in cyclophosphamide primed animals subsequently challenged with
a high dose of the same compound.
294
CHAPTER 19
TUMOUR GLUTATHIONE AND GLUTATHIONE TRANSFERASE LEVELS
19.1 Introduction
Modulation of cytotoxic drug toxicity could prove to be a
very important development in cancer chemotherapy. However,
the clinical role for drug priming remains undetermined until
the effect of this on tumour tissue is fully evaluated.
Obviously, the potential for 'priming' tumour tissue is
theoretically possible. Should this be substantiated then the
beneficial effects of drug priming would be negated, resulting
in an unchanged therapeutic index. Therefore the effect of
cytotoxic drugs on tumour glutathione and glutathione
transferase levels was investigated in a number of experiments.
Initial experiments were performed with human lung cancer
lines, to determine the effect of cell type on glutathione and
glutathione transferase levels. Experiments were then
performed to determine whether glutathione levels in liver or
bone marrow were affected by immunosuppressive procedures.
Following this, experiments were carried out to mesure
glutathione levels in human lung cancer xenografts of
different histologies. The effect of maximum tolerated doses
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of various cutotoxic drugs on tumour glutathione levels was
then assessed and finally, experiments were performed to
determine whether tumour tissue can be primed by low doses of
alkylating agents.
19.2 Glutathione and Glutathione Levels in Human Tumour Cell
Lines
19.2a Materials and Methods
The human tumour cell lines were kindly provided by
Dr A. F. Gazdar, NCI-Navy Medical Oncology Branch, National
Cancer Institute, Bethesda, Maryland, USA. Thirty-one lung
cancer cell lines were used, 16 small cell lung cancer cell
lines and 15 non-small cell lung cancer cell lines. Of the
small cell lines, 6 were derived from patients who had received
no chemotherapy, prior to establishment of the cell line,
whereas the remainder were derived from previously treated
patients. Three cell lines exhibited characteristics of the
variant phenotype (Gazdar et al 1985). The fifteen non-small
cell lines comprised of ^ adenocarcinoma, 3 large cell
carcinoma, 2 adenosquamous, 2 squamous, 2 bronchiolo-alveolar
and 2 mesothelioma cell lines.
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All cell lines, apart from 1 small cell line NCI-H510,
were grown in Roswell Park Memorial Institute (RPMI) medium
(Gibco) supplemented with 10% (v/v) foetal calf serum with
added penicillin and streptomycin. NCI-H510 cells were grown
in the serum-free defined medium - HUES (Simms et al 1980).
All cell lines were shown to be mycoplasma free and were
maintained in exponential growth phase. Cells were disag¬
gregated and passaged 1 week before and fresh medium added 18
hours before harvesting of the cells for all assays.
All small cell lines, apart from NCI-H811,grew as floating
aggregates. They were harvested on the day of the experiment,
centrifuged at 250 g for 5 minutes, washed 3 times in ice-cold
phosphate buffered saline, then resuspended in 2 ml of the
appropriate solution. Glutathione assays were performed using
a modification of the Tietze assay (1969). Following washing
in ice-cold phosphate buffered saline, cells were resuspended
in 2 ml of 0.6$ sulphosalicylic acid, sonicated for 5 seconds,
then centrifuged at 650 g for 5 minutes at I^C. The super-
natent was assayed for glutathione content, and the residual
cell pellet assayed for protein. (Lowry et al 1951). For
glutathione transferase estimations, cells were resuspended in
phosphate buffer, and stored at -70°C awaiting completion of
the assay.
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All non-small cell lung cancer lines grew as monolayer
cultures. Cells were detached from the plastic and disag¬
gregated using a 5 minute trypsin wash at 37°C. Trypsin was
then inactivated by adding an equal volume of serum containing
medium. Thereafter, cells were treated in a similar manner to
the small cells described above.
19.2b Results
Glutathione levels for the small cell lines are listed in
Table 19.1 with duplicate values for each cell line.
Duplicate assays were performed on cells from different tissue
culture flasks. Table 19.2 lists glutathione levels for the
non-small cell lung cancer cell lines. Glutathione levels
were found to be higher in the more resistant non-small cell
lines, with particularly high values in squamous carcinoma and
mesothelioma cell lines. Glutathione transferase levels for
all 31 cell lines are illustrated in Table 19.3.
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19.3 Effect of Immune-Deprivation on Tissue Glutathione Levels
19.3a Materials and Methods
Hepatic and bone marrow glutathione levels were measured
in stock CBA mice using the fluorometric assay of Hissin and
Hilf (1976). Four mice per group were used in the following
groups;
(1) Control untreated mice
(2) Thymectomised, irradiated mice
(3) Tumour-bearing, thymectomised, irradiated mice.
Animals were sacrificed by cervical dislocation, and
specimens collected, as described in Chapter 7.
19.3b Results
Hepatic and bone marrow glutathione levels are shown in
Table 19.^ for all 3 groups. No difference was observed
between control mice and mice immune-deprived by means of
thymectomy and total body irradiation. However, significantly
depleted hepatic glutathione levels were detected in tumour
bearing immune-deprived mice, although normal bone marrow
values were observed in these mice.
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Table 19.1 Glutathione levels measured in human small cell
lung cancer cell lines.
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Table 19.2 Glutathione levels measured in human non-small cell
lung cancer cell lines.
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Table 19.3 Glutathione transferase levels in human lung cancer
cell lines.
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19.4 Tumour Glutathione Levels
Glutathione levels were found to vary between tumours.
This variation was evident between tumours of the same histo¬
logical type, and also between different tumour types.
Glutathione levels of approximately 16 nanomoles/mg protein
were detected, although variation between tumours was approxi¬
mately 25%. Mean glutathione levels were determined in 4
tumour lines with the highest value detected in NX 002 xeno¬
grafts, 24.2 nanomoles/mg protein, with CX 140 16.2 nano¬
moles/mg protein, CX 143 10.73 nanomoles/mg protein and CX 117,
6.66 nanomoles/mg protein. However, a number of factors can
affect these levels, however. The size and growth rate of the
tumours are important, in addition to the nutritional status of
the host animal.
19.5 Effect of Maximum Tolerated Doses of Cytotoxic Drugs on
Tumour Glutathione Levels
19.5a Materials and Methods
Three human non-small cell lung cancer xenograft lines
were used for these studies; NX 002, and CX 140, both moder¬
ately differentiated squamous carcinomas and CX 143, an
303
Group Liver Bone Marrow
1. Control 2.28 mM ± 8? 3.87 x 1o~10 micromoles/cell
± 10?
2. Thymectomised/ 2.01 mM ± 12? 1.7 x 10~10 micromoles/cell
irradiated ± 8?
3. Tumour-bearing/ 1.36 mM ± 15? 1.8 x 10~10 micromoles/cell
Immune-deprived ± 10?
Table 19.1 Hepatic and bone marrow glutathione levels in; (1)
control CBA mice; (2) immune-deprived CBA; (3) tumour-bearing,
immune-deprived mice.
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adenosquamous carcinoma. Mice were stratified into groups
according to sex and to tumour size. For each xenograft line
the following groups were studied:-
(i) Control
(ii) Cyclophosphamide 200 mg/kg i.p.
(iii) Vindesine 2 mg/kg i.p.
(iv) Cis-platinum 7 mg/kg i.p.
Using 4 animals per group, maximum tolerated doses of
cytotoxic drugs were administered intra-peritnoneally 48 hours
prior to sacrifice of the mice. Tumours were prepared for
analysis as described in Chapter 7, with bone marrow samples
obtained simultaneously. Glutathione levels were performed
using the method described by Hissin and Hllf (1976).
19.5b Results
Glutathione levels, expressed as a percentage of control
are illustrated in Table 19.5. Bone marrow glutathione levels
were depleted by all drugs, although less depletion was
observed with cis-platinum. A slightly different picture
emerged on analysis of tumour glutathione levels. Tumour
glutathione levels were unaffected by vindesine, which was
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found to be inactive in these xenografts. Likewise, cis-
platinum was found to be inactive against the adenosquamous
xenograft CX 143, with no depletion of glutathione observed in
these tumours. In contrast, cis-platinum, which had the
highest activity of any single agent in the xenograft line,
NX 002, causing a growth delay of 2.0 doubling times depleted
glutathione levels to 56.2% of control in this line.
However, no detectable change in glutathione levels was
observed in the CX 140 xenograft line, despite marginal
activity with cis-platinum. Conversely, cyclophosphamide,
which had minimal effect on the growth of NX 002 xenografts,
was shown to deplete glutathione levels to 68% of control in
these tumours.
19.6 Effect of Priming Doses of Cyclophosphamide on Tumour
Glutathione and Glutathione Transferase Levels
The effect of cyclophosphamide (75 mg/kg) on tumour
glutathione and glutathione transferase levels was studied in
three non-small cell lung cancer xenografts, and in small cell
lung cancer xenografts kindly supplied by Dr A F Gazdar, Navy
Medical Oncology Branch, National Cancer Institute, Bethesda,
USA.
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Xenograft Treatment Tumour Bone Marrow
Glutathione Glutathione





cyclophosphamide 200 mg/kg 68.3 25.3
vindesine 2 mg/ kg 89.5 56.0
cis-platinum 7 mg/kg 56.2 49.3
control 100 100
cyclophosphamide 200 mg/kg ND ND
vindesine 2 mg/kg 82.9 50.6
cis-platinum 7 mg/kg 83.0 79.5
control 100 100
cyclophosphamide 200 mg/kg 86.8 47.0
vindesine 2 mg/kg 119.0 -
cis-platinum 7 mg/kg 92.9 76.0
Table 19.5 Effect of maximum tolerated doses of cytotoxic drugs on
tumour and bone marrow glutathione levels in tumour-bearing immune-
deprived CBA mice.
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19.6a Materials and Methods
(i) Non-small cell lung cancer xenografts
Immune-deprived CBA mice, as previously described for the
xenograft studies, were used. Three xenograft lines were
studied, NX 002, CX 117 and CX 143. For each part of this
experiment animals of the same age and sex were used, although
both male and female mice were used at different stages. The
mice were immune-deprived and transplanted with tumour on the
same day. Tumours of 0.3 cm3 or greater were included with
equivalent numbers of tumours included in both treated and
control groups. Groups were stratified according to tumour
size with a minimum of 4 tumours included per group. The mice
received either cyclophosphamide 75 mg/kg or saline i.p. For
the pilot study using the xenograft line CX 117, animals were
sacrificed on days 2, 4 and 5 after injection. Thereafter
definitive studies were performed sacrificing mice on days 2,
6 or 10 following cyclophosphamide administration. Tumour
samples were prepared for glutathione and glutathione trans¬
ferase estimations with assays performed as described in
Chapter 7. Simultaneously, femurs from these mice were removed
and the bone marrow cells assayed for glutathione and
glutathione transferase levels. Tumour levels were evaluated
on a per milligram protein basis (Lowry et al 1951), with bone
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marrow values expressed per 1C)6 cells as before. All results
were subsequently expressed as a percentage of control values,
(ii) Small Cell Lung Cancer Xenografts
This experiment was performed in an identical fashion to
the previous experiment. Two small cell lung cancer cell lines
were grown as xenografts in nude mice. NCI-H209 a cell line
showing classical small cell features, and NCI-H82 a line
exhibiting variant small cell morphology (Gazdar et al 1985;
Carney et al 1985) were used for this study. NCI-H209 was
derived originally from an untreated patient with NCI-H82
derived from a patient who had relapsed following treatment
with cyclophosphamide, adriamycin, vincristine and procar-
bazine.The nude mice were housed in specific pathogen free
conditions. Cyclophosphamide 75 mg/kg or saline, was admin¬
istered intraperitoneally and mice subsequently sacrificed on
days 2, 6 and 10 thereafter. Bone marrow and tumour specimens
were prepared as previously described (Chapter 7).
19.6b Results
(i) Non-Small Cell Lung Cancer Xenografts
The pilot experiment, using CX 117, tumours confirmed the
overshoot in bone marrow glutathione levels following low dose
cyclophosphamide, with observed values relative to control of
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64? on day 2, 110? on day 4, 140? on day 5 and 129? on day 6.
However, no overshoot in glutathione levels was observed in
tumour tissue. Initially, depletion of glutathione levels was
observed (56? on day 2, 58? on day 4), although these returned
to normal by day 5 (95? of control).
Bone marrow and tumour glutathione estimations from
experiments using the xenograft lines NX 002 and CX 143 are
shown in Figure 19.1, with levels illustrated in each group as
a percentage of control. A decrease in bone marrow
glutathione content was observed on day 2, followed by recovery
and overshoot by day 6, with values returning to normal by day
10. This trend was similar for both lines, although absolute
glutathione values differed. The observed glutathione over¬
shoot (147?) was less than that previously seen in non-tumour
bearing animals. A similar trend in glutathione transferase levels was seen, v
the results from the NX 002 xenograft illustrated in
Figure 19.2
Tumour glutathione levels show a different trend,
however, with no depletion observed in these non-small cell
xenografts on day 2. By day 6 tumour glutathione levels in the
NX 002 group remained less than control values, with minimal
Fig.19.1Effectofcyclophosphamideprim ngntumourab arrowglutathionevelsi us p¬ pressedCBAmicebearingnon-smallcellucancerx ografts.̂NX002bo em ow |NX002tumourQCX143bonemarroŵ43tum ur.
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elevation observed in the CX 1^3 group (115$ of control).
Likewise, at day 10 no overshoot was observed, with no
statistically significant difference in tumour glutathione
levels noted between cyclophosphamide treated and control mice
at any of the time points. Corresponding glutathione trans¬
ferase values are illustrated in Figure 19.2. Once again no
elevation of glutathione transferase level was observed at any
of these time points.
(ii) Small cell lung cancer xenografts
Following the administration of cyclophosphamide
75 mg/kg, glutathione and glutathione transferase levels were
measured in bone marrow cells and tumour tissue from nude mice
bearing small cell lung cancer xenografts. The results are
illustrated in Figure 19.3. Glutathione levels were measured
using the method of Hissin & Hilf (1976) as previously
described. As the specificity of this assay has been
questioned, these results were validated using a more specific
assay (Tietze 1969), measuring total glutathione by cyclic
reduction of Elmans reagent glutathione reductase and NADPH. A
similar trend was observed with both assays.
I60r
Kvvvl■■■l\\\\tVsXXtDay26Day10 Days
Fig.19.2Effectofcyclophosphamideprim ngntumouranb arrowlutathionetra sfe ase activityinimmunesuppressedCBAcbear ngnon- malllll cancerx ogr fts.■o e marrowNx002^Tumour
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As is shown in Figure 19.3, using the assay described by
Hissin and Hilf (1976), depletion of glutathione levels is
observed in the bone marrow on day 2 with elevation of gluta¬
thione levels seen by day 6, reaching 122% in NCI-H82 and 146%
in NCI-H209. These values had returned to normal by day 10. In
tumour tissue, however, glutathione levels were essentially
unchanged on day 2, with depletion of levels observed on days 6
and 10 in NCI-H209 and on day 10 with NCI-H82. No significant
overshoot in glutathione levels was observed on day 6 in either
xenograft line. Using the Tietze assay (1969), similar trends
were observed. In bone marrow samples glutathione depletion
was observed on day 2, in mice bearing NCI-H82 xenografts
levels fell to 55%, and with NCI-H209 to 80% of control values.
On day 6, elevation of glutathione to 142% and 127% of control
levels were seen in NCI-H82 and NCI-H209 respectively although
these values had returned to normal by day 10.
In tumour tissue from NCI-H82, glutathione levels were
nimimally depleted; day 2 88.7%, day 6 84.7% and day 10 88.7%
of control. With NCI-H209, a more chemosensitive tumour,
values of 72.7%, 65.6% and 95.2% of control were observed on





Fig.19.3Effectofcyclophosphamideprim ngntumourandb emarrowglutathio elevelsi athymicnudemicbearingsmallcelluna c rxenografts.^NC1-H209bone marrowHNC1-H209tumour0NCI-H82b nerrow^ C1-48tumour.
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Glutathione transferase levels were measured in the same
samples. Depletion of bone marrow glutathione transferase
levels were seen on day 2 following cyclophosphamide, 5^% of
control in NCI-H82 and 62$ in NCI-H209. No significant
overshoot in bone marrow or tumour glutathione transferase
levels were observed during this experiment.
19.7 Discussion
A number of interesting findings are presented in this
chapter. The difference in basal glutathione levels between
small cell and non-small cell lung cancer cell lines is
extremely interesting. Non-small cell lung cancer is markedly
more resistant to chemotherapy and radiotherapy than small cell
lung cancer, with glutathione levels in the non-small cell
lines almost universally higher. Of particular interest,
mesothelioma cell lines had the highest glutathione levels,
with this cell type highly resistant clinically. It was hoped
that a similar difference would have been observed between
small cell lines derived from treated and untreated patients,
as the former are frequently resistant to chemotherapy.
However, no obvious difference in glutathione levels was
detected between these groups. It is possible, that when no
longer stressed by cytotoxic drugs, that glutathione levels in
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small cell lines derived from previously treated patients
returned towards basal values. Alternatively, it is conceiv¬
able that clones of cells low in glutathione content grow out
in culture. Certainly, in recent experiments performed by the
author, using a human ovarian cancer cell line it was found
that by second passage the glutathione level had fallen to 30%
of the level detected in the original tumour tissue. Although
glutathione transferase levels tended to be slightly higher in
non-small cell lines, no obvious difference was observed
between groups.
Immune-deprivation had minimal effect on hepatic
glutathione but tumour bearing animals had significantly
depleted values. No difference was noted in bone marrow
glutathione levels in any of these groups, however.
Glutathione levels varied between xenograft lines with also a
significant variation in levels between tumours of the same
xenograft line. Standard derivations of ±25? were observed in
these measurements. To obtain valid results, using tumour
tissue,a number of factors require to be addressed. In
particular, attention should be paid to the size and growth
pattern of the tumour. Maximum tolerated doses of cytotoxic
drugs caused depletion in tumour glutathione levels at 48
hours. This depletion bore some relationship to the chemo-
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sensitivity of the tumour to that agent, but was not directly
related as may have been predicted. Other factors, such as the
affinity of the drug for glutathione, are also likely to be
important.
In both the cyclophosphamide priming experiments elev¬
ation in bone marrow glutathione and glutathione transferase
levels were observed in tumour-bearing animals 6 days after
priming dose of cyclophosphamide. The magnitude of this
overshoot was reduced in comparison with the studies carried
out in normal CBA mice. It remains to be elucidated whether
this reduction is a true difference, relating to alterations in
the response normal tissues of tumour-bearing animals to
cytotoxic drugs. Alternatively, in view of the time taken to
process tumour samples this difference could merely indicate
increased autooxidation of glutathione. Processing of the
tumour samples caused a delay in the preparation of bone marrow
samples which may have resulted in diminished glutathione
levels. Further studies are indicated to resolve this
question.
Depletion of tumour glutathione and glutathione
transferase levels were seen on day 2 after the priming dose of
cyclophosphamide (75 mg/kg) but no significant overshoot of
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these values were observed on day 6 in tumour tissue, either in
the relatively resistant non-small cell xenografts or in small
cell lung cancer xenografts.
We know that we can protect animals from the lethal
effects of cyclophosphamide by pre-treatment with a smaller
priming dose. This protection is accompanied by elevation in
glutathione and glutathione transferase levels in granulocytes,
which recover more rapidly in pre-treated animals. From these
studies, no significant elevation of glutathione or glutathione
transferase levels are observed in tumour tissue at the time of
maximal protection from the lethal effects of cyclophosphamide.
Thus, from this aspect no priming effect is observed in tumour
tissue. The potential remains therefore, to enhance the
therapeutic index of cyclophosphamide by pretreatment with low
doses.
Previously Jeney and Connors (1968) showed diminished
activity of melphalan by pretreatment with low dose alkylating
agents with activity assessed by measurement of DNA cross¬
links. The study suggested that tumour protection could occur
with priming doses of alkylating agents. In contrast, Evans et
al (1982) showed that much higher doses of cyclophosphamide
were tolerated by mice when administered by divided dose
schedule, with minimal loss of anti-tumour activity. The
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findings in these experiments are more in keeping with the
latter study. However, it has previously been recognised that
not all alkylating agents can 'prime', and that molecular
structure may be important. This could well be a significant
factor in the protection afforded by cyclophosphamide with its
unusual metabolism and toxicities.
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CHAPTER 20
MODULATION OF GLUTATHIONE LEVELS
20.1 Introduction
Glutathione levels have been shown to be important in the
response of various tissues to both radiation and certain
cytotoxic drugs. In general, reduction of glutathione levels
will enhance the effect of many cytotoxic drugs, including
adriamycin and cis-platinum, and also radiation, particularly
in anaerobic conditions. There are a number of methods of
depleting intracellular glutathione. Many toxic compounds will
cause a non-specific decrease in glutathione level, although
several agents are now available which will significantly
deplete glutathione levels with a degree of selectivity.
N-ethyl-maleamide depletes glutathione by forming covalent
adducts with cellular thiols, including protein sulfhydryls.
However, the high reactivity of N-ethyl-maleamide affords
minimal specificity and considerable toxicity. Diethylmaleate
is less reactive, and as it is a substrate for glutathione
transferase, can more specifically deplete glutathione levels.
Ethacrynic acid is converted to a substrate for glutathione
transferase in hepatocytes, and has been used to deplete
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glutathione in cell culture (Habig et al 1974; Klassen and
Fitzgerald 1974). Another approach is to reduce glutathione to
the disulphide with diamide the most popular reagent (Harris et
al 1971), although this compound has been shown to exhibit
non-specific reactivity (Harris and Biaglow 1972). Glutathione
levels can also be reduced by limiting synthesis. This can be
achieved by impairing the reductive capability of the cell
either directly by inhibition of glutathione reductase with
nitrosoureas (Babson et al 1981; Smith and Boyd 1984;
Paraidathathu et al 1985) or indirectly by decreasing NADPH
generation through inhibition of glucose-6-phosphate dehydrog¬
enase with dihydroepiandrosterone (Lopes-S and Rene 1973). On
the other hand, a more specific glutathione depletion is
afforded by sulfoximine derivatives such as methionine and
buthionine sulfoximine (Rowe et al 1969). These compounds
directly inhibit y-glutamyl cysteine synthetase with buthionine
sulfoximine the drug of choice, as it has no other documented
primary effects on the cell.
In contrast, fewer methods of increasing intracellular
glutathione levels are available. Elevations of glutathione
levels are observed following treatment with 2-oxothiazolidine-
4-carboxylate (Boettcher and Meister 1984) which stimulates
glutathione synthesis by providing high levels of intracellular
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cysteine following cleavage with oxoprolinase. Unfortunately
glutathione itself is a tripeptide that does not readily enter
into the cell because of exofacial membrane non-permeability.
It is known that the anionic function of the carboxyl group
restricts the flow of glutathione into the cell. Removal of
this anion can be accomplished by the production of a
glutathione ester, which is permeable, and is cleaved intra¬
cellular^ to glutathione. Monoethyl and diethylesters of
glutathione were synthesized and supplied by Dr Angelo Russo of
the National Cancer Institute, USA. These esters have been
shown to be capable of increasing intracellular glutathione
levels (Puri and Meister 1983; Wellner et al 1984).
In view of their relative specificity, two compounds were
selected for further investigation. Buthionine sulfoximine was
used to deplete glutathione levels, and the monoethylester of
glutathione was used in an attempt to elevate intracellular
glutathione levels.
The first experiment was designed to address the question
of whether the increase in glutathione and glutathione
transferase levels observed 5 days after a cyclophosphamide
priming dose, related to a compensatory synthetic process, or
merely represented survival of cells originally high in
glutathione content. This was achieved with the use of
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buthionine sulfoximine following the priming dose of cyclophos¬
phamide. Further studies were then performed with buthionine
sulfoximine to assess the degree and kinetics of glutathione
depletion in different tissues.
A number of studies were carried out using the
monoethyl ester of glutathione. Initial studies concentrated
on validation of the structure of the ester. Thereafter,
assessments were made of the activity of the ester both in
vitro and ijn vivo. In addition, the potential of this compound
as a means of rescue following treatment with buthionine
sulfoximine was studied.
20.2 Effect of Buthionine Sulfoximine on Cyclophosphamide
Priming
20.2a Materials and Methods
C3H mice were supplied by Frederick Animal Centre,
Maryland, USA with all animals 8-12 weeks of age. Survival
studies were carried out on groups of 8 mice with biochemical
experiments performed on separate groups of 3 mice. Cyclophos¬
phamide was administered at a dose of 75 mg/kg as a priming
dose, with toxic doses of 350 mg/kg or 500 mg/kg. In CBA mice
350 mg/kg was lethal to all controls, but caused no lethality
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in control C3H mice, with 500 mg/kg found to be lethal to all
C3H animals. Buthionine sulfoximine was given intraperi-
toneally at a dosage of 26.5 mg/mouse on either one or two
occasions at 6 hour intervals prior to the lethal doses of
cyclophosphamide for the survival studies, or prior to
sacrifice in the biochemical study. Six treatment groups were
investigated, as described in Table 20.1. Animal survival was
assessed at 14 days with glutathione assayed as previously
described (Tietze 1969). Glutathione levels were expressed as
micromoles per 10^ cells and micromoles per milligram protein.
Glutathione transferases were measured as previously described
using chlorodinitrobenzene as a substrate. Studies were
limited to bone marrow, with samples prepared as described in
Chapter 7.
20.2b Results
The results of lethality experiments are summarised in
Figures 20.1a and 20.1b. Fifty per cent survival was observed
in animals pretreated with cyclophosphamide 75 mg/kg 5 days
before a lethal dose of 500 mg/kg. The protective effect of a
cyclophosphamide priming dose is completely lost in animals
subsequently treated with buthionine sulfoximine. In fact,
enhanced toxicity is observed in buthionine sulfoximine treated
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buthionine sulfoximine x 1
6 hrs before
buthionine sulfoximine x 2
12+6 hrs before
buthionine sulfoximine x 1
6 hrs before
buthionine sulfoximine x 2
12+6 hrs before
saline
Table 20.1 Treatment groups for the study of buthionine
sulfoximine treatment on the response of C3H mice
to a cyclophosphamide priming dose
326
animals receiving cyclophosphamide 350 mg/kg, irrespective of
previous treatment. In contrast, cyclophosphamide 350 mg/kg
was not lethal in control or primed animals not receiving
buthionine sulfoximine.
Glutathione and glutathione transferase levels are shown
in Table 20.2. Elevations are observed in both measurements
following low dose cyclophosphamide. Buthionine sulfoximine
treatment resulted in lowering of the bone marrow glutathione
level in untreated mice to 68? of control. Cyclophosphamide
pretreatment resulted in elevation of glutathione levels to
143? of control. However, in cyclophosphamide pre-treated mice
who were subsequently treated with buthionine sulfoximine,
glutathione levels fall to 47? of control values. Similar
figures were obtained following 1 or 2 injections of buthionine
sulfoximine. Glutathione transferase levels were elevated in
animals pre-treated with cyclophosphamide, irrespective of
subsequent therapy. Buthionine sulfoximine therapy had no
effect on glutathione transferase levels. These experiments




Fig. 20.1 14 day lethality in C3H mice following (a) cyclophosphamide 350mg/kg or (b)
cyclophosphamide 500mg/kg. Group 1 control; Group2 cyclophosphamide 75mg/kg 5 days before;
Group 3 buthionine sulfoximine 6 hours before; Group 4 buthionine sulfoximine X 2, 6 and 12
hours before; Group 5 cyclophosphamide 75mg/kg 5 days before and buthionine sulfoximine X1;
Group 6 cyclophosphamide 75mg/kg 5 days before and buthionine sulfoximine X2.
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Group *GSH % Control +GST % Control
1. Control 0.81 + 0.108 100.0 6.87 ± 2.21 100.0
2. CTX 75 mg/kg 1.15 ± 0.09 113.0 13.38 ± 1.18 191.8
3. BSO x 1 0.511 + 0.121 67.2 6.55 + 2.89 95.3
4. BSO x 2 0.561 ± 0.078 69.6 7.55 + 1.9 109.8
5. CTX 75 mg/kg + 0.103 ± 0.118 19.8 13.36 + 3.11 191.5
BSO x 1
6. CTX 75 mg/kg + 0.361 ± 0.101 11.8 15.70 + 1 .96 228.5
BSO x 2
Table 20.2 Glutathione and glutathione transferase levels in
murine bone marrow. Effect of buthionine
sulfoximine on the response to low dose cyclophos¬
phamide (75 mg/kg).
*Glutathione content expressed in nanomoles per 10^
cells ± S.D.
+Glutathione-S-transferase specific activity (x
10"^) per 1q6 cells ± S.D.
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20.3 In Vitro Depletion of Glutathione Levels Using Buthionine
Sulfoximine
Many cell lines have been shown to decrease intracellular
glutathione levels in response to buthionine sulfoximine. Ten
millimolar buthionine sulfoximine has been shown to deplete
glutathione to undetectable levels within 4 hours using Chinese
hamster lung V79 fibroblast cells. However, no decrease in
viability of these cells is observed until cells are incubated
for 16 hours or greater at this concentration. Using the same
concentration of buthionine sulofximine it takes 16 hours to
deplete glutathione levels in the adenocarcinoma cell line A5^9
to less than 1$ of control making the drug less effective as a
sensitiser to drugs or radiation in this cell line. The length
of time taken for any particular cell to deplete its
glutathione is variable and dependent on numerous factors.
20.H In Vivo Depletion of Tissue Glutathione Levels Using
Buthionine Sulfoximine
Buthionine sulfoximine depleted glutathione in all of the
cell lines tested, although the rate of depletion varied with
the cell line. In these experiments buthionine sulfoximine was
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used to deplete glutathione _in vivo. Different tissues were
studied to assess the degree of depletion obtainable and the
rate of this depletion.
20.4a Materials and Methods
C3H mice 8-12 weeks of age (approximately 20 g weight)
were injected with buthionine sulfoximine 26.5 mg intra-
peritoneally every 6 hours. Four animals were used per group,
with mice sacrificed by decapitation and organs removed and
processed rapidly. The following tissues were studied, bone
marrow, liver, kidney, heart, muscle and spleen. Bone marrow
and liver specimens were prepared as described in Chapter 7.
The remaining tissues were dissected using crossed scalpels and
homogenised using a Polytron homogeniser. Thereafter, speci¬
mens were spun at 30,000 g for 30 minutes and supernatants
assayed for glutathione content. Protein estimations were
performed using the method of Lowry (1951).
20.4b Results
The effect of buthionine sulfoximine, given as 2
injections of 26.5 mg per mouse, on tissue glutathione levels
is shown in Table 20.3. Hepatic levels were reduced to 76? of
control with control livers having values of 89 nanomoles
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glutathione per mg protein. Cardiac glutathione was reduced to
21? of control with these levels remaining low 12 hours after
the last buthionine sulfoximine injection. Skeletal muscle
exhibited a fall in glutathione level to 16? of control values.
Control cardial muscle had a glutathione level of 31-8
nanomoles per mg protein and skeletal muscle 27.8 nanomoles
glutathione per mg protein.
Further studies were performed with buthionine
sulfoximine administered for 4 days, and organs assayed for
glutathione 24 hours after the last dose of buthionine
sulfoximine. The results are illustrated in Table 20.4. The
more prolonged treatment with buthionine sulfoximine caused a
greater depletion of bone marrow glutathione to 52? of control
with a similar depletion observed in skeletal muscle (18? of
control). Once again elevation of renal glutathione was seen
(153? of control).
The final study was performed to obtain a more detailed
assessment of response of renal glutathione levels to
buthionine sulfoximine. The results are illustrated in
Table 20.5
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20.5 Studies with the Glutathione Monoethyl Ester
The monoethyl ester of glutathione was synthesised by
Dr Angelo Russo (Radiation Oncology Branch, National Cancer
Institute, Bethesda, Maryland, USA) according to the method
of Anderson et al (1985) and separated by column chromatog¬
raphy. Using 220 megahertz nuclear magnetic resonance
spectroscopy, performed by Dr Russo, it was shown that the
glycyl portion of the glutathione was esterified, as shown in
Figure 20.2. By utilising different pH conditions, the
deprotonation of carboxyl groups is apparent. It can be seen
that the singlet at 3.8 parts per million does not shift with
varying pHs; therefore establishing that the glycyl alpha
proton must be associated with the ester carboxyl group.
Further studies were then performed to assess the functional
activity of this ester by measurement of glutathione levels
both in vitro and in vivo.
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Control Buthionine Glutathione Buthionine
Sulfoximine Ester Sulfoximine












+ 2 Heart 18.4 8.04
Kidney 1.82 3.54
Liver 61 .66 49.5
Muscle 15.78 6.49
+ 3 Heart 6.95 15.22 7.60
Kidney 1 .74 1.36 2.01
Liver 67.57 91 .5 55.1
Muscle 5.08 1 6.26 5.97




+ 6 Heart 6.75 17.8 6.00
Kidney 1 .70 1.029 1 .97
Liver 67.57 78.72 52.15
Muscle 4.56 10.46 4.30
Table 20.3 Effect of buthionine sulfoximine and glutathione monoethyl-
ester on mouse tissue glutathione levels. Each glutathione measurement




Tissue Control Buthionine sulfoximine (x 16) % Control
Liver 78.72
Kidney 0.918 1.41 153
Bone marrow 41.56 21 .68 52.2
Spleen 26.94 18.2 67.2
Muscle 27.87 1.41 17.9
Table 20.4 Effect of buthionine sulfoximine given for 4 days on tissue
glutathione. Glutathione measured 24 hours after final injection of
buthionine sulfoximine.
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20.5a In Vitro Studies with a Glutathione Monoethyl Ester
A5^9, a human lung adenocarcinoma cell line, was used for the in
vitro studies. Cells were incubated with the ester in culture medium for
varying lengths of time. For processing the cells were centrifuged at
250 g for 5 minutes, then washed three times with phosphate buffered
saline. The cells were resuspended in 0.6$ sulphosalicylic acid and
glutathione measured using the method described by Tietze (1969). With
A5^9 cells minimal elevation in glutathione levels was observed, reaching
120$ of control values at 30 minutes. With more prolonged exposure to
ester no further increase in glutathione was observed. However, using
Chinese hamster lung V79 cells, values of greater than 200$ of control
were achieved at 1 hour in 3 separate experiments using the same
monoethyl ester.
20.5b In Vivo Studies with a Glutathione Monoethyl Ester
Studies were performed to assess the degree of uptake of
the monoethyl ester in different tissues. The following
tissues were studied; heart, kidney, liver and muscle. The
effect of the ester alone was studied and in addition the
ability of the ester to rescue tissues from the effects of
buthionine sulfoximine was assessed. The following M groups
were studied.
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Group No. of BSO Time of sacrifice Glutathione % Control
injections after final BSO nanomoles/mg
injection protein
Kindey Control — 1.28 ± 0.13 —
1 +2 1.34 + 0.16 105
+ 5 1 .84 ± 0.29 1 44
5 +2 2.76 + 0.36 215
+ 5 1 .87 ± 0.19 146
+ 9 3.20 + 0.09 179
9 + 1 2.75 + 0.29 215
+2 2.20 ± 0.13 172
+ 5 2.98 ± 0.19 233
Bone marrow Control - 23.94 + 3.40 -
9 +2 4.92 + 0.63 20.1
Liver Control - 70.50 ± 10.1 -
1 +2 49.80 + 11.3 9.<
+ 5 6.23 + 0.92
5 +5 7.81 ± 1 .21 11.i
+ 9 25.35 + 4.39 36. i
9 + 1 18.60 + 6.92 26.
+ 2 12.85 ± 4.06 18.;
+5 9.25 ± 2.64 13.i
+ 9 27.6 jb ;5.57 39J












Fig. 20.2 220 mega—Hertz proton nuclear magnetic resonance
spectra of glutathione and its monoethylester, performed In DgO
using trimethylallyl propionate as reference. The protons are
labelled alphabetically on the chemical structure, and corresponding
labelling Is seen on the spectra. (A) Glutathione pH 1.5, (B)
Glutathione pH 10.0, (C) Glutathione monoethyl ester pH 1.5,
(D) Glutathione monoethyl ester pH 10.0.
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(1) control
(2) buthionine sulfoximine (26.5 mg i.p. x 6 hourly)
(3) glutathione monoethylester (MO mg i.p. at Time 0)
(M) buthionine sulfoximine + glutathione monoethylester
Buthionine sulfoximine 26.5 mg was administered intraperi-
toneally every 6 hours for 2M hours prior to commencement of
the study, with the glutathione ester (MO mg per mouse)
administered intraperitoneally at time 0. At specified times
thereafter, groups of 3 mice were sacrificed and prepared for
glutathione estimations. Mice were decapitated, and deblooded
organs were removed and weighed. Tissue was then transferred
to test tubes and 2 ml of phosphate buffered saline with 1
millimolar EDTA was added. Specimens were minced, homogenised
and then centrifuged at 30,000 g for 30 minutes at MOc. The
supernatant was removed and frozen at ~70°C prior to assay.
Glutathione was assayed according to the method described by
Tietze (1969). The results are summarised in Table 20.3.
Buthionine sulfoximine caused a fall in glutathione values in
heart, liver and muscle, although kidney values were above
control levels. Ester treatment caused no elevation in
glutathione levels in any of the tissues investigated apart
from minimal increase in kidney levels at 2 hours. If any¬
thing, levels were lower in mice treated with the ester
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compared with control. The use of the ester in an attempt to
rescue tissues following buthionine sulfoximine treatment gave
interesting results. Ester treatment had minimal effect on the
tissues apart from kidney samples. Very high glutathione
levels (1900?) were observed in the kidney 1 hour after
injection of the ester in buthionine sulfoximine treated mice,
with levels remaining slightly elevated for 6 hours.
20.6 Effect of Buthionine Sulfoximine and Glutathione Ester
on Tumour Glutathione Levels
Glutathione levels were measured in 2 small cell lung
cancer xenografts, NCI-H209 and NCI-H82, the details of which
were described in Chapter 19. The xenografts were grown in
nude mice and were treated with either buthionine sulfoximine
26.5 mg intraperitoneally on 2 occasions, 6 and 12 hours before
sacrifice, or glutathione ester MO mg intraperitoneally 2 hours
before killing. Tumour tissue was excised immediately and
homogenised using a polytron homogeniser. Glutathione levels
were assayed using both methods described previously. The
results are summarised in Table 20.6. Buthionine sulfoximine
significantly depleted glutathione levels in both xenograft
lines (approximately 30? of control) using
both assays. However, ester treatment resulted in no signifi-
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cant elevation in glutathione levels, levels ranging from
76-116? of control values in both assays. Experiments to
ascertain whether buthionine sulfoximine-treated tumour tissue
can be rescued with a glutathione ester have yet to be
performed.
20.7 Discussion
Buthionine sulfoximine treatment was shown to signific¬
antly deplete glutathione levels in many tissues including
cardiac muscle, liver, skeletal muscle, and tumour tissue.
Levels in tumour tissue fell to 30? of control values following
2 injections of buthionine sulfoximine over 12 hours. In
contrast, minimal depletion of glutathione values (67? of
control) are observed in bone marrow specimens. Interestingly,
minimal haematological toxicity has been observed using
buthionine sulfoximine in combination with melphalan (Hamilton
- personal communication; Russo et al 1986). In the case of
melphalan, significantly enhanced anti-tumour activity is
observed in combination with buthionine sulfoximine with
minimal, if any, increase in toxicity. No enhancement of bone
marrow toxicity is observed in these studies with minimal
depletion of glutathione seen in this tissue. Substantial
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Glutathione Content (% control)
Fluorimetric Assay Tietze Assay
Xenograft Line BSO GE BSO GE
NCI-H82 29.4 96.9 37.8 116
NCI-H209 24.9 76.1 30.3 77
Table 20.6 Effect of buthionine sulfoximine (BSO) and
glutathione monoethyl ester (GE) on small cell lung cancer
xenograft glutathione levels. Glutathione measured using 2
methods; fluorimetric assay and Tietze assay.
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overshoot in glutathione levels is normally observed in the
bone marrow following cyclophosphamide priming. However, in
mice subsequently challenged with buthionine sulfoximine a more
profound fall in glutathione content is seen. Levels of 47$ of
control are observed in contrast to the 180$ normally seen
after drug priming. This result is highly suggestive that a
compensatory synthetic process is being interrupted by
buthionine sulfoximine treatment. The protective effect of low
dose cyclophosphamide (75 mg/kg) on animal survival is
completely lost in these mice subsequently treated with
buthionine sulfoximine with, in fact, enhanced toxicity
observed compared with control mice. However, it should be
stressed that buthionine sulfoximine could be depleting
glutathione in other organs which could account for some of the
increase in mortality. The fact that the protective effect of
cyclophosphamide is lost with subsequent buthionine sulfoxi¬
mine treatment is very interesting. This treatment prevents
the overshoot in glutathione levels without impairing the
overshoot in glutathione transferase levels. This suggests that
glutathione is more important in this protection, and that the
glutathione transferase increase is relatively impotent in the
presence of diminished substrate (glutathione) concentrations.
3^3
However, whether increased levels of glutathione transferase
would be protective if the glutathione level could be main¬
tained at 100| of control remains a matter for conjecture.
The structure of the glutathione ester was confirmed using
proton nuclear magnetic resonance spectroscopy with the ester
shown to be attached to the glycyl portion of the compound.
However, studies with the ester have been relatively disap¬
pointing. In vitro studies with V79 cells have shown good
uptake at 30 minutes to 2 hours with glutathione values
reaching 200? of control levels. With A51<9 cells however,
minimal elevation of glutathione was detected over this period.
Perhaps consideration should be given to basal glutathione
levels in these cell lines, however as A519 cells have very
high levels in comparison to V79 cells. Further studies are
required using a range of cell lines to ascertain whether ester
uptake is affected by the basal glutathione level. In vivo
studies have been particularly disappointing with no increase
in glutathione detected in cardiac muscle, liver or striated
muscle. Renal glutathione levels were minimally elevated
following ester administration. Surprisingly, renal
glutathione levels were not depleted by buthionine sulfoximine,
in contrast slight elevation in levels were detected. In mice
treated with both buthionine sulfoximine and the glutathione
3^4
ester however, there was a dramatic increase in glutathione
level at 1 hour with values of 1800% of control observed.
Glutathione levels remained elevated for 6 hours following
injection of the ester in buthionine sulfoximine treated
animals. The high renal glutathione values could be related to
high renal excretion of the ester. Alternative methods of
ester administration such as continuous low dose infusion are
now being studied to assess whether higher, potentially
protective, glutathione levels can be achieved in other
tissues.
A major problem was encountered with the studies performed
on renal tissue. Although actual values for other tissues
correlate well with reported glutathione values, renal
glutathione levels reported in these experiments were much
lower than in previously reported studies. It is possible that
glutathione was unstable in the preparations used, as tissues
high in Y-glutamyl transpeptidase have previously been shown to
interfere with glutathione levels. Further studies are now
being performed to address this problem
In the 2 small cell lung cancer xenografts, buthionine
sulfoximine caused a significant fall in glutathione levels.
Although the degree of this depletion was similar to some other
tissues, such as cardiac and striated muscle, it was much
3^5
greater than the depletion observed in bone marrow cells.
Potentially, this could be of great value clinically by
increasing the therapeutic index of drugs that are detoxified
by the glutathione redox system, if their dose-limiting
toxicity is haematological. Certainly, buthionine sulfoximine
can enhance the cytotoxicity of melphalan without significantly
altering the haematological toxicity or survival in these mice.
It should be stressed that caution is still recommended in the
use of buthionine sulfoximine with drugs that have dose-
limiting toxicities other than haematological. Caution should
also be exercised in the presence of a regenerating bone marrow
as a greater depletion in glutathione levels may be observed
with consequently increased toxicity. In addition, one should
remain alert to the possibility of unexpected major organ
toxicities with combinations of buthionine sulfoximine with
myelotoxic cytotoxic drugs.
The use of the glutathione ester to rescue cells from
buthionine sulfoximine toxicity was not successful, although
optimal scheduling of administration of the ester remains
undefined. Encouraging results were obtained with a combin¬
ation of buthionine sulfoximine and ester in the kidney, with
consistent elevation in renal glutathione levels. This
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certainly justifies an in vivo experiment using these two
agents in an attempt to reduce the renal toxicity of cis-
platinum which is often dose-limiting.
Further _in vivo experiments are certainly indicated using
buthionine sulfoximine in combination with various cytotoxic
drugs to ascertain whether the therapeutic index of these drugs
can be improved. Esters of glutathione potentially offer
interesting possibilities of rescue although the optimal ester
and schedule of administration of these esters remain unclear.
3^7
CHAPTER 21
GENERAL CONCLUSIONS AND FURTHER STUDIES
Human tumour xenografts were established from lung cancer
specimens using CBA mice immune-deprived by means of thymec¬
tomy, cytosine arabinoside priming and total body irradiation.
Tumour tissue was obtained primarily at thoracotomy although a
few specimens obtained at bronchoscopy were included. Xeno¬
graft lines were successfully established in 31 % of samples
with similar take rates observed using both squamous and
adenocarcinoma samples. Lower take rates were achieved using
anaplastic carcinomas, both small cell and large cell, although
numbers were small. Proportionately fewer continuous xenograft
lines were established in this study than in the previous study
reported by Shorthouse (1981). Delay in transplantation of
tumour tissue is likely to have been the predominant reason for
this discrepancy. These delays occurred both at the time of
excision of the tumour, prior to placement into tissue culture
medium, and also before implantation into the immune-deprived
host. Following growth in the primary man to mouse passage,
subsequent take rates were similar to previously reported
3^8
studies. A range of 16 lung cancer xenografts were
established, including squamous carcinoma, adenocarcinoma,
adenosquamous carcinoma and small cell carcinoma lines.
Generally, moderately to poorly differentiated tumours were
grown more successfully, with no well differentiated tumours
established. Following a presumably infective outbreak in the
mouse colony, 9 xenograft lines were salvaged of which 6
non-small xenografts cell and 1 small cell xenograft were
selected for chemotherapy studies, with the growth character¬
istics of these xenografts similar to previously described
studies. Tumour volume doubling times varied from passage to
passage, and also within the same passage, although no obvious
growth pattern was evident. Histologically, the xenografts
retained similar morphological features to the original donor
tissue. However, minor changes in differentiation were seen
with different passages, although no reliable pattern was
evident with both increased and decreased differentiation
observed.
The six non-small cell xenografts used for the chemo¬
therapy studies included 1 adenocarcinoma and 1 adenosquamous
carcinoma and M squamous cell lines. As may have been
expected, all xenografts were generally resistant to single
agent chemotherapy. Of the single agents tested, cis-platinum
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was the most active, with ifosfamide also exhibiting some
activity. The platinum analogues carboplatin (JM8) and JM40
were more active than cyclophosphamide, vindesine or etoposide
but were less active than cis-platinum. However, carboplatin
is certainly worthy of further study in view of its slightly
different spectrum of activity and diminished toxicity in
comparison to cis-platinum. A limited number of drug combin¬
ations were tested with none of these combinations showing
greater activity than maximum tolerated doses of the most
active single agent.
The interferon experiments were extremely interesting.
Certainly supra-additive results were achieved with combin¬
ations of human lymphoblastoid interferon and cis-platinum.
Recently these results have been confirmed by Dr R Fergusson in
the ICRF Medical Oncology Unit using recombinatn human alpha
interferon in combination with cis-platinum or ifosfamide.
However, prior to the incorporation of interferon combinations
in to clinical trials, a number of important questions require
to be addressed. The testing of schedules that would realisti¬
cally be acceptable to the majority of patients is a priority.
In addition, the testing of a wide range of cytotoxic drugs
both as single agents and in combination should be carried out
with human interferon in an attempt to define the optimal
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therapy. Likewise, it would appear important to assess the
effect of interferon on drug metabolism. The use of a hybrid
interferon that affects both human and mouse tissues could be
used in this model to help answer this question. An under¬
standing of the aetiology of this potentiation could obviously
be of great value. Following optimisation of conditions, the
use of interferon in combination with cytotoxic drugs could
prove to be a significant advance in the treatment of many
solid tumours refractory to standard chemotherapy, such as
non-small cell lung cancer.
The use of the calcium channel blocker verapamil in
combination with vindesine was singularly unsuccessful in these
xenografts. Vindesine itself was inactive in all xenografts
tested, and when used in combination with verapamil, toxicity
was severe with all animals dead by day 10. Death was not
related to haematological toxicity, with enhanced local
peritoneal toxicity the likely aetiology. However, the
addition of verapamil was unlikely to have significantly
altered the cytotoxicity of vindesine in these xenografts, as
calcium channel blockers preferentially enhance the activity
of certain cytotoxic drugs n pleiotropically resistant cells.
Pleiotropic resistance is often associated with the presence of
p-glycoprotein, a 180,000 dalton molecular weight membrane
351
glyco protein (Riordan and Ling 1985). In recent studies we
have shown that pleiotropically resistant cells are
'collaterally sensitive' to calcium channel blockers. There
are many unanswered questions relating to the aetiology of
pleiotropic drug resistance. Answers to these questions may
well improve the chemotherapy of solid tumours.
Another potential means of modulating cytotoxic drug
action is by the use of low doses or priming doses of cytotoxic
drugs. In these studies, it was confirmed that low dose
cyclophosphamide could protect against the lethal effects of a
subsequently administered high dose of the same compound. The
protection is maximal 5 to 7 days after the priming dose, the
time of maximal overshoot in glutathione levels in the bone
marrow. The overshoot in glutathione level is found predomin¬
antly in the granulocytic fraction, with granulocytes the bone
marrow cells which recover most rapidly following the 'lethal'
dose. In a similar manner, the bladder can be protected
against potentially lethal doses of cyclophosphamide. From
these studies it remains unclear whether the increased survival
in primed mice is due to reduced bone marrow toxicity, reduced
bladder toxicity, or both. Limited studies on bladder
glutathione have suggested that a similar overshoot in
glutathione level is observed following a priming dose of
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cyclophosphamide. It is far from clear which metabolite of
cyclophosphamide is responsible for this protection, or which
metabolite caused the increase in glutathione and glutathione
transferase levels. It seems likely that many metabolites are
involved, as acrolein, phosphoramide mustard and 4-hydroxy-
cyclophosphamide have all been shown to form adducts with
glutathione. Acrolein was also shown to be capable of
protecting animals from the lethal effects of high dose
cyclophosphamide, although was less effective than low dose
cyclophosphamide. As revealed by the experiments using
buthionine sulfoximine, it seems likely that the overshoot in
glutathione levels seen following drug priming results from a
compensatory synthesis process. Of great importance is the
lack of apparent priming in tumour tissue which is certainly
gratifying from the clinical point of view, as it had
previously been suggested that sulfhydryl-containing compounds
were unlikely to be protective in view of their lack of
specificity (Connors 1966). However, this is probably true for
many exogenously administered sulphydryl-containing compounds.
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The studies with buthionine sulfoximine and the monoethyl
ester of glutathione were extremely interesting. Certainly, in
vitro these compounds are able to selectively alter intra¬
cellular glutathione levels and, as a result, could potentially
modify cytotoxic activity of numerous drugs.
Modulation of glutathione levels can significantly affect
the activity of drugs that are either activated (De Graff et al
1985) or detoxified by the glutathione redox system. However,
the results from _in vivo studies are less clear cut. Buthionine
sulfoximine can reduce tumour glutathione levels to
approximately 25$ of control over 12 hours. This offers the
potential to increase the therapeutic index of drugs detoxified
by glutathione, particularly if haematological toxicity is
dose-limiting, as bone marrow glutathione levels are minimally
affected by buthionine sulfoximine. Using 1 injection of the
glutathione ester at a dose of 10 mg per mouse intra-perito-
neally, tumour glutathione levels were unaffected although a
small increase in renal glutathione was observed. However,
buthionine sulfoximine treatment, followed by administration of
the glutathione ester resulted in a dramatic increase (1800$)
in renal glutathione levels. Potentially, the increase in
renal glutathione levels could be exploited clinically by
protection from cis-platinum-induced renal damage, although
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further jin vivo studies are indicated to validate the renal
glutathione experiments, and examine this hypothesis. Another
important question to address is whether increased glutathione
levels can be achieved in other tissues by administration of
the ester, perhaps in alternative schedules.
In conclusion, a panel of human lung cancer xenografts
have been established which are being maintained in immune-
deprived mice. Experimental work has predominantly centred on
the non-small cell lung cancers. These xenografts maintained
human characteristics and exhibited a similar chemosensitivity
profile to that observed clinically. Responses were poor, both
to single agent and combination chemotherapy, although encour¬
aging results were obtained with interferon-cytotoxic drug
combination. Further studies are indicated for the development
and testing of more realistic schedule for interferon-drug
combinations. In addition, this human tumour xenograft model
could be used for the study of novel drug schedules and other
methods of modulating chemotherapy, apart from the mechanisms
discussed in this text.
It seems likely that increased glutathione levels, either
in the bone marrow or bladder, may play a role in the survival
protection afforded by low dose alkylating agents such as
cyclophosphamide. Bone marrow and bladder tissue can be
355
protected against the toxic effects of high dose cyclophos¬
phamide, but in these studies no protection, in terms of
increased glutathione or glutathione transferase levels, was
observed in tumour tissue.
A more detailed _in vivo assessment of the effects of
buthionine sulfoximine on different tissues would be worth¬
while. Data using the glutathione monoethyl ester remains
preliminary, although the potential remains to rescue tissues
from buthionine sulfoximine related toxicity.
There have been many exciting advances in our under¬
standing of the development and treatment of cancer over the
past 10 years. There is increasing awareness of the prevalence
and importance of various proto oncogenes (Little et al 1983).
and increasing understanding of the effects of various growth
factors on tumour cell growth (Cuttita et al 1985). Develop¬
ments in the production, and the use of monoclonal antibodies
both diagnostically and therapeutically, may be used over the
next 10 years to increase our understanding of tumour biology.
Likewise, increased awareness of the effects of many biological
response modifiers may alter our therapeutic approach to the
treatment of many forms of cancer. However, there is likely to
be a considerable delay before any radical changes are made in
our approach to the treatment of solid tumours. In the
356
interim, a large number of patients with poorly responsive
solid tumours will be treated with combination chemotherapy as
described in the clinical studies. A number of the strategies
discussed in this volume could, potentially, be of value by
reduction of the toxicity associated with combination chemo¬
therapy. However, whether these strategies could result in
higher response rates clinically remains less clear. Priming
doses of cyclophosphamide have been used clinically to reduce
the toxicity of high dose chemotherapy with cyclophosphamide or
melphalan. It would be interesting to ascertain whether a
similar reduction in 'host' toxicity could be achieved with
standard doses of chemotherapy using this technique.
There are many potential ways of modulating the response
to cytotoxic drugs. Alteration of glutathione homeostasis is
just one method, although the human xenograft model is an
excellent model for the study of a number of these strategies.
The long-term results of chemotherapy of lung cancer remains
disappointing, even in small cell lung cancer where initial
response rates are high. It is hoped that modulation of the
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